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Abstract 
 
Vaccinia virus is one of several live viruses currently being evaluated in clinical trials as cancer 
therapies. One oncolytic virus, T-VEC, is already in clinical use and is NICE approved for the treatment 
of melanoma. 
We have investigated a genetically modified, Copenhagen strain vaccinia virus encoding the fusion 
suicide gene (FCU1) that is able to convert non-toxic fluorocytosine into the active compound 
fluorouracil. The mode of cell death attributed to vaccinia virus is variable and multiple modes have 
been implicated based on tumour type. Through our work with colorectal cancer cell lines we have 
established that this form of oncolytic vaccinia virus induces cell death through a predominant picture 
of apoptosis. Furthermore, assessment of its immunogenicity has found there to be an increase in 
markers of immunogenic cell death following infection with the virus. 
We have developed an organotypic culture system in our laboratory which enables us to assess 
oncolytic viruses on ex vivo tissue. Treatment of organotypic cultures from colorectal liver metastases 
have shown that vaccinia virus successfully infects and replicates in the tumour tissue. A dose-
response relationship was observed with the highest doses of virus exerting the most effect on tumour 
tissue. Assessment of the pro-drug activation system through the conversion of 5-fluorocytosine to 5-
fluorouracil in supernatant showed a high percentage conversion, whilst immunohistochemical 
staining did show evidence of an improved effect with the pro-drug system compared with virus alone. 
We have evaluated the combination of cavitational ultrasound and sulphur hexafluoride microbubbles 
to enhance infection with oncolytic virus. Our results have shown that this method enhances infection 
of organotypic cultures treated with oncolytic vaccinia virus. This has enabled the use of a lower dose 
of virus whilst maintaining the same effects in tissue as that of virus at higher doses. This finding has 
translational implications that may enhance the efficacy of systemically administered oncolytic 
vaccinia virus.    
4 
 
Acknowledgements 
 
Firstly, I would like to thank Professor Nariman Karanjia and the Liver Cancer Surgery Appeal charity 
for providing me with the funding and the opportunity to undertake this period of research. Professor 
Karanjia has been a great source of knowledge and support, providing me with invaluable advice and 
encouragement during both my time in research and in my clinical work.  
I would also like to thank my academic supervisor Professor Hardev Pandha for taking me into his 
laboratory and allowing me to develop the organotypic culture model. It has been an extremely 
challenging but rewarding experience. I am grateful to Dr Nicola Annels, Dr Guy Simpson and Michael 
Denyer for all of their patience, tutelage and assistance during my time in the laboratory and for 
providing me with the lab skills required to make the project a success.   
To all of the patients that have provided us with tissue samples I express my sincere thanks. Without 
their consent this project would not have been possible. The GUTS charity and Mr Iain Jourdan were 
also helpful, assisting me towards the end of my research period and I would like to say a big thank 
you to them for this.  
Finally, I would like to thank my family, Helen and Ella for supporting me through my studies. You both 
mean the world to me. I could not have done this without your love and support. 
 
 
 
 
 
 
5 
 
Table of Contents 
 ................................................................................................................................................................ 1 
Declaration of Originality ........................................................................................................................ 2 
Abstract ................................................................................................................................................... 3 
Acknowledgements ................................................................................................................................. 4 
Abbreviations .......................................................................................................................................... 8 
List of figures ......................................................................................................................................... 13 
List of Tables ......................................................................................................................................... 16 
Chapter 1 - Introduction ....................................................................................................................... 18 
1.1 Hallmarks of cancer ..................................................................................................................... 18 
1.2 Colorectal Cancer ........................................................................................................................ 20 
1.2.1 Epidemiology ........................................................................................................................ 20 
1.2.2 Risk factors ........................................................................................................................... 22 
1.2.3 Molecular mechanisms of CRC pathogenesis ...................................................................... 23 
1.2.4 Epidemiology ........................................................................................................................ 23 
1.2.5 Prognosis .............................................................................................................................. 25 
1.2.5 Classification of colorectal cancer ........................................................................................ 25 
1.2.6 Pathogenesis of colorectal cancer ....................................................................................... 27 
1.2.7 Markers of prognosis ........................................................................................................... 29 
1.2.8 Diagnosis of colorectal cancer ............................................................................................. 30 
1.2.9 Staging of disease ................................................................................................................. 30 
1.2.10 Metastatic colorectal cancer.............................................................................................. 31 
1.2.11 Management of patients with metastatic colorectal cancer ............................................. 31 
1.3 Oncolytic virotherapy .................................................................................................................. 35 
1.3.1 Introduction ......................................................................................................................... 35 
1.3.2 Mechanism of oncolytic virus activity .................................................................................. 37 
1.3.3 Factors affecting oncolytic virus spread .............................................................................. 41 
1.3.4 Oncolytic virus development ............................................................................................... 42 
1.3.5 Oncolytic viruses in clinical development ............................................................................ 47 
1.4 Summary ..................................................................................................................................... 61 
1.5 Hypothesis ................................................................................................................................... 62 
Chapter 2 – Materials and methods ................................................................................................. 65 
2.1 Cell lines, treatment and media .............................................................................................. 65 
2.2 Tissue Culture .......................................................................................................................... 66 
2.3 Evaluation of cell line treatment with vaccinia virus .............................................................. 68 
2.4 Organotypic culture ................................................................................................................ 75 
6 
 
 ...................................................................................................................................................... 77 
2.5 Evaluation of VACV in organotypic culture ............................................................................. 80 
2.6 Statistical Analysis ................................................................................................................... 83 
Chapter 3 – Evaluation of the effects of oncolytic vaccinia virus in colorectal cancer cell lines .......... 85 
3.1 Introduction ................................................................................................................................ 85 
3.1.1 Aims...................................................................................................................................... 87 
3.2 Results ......................................................................................................................................... 88 
3.2.1 Susceptibility of colorectal cancer cell lines to Vaccinia Virus ............................................. 88 
3.2.2 Assessment for presence of vaccinia virus through expression of green fluorescent protein 
in cell lines using fluorescent microscopy ..................................................................................... 89 
3.2.3 Control experiments ............................................................................................................ 94 
3.2.4 Comparison of effects of VV-GFP and VV-FCU1 .................................................................. 95 
3.2.5 Determination of mode of cell death .................................................................................. 96 
3.2.6 Assessment of immune mediated cell death ..................................................................... 105 
3.3 Discussion .................................................................................................................................. 112 
3.4 Conclusion ................................................................................................................................. 115 
Chapter 4 – Development of an organotypic culture model and evaluation of the use of oncolytic 
vaccinia virus in colorectal cancer ...................................................................................................... 117 
4.1 Introduction .............................................................................................................................. 117 
4.1.2 2D monolayers of tumour cells .......................................................................................... 117 
4.1.3 3D culture models .............................................................................................................. 118 
4.1.4 Patient derived xenografts ................................................................................................. 119 
4.1.5 Organotypic cultures .......................................................................................................... 119 
4.2 Results ....................................................................................................................................... 124 
4.2.1 Development of an organotypic tissue culture model in our laboratory .......................... 124 
4.2.2 Tissue slice viability ............................................................................................................ 124 
4.2.3 Preliminary viability results of organotypic cultures ......................................................... 124 
4.2.4 Adaptation of culture conditions to improve organotypic culture viability ...................... 126 
4.2.5 Treatment of organotypic colorectal liver metastases with Vaccinia Virus ...................... 132 
4.2.6 Assessment of FCU1 pro-drug activation in organotypic model ....................................... 145 
4.3 Discussion .................................................................................................................................. 151 
4.4 Conclusion ................................................................................................................................. 157 
Chapter 5 - Treatment of organotypic cultures derived from colorectal liver metastases with 
oncolytic vaccinia virus and exposure to cavitational ultrasound and sulphur hexafluoride 
microbubbles ...................................................................................................................................... 159 
5.1 Introduction .............................................................................................................................. 159 
5.2 Strategies to improve intravenous delivery of oncolytic virus therapy .................................... 160 
7 
 
5.2.1 Limiting viral sequestration in the liver and spleen ........................................................... 160 
5.2.2 Evasion of viral neutralisation by serum factors ................................................................ 161 
5.2.3 Increasing the permeability of tumour blood vessels ....................................................... 161 
5.3 Systemic administration of vaccinia virus ................................................................................. 162 
5.3.1 Evasion of the immune response by Vaccinia Virus .......................................................... 163 
5.4 Challenges faced in the systemic administration of oncolytic virus to treat solid tumours ..... 168 
5.4.1 Tumour vasculature ........................................................................................................... 168 
5.4.2 Tumour extracellular matrix .............................................................................................. 169 
5.5 Therapeutic Ultrasound ............................................................................................................ 170 
5.5.1 Ultrasound induced heating .............................................................................................. 170 
5.5.2 Cavitation and gas body activation .................................................................................... 170 
5.5.3 Cavitation Nuclei ................................................................................................................ 171 
5.5.4 Thermal ultrasound applications ....................................................................................... 171 
5.5.5 Non-thermal ultrasound applications ................................................................................ 173 
5.5.6 Use of ultrasound with oncolytic virotherapy ................................................................... 174 
5.6 Aims........................................................................................................................................... 177 
5.7 Results ....................................................................................................................................... 178 
5.7.1 Assessment of the combination of oncolytic vaccinia virus with ultrasound and sulphur 
hexafluoride microbubbles in the treatment of organotypic cultures derived from colorectal 
liver metastases .......................................................................................................................... 178 
5.7.2 Treatment of organotypic cultures with vaccinia virus in combination with cavitational 
ultrasound and sulphur hexafluoride microbubbles at a lower concentration of virus ............. 184 
5.7.3 Evaluation of the treatment of colorectal liver metastases with vaccinia virus at 1x105 
pfu/ml, cavitational ultrasound and sulphur hexafluoride microbubbles .................................. 187 
5.8 Discussion .................................................................................................................................. 195 
5.9 Conclusion ................................................................................................................................. 199 
Chapter 6 – General discussion ........................................................................................................... 201 
6.1 Oncolytic vaccinia virus in the treatment of colorectal cancer ................................................ 201 
6.2 Assessment of the pro-drug activation system with the fusion suicide gene (FCU1) .............. 203 
6.3 The organotypic culture model ................................................................................................. 205 
6.4 Use of cavitational ultrasound to improve the effects of oncolytic vaccinia virus ................... 206 
6.5 Future work ............................................................................................................................... 208 
References .......................................................................................................................................... 210 
 
 
 
8 
 
Abbreviations 
 
7-AAD    amino-actinomycin D 
5-FdUMP  5-fluor-deoxyuridine monophosphate 
5-FU   5-fluorouracil 
5-FUMP 5-fluorouridine monophosphate 
5-FUTP  5-fluorouridine triphosphate 
A56  haemagglutinin 
ALARA   as low as reasonably achievable 
ANOVA  analysis of variance 
APAF1   adaptor protein apoptotic protease-activating factor-1 
APC   antigen presenting cell 
ATCC   American type culture collection 
ATP   adenosine triphosphate 
BCA   bicinochoninic acid 
BCL   B cell lymphoma 
CAF   cancer associated fibroblast 
CAR   coxsackie-adenovirus receptor 
CDase   cytosine deaminase 
CEA   carcinoembryonic antigen 
CEV   cell associated enveloped virion 
CIMP   CpG island methylator phenotype 
CIN   chromosomal instability 
CK7   cytokeratin 7 
CK20   cytokeratin 20 
CRC   colorectal cancer 
CRLM   colorectal liver metastases 
CRT   calreticulin 
CT   computed tomography 
CTL   cytotoxic T lymphocytes 
DAB   3,3′-Diaminobenzidine 
9 
 
DAF   decay accelerating factor 
DAMPS  damage associated molecular patterns 
DMEM   dulbecco’s modified eagle’s medium 
DMSO   dimethyle sulphoxide 
DNA   deoxyribonucleic acid 
EEV   extracellular enveloped virion 
EGFR   epidermal growth factor receptor 
ELISA   enzyme linked immunosorbent assay 
FAP   familial adenomatous polyposis coli 
FAS   first apoptosis signal receptor 
FBS   fetal bovine serum 
FCU1  fusion suicide gene 
FOLFIRI  5-fluorouracil/leucovorin plus irinotecan 
FOLFIRINOX  5-fluorouracil/leucovorin, oxaliplatin and irinotecan 
FOLFOX  5-fluoruracil/leucovorin plus oxaliplatin 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GFP   green fluorescent protein 
GMCSF   granulocyte macrophage colony stimulating factor 
HI   heat inactivated 
HIFU   high intensity frequency ultrasound 
HLA   human leukocyte antigen 
HMGB1  high mobility group box 1 protein 
HNPCC   hereditary non-polyposis colon cancer 
HPLC   high-performance liquid chromatography 
HRP   Horseradish Peroxidase 
HSP   heat shock proteins  
HVEM   herpesvirus entry mediator 
ICD   immunogenic cell death 
ICAM-1  intracellular adhesion molecule 1 
IDO   indoleamine-2,3-dioxygenase 
IEV   Intracellular enveloped virion 
10 
 
IFN   interferon 
IHC   immunohistochemistry 
IL   interleukin 
IMV   intracellular mature virion 
IRF  interferon regulatory factor 
IT   intra-tumoral 
JAK   janus kinase 
KDa   kilodaltons 
MHC   major histocompatibility complex 
MLKL   mixed lineage kinase domain-like 
MDSCs   myeloid derived suppressor cells 
MOI   multiplicity of infection 
MOPS   3-(N-morpholino) propansulfonic acid 
mRECIST  modified response evaluation criteria in solid tumours 
MRI   magnetic resonance imaging 
MSI   microsatellite instability 
mTOR   mammalian target of Rapamycin 
MTS  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
MTX   mitoxantrone 
MV   mature virion 
MVA   Modified vaccinia virus Ankara 
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NICE  The National Institute for Health and Care Excellence  
NK   natural killer cells 
NLRP1  nucleotide-binding domain leucine-rich repeat and pyrin domain containing protein 
1 
OD   optical density 
OV   oncolytic virus 
PAMPs   pathogen-associated molecular patterns 
PARP   Poly (ADP-ribose) polymerase 
PBS   phosphate buffered saline 
11 
 
PD-L1   programmed death ligand 1 
PDMS   polydimethylsiloxane 
PE   phycoerythrin 
PEG   polyethylene glycol 
Pfu   plaque forming units 
PKR   protein kinase R 
PRRs   pattern recognition receptors 
PS   phosphatidylserine 
qPCR   quantitative polymerase chain reaction 
RECIST   response evaluation criteria in solid tumours 
RFA  radiofrequency ablation 
RIG1   retinoic inducible gene 1 
RIP   receptor-interacting protein 
RIPA   radioimmunoprecipitation 
SABR  stereotactic ablative radiotherapy 
SAT   System for Acoustic Transfection 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SIRT  selective internal radiation therapy 
STAT   signal transducer and activation of transcription 
TGF-β   transforming growth factor beta 
TK   thymidine kinase 
TLR   toll-like receptors 
TNF   tumour necrosis factor 
TRAF   tumour necrosis factor associated factor 
TMBIM  transmembrane Bax inhibitor-containing motif 
T-VEC   talimogene laherparepvec 
UPRTase  uracil phosphoribosyltransferase 
US   ultrasound 
UT   untreated 
VACV   vaccinia virus 
vCCI   vaccinia virus CC chemokine inhibitor 
12 
 
VCP   vaccinia virus complement protein 
VEGF-A  vascular endothelial growth factor A 
VGF   vaccinia growth factor 
vGAAP   viral Golgi anti-apoptotic protein 
VSV   vesicular stomatitis virus 
vvDD   double-deleted vaccinia virus 
WHO   World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
 
List of figures 
 
Figure 1.1  Estimated age-standardised colorectal cancer incidence for men in 2008 
Figure 1.2  Representative diagram of the adenoma-carcinoma sequence in the development of 
colorectal cancer 
Figure 1.3  Promotion of viral spread and immune evasion by oncolytic virus in cancer cells 
Figure 1.4  Induction of the immune system by oncolytic virus 
Figure 1.5  Targeting of the Ras signalling pathway by oncolytic vaccinia virus 
Figure 1.6  5-fluorouracil metabolism and effects 
Figure 1.7  Schematic representation of VV-FCU1 
Figure 2.1  Workflow demonstrating retrieval of surgical specimen to production of organotypic 
cultures ready for incubation 
Figure 2.2  Schematic representation of instrument set up and organotypic culture position for 
exposure to cavitational ultrasound 
Figure 3.1  Cell proliferation assay at 72 hours following treatment of colorectal cancer cell lines 
with oncolytic vaccinia virus 
Figure 3.2  Evidence of viral infection in tissue culture using immunofluorescence 
Figure 3.3  Evidence of cell death in HT29 cells following treatment with vaccinia virus 
Figure 3.4  Effects of vaccinia virus following heat inactivation 
Figure 3.5  Effects of vaccinia virus and positive and negative controls on colorectal cancer cell 
lines 
Figure 3.6  Effects of both forms of vaccinia virus used in our experiments on colorectal cancer 
cell lines 
Figure 3.7  Assessment of mode of cell death in colorectal cancer cell lines treated with vaccinia 
virus compared with controls 
Figure 3.8  Assessment of apoptotic cell death in colorectal cancer cell lines treated with vaccinia 
virus using western blotting 
Figure 3.9  Assessment of necroptotic cell death in colorectal cancer cell lines treated with 
vaccinia virus 
Figure 3.10  Markers of immunogenic cell death in HCT116 colorectal cancer cell lines treated with 
vaccinia virus 
14 
 
Figure 3.11  Markers of immunogenic cell death in SW620 colorectal cancer cell lines treated with 
vaccinia virus 
Figure 3.12  Markers of immunogenic cell death in HT29 colorectal cancer cell lines treated with 
vaccinia virus 
Figure 3.13  Appearances of HT29 cell line following treatment with VV-GFP at MOI 1 at 24 and 72 
hours 
Figure 4.1  Organotypic cultures obtained during the preliminary experiment set up 
Figure 4.2  IHC images of tissue prepared using our initial culture conditions 
Figure 4.3  IHC images of prepared organotypic cultures using adjusted culture conditions up to 
264 hours 
Figure 4.4  Comparison of organotypic culture architecture compared with histopathology blocks 
prepared from the original tumour specimen 
Figure 4.5  Staining for immunomarkers in prepared organotypic cultures for comparison with 
original histopathology blocks 
Figure 4.6  Evidence of viral presence in treated organotypic cultures compared with untreated 
controls 
Figure 4.7  Control experiment confirming no effect on tissue slices treated with heat inactivated 
vaccinia virus at 107 pfu/ml 
Figure 4.8  Quantification of anti-GFP and cleaved caspase 3 antibody staining in four patients 
treated with increasing pfu/ml of vaccinia virus expressing GFP compared with 
untreated controls 
Figure 4.9  Confirmation of viral presence through the expression of GFP in treated 4µm tissue 
slice compared to untreated control 
Figure 4.10  Original z-stack imaging and volume snapshots of organotypic culture treated with 
VVGFP 107 pfu/ml 
Figure 4.11  Viral titres in supernatants of tissue slices from 3 patients with colorectal liver 
metastases treated with increasing concentrations of virus and assessed at 24-hour 
intervals up to 96hrs 
Figure 4.12  Z-stack imaging using confocal microscopy confirming the spread of virus through 
tissue slices over a 120 hour time period. Evidence of viral replication through 
increased expression of GFP throughout the tissue slices 
Figure 4.13  Percentage conversion of 5-FC to 5-FU following its addition to organotypic cultures 
of colorectal liver metastases treated with vaccinia virus expressing the FCU1 fusion 
suicide gene 
Figure 4.14  IHC staining for cleaved caspase 3 in organotypic cultures left untreated in media; 
treated with media and 5-FC; treated with virus alone and treated with virus and 5-FC 
15 
 
Figure 4.15  Quantification of anti-VV and cleaved caspase 3 antibody staining in two patients 
treated with media alone; media and pro-drug; virus alone and virus plus pro-drug to 
assess the pro-drug activation model in organotypic cultures 
Figure 4.16  HMGB1 staining in original histopathology blocks in four patients and staining of 
treated and untreated control in prepared organotypic cultures 
Figure 5.1  Confocal microscope image of organotypic cultures from the same patient treated 
with vaccinia virus expressing green fluoresecent protein compared with untreated 
control 
Figure 5.2  Z-stack imaging demonstrating green fluorescent protein expression in organotypic 
cultures treated with vaccinia virus and vaccinia virus plus ultrasound and sulphur 
hexafluoride microbubbles compared with untreated control 
Figure 5.3  Immunohistochemical staining for cleave caspase 3 in organotypic cultures from the 
same patient either untreated or treated with cavitational ultrasound alone, 
cavitational ultrasound and sulphur hexafluoride microbubbles, vaccinia virus alone 
or vaccinia virus plus cavitational ultrasound and sulphur hexafluoride microbubbles 
Figure 5.4  Percentage positive staining of cleaved caspase 3 comparing combination treatment 
with other controls. 
Figure 5.5  Z-stack imaging demonstrating green fluorescent protein expression in organotypic 
cultures treated with vaccinia virus and vaccinia virus plus ultrasound and sulphur 
hexafluoride microbubbles compared with untreated control 
Figure 5.6  Z-stack images from confocal microscopy demonstrating increased expression of 
green fluorescent protein on organotypic culture treated with vaccinia virus at 1x105 
pfu/ml plus cavitational ultrasound and microbubbles in comparison with virus 
treatment alone and untreated controls 
Figure 5.7  Z-stack images from confocal microscopy with no evidence of viral infection following 
combination treatment with vaccinia virus at 1x105 pfu/ml plus cavitational 
ultrasound and microbubbles 
Figure 5.8  IHC images of organotypic cultures derived from colorectal liver metastasis in one 
patient following immunohistochemical staining for both H&E and cleaved caspase 3 
for untreated control; cavitational ultrasound and microbubbles alone; vaccinia virus 
alone and vaccinia virus in combination with ultrasound and microbubbles 
Figure 5.9  Percentage positive staining for cleaved caspase 3 in a colorectal liver metastasis 
comparing no treatment, cavitational ultrasound and microbubbles; virus alone or 
virus in combination with ultrasound and microbubbles 
Figure 5.10  Percentage positive staining for cleaved caspase 3 in another patient with colorectal 
liver metastasis, comparing no treatment; cavitational ultrasound and microbubbles; 
virus alone or virus in combination with ultrasound and microbubbles 
Figure 5.11  Comparison of immunohistochemical staining for H&E in organotypic cultures from 
two patients that underwent combination treatment of vaccinia virus with 
cavitational ultrasound and sulphur hexafluoride microbubbles 
 
16 
 
List of Tables 
 
Table 1.1  Classification of colorectal cancer according to tumour depth (T stage), lymph node 
involvement (N stage) and presence of metastasis (M stage). Adapted from the TNM 
Classification of malignant tumours, 7th edition 39 
Table 1.2  Colorectal cancer stage according to the Union Internationale Contre le Cancer 
classification 
Table 1.3  A summary of clinical and pre-clinical trials using oncolytic vaccinia virus in the 
treatment of colorectal cancer 
Table 2.1  Vaccinia viruses supplied by Transgene SA, France and storage conditions 
Table 2.2  Cell culture media and additional supplements used in experiments 
Table 2.3  Cell lines used in tissue culture experiments 
Table 2.4  Primary and secondary antibodies used in the assessment of immunogenic cell death 
Table 2.5  Cell viability staining kit used in the assessment of immunogenic cell death 
Table 2.6  Primary antibodies used in western blotting 
Table 2.7  Secondary antibodies used in western blotting 
Table 2.8  Primary antibodies used for immunohistochemical staining 
Table 4.1  Summary of viability assessment for organotypic cultures prepared from resected 
tumour specimens in four patients 
 
 
 
 
 
 
 
 
 
17 
 
Chapter 1 
 
 
 
 
 
Introduction  
18 
 
Chapter 1 - Introduction 
 
1.1 Hallmarks of cancer 
 
Hanahan and Weinberg proposed six hallmarks of cancer that provide a framework for the 
understanding of the diversity of neoplastic diseases 1. As normal cells evolve towards a neoplastic 
state they acquire a succession of these hallmark capabilities. These hallmarks include: sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis 1. Recently two emerging 
hallmarks have been added to this list. These emerging hallmarks include: reprogramming of energy 
metabolism and evasion of immune destruction 1. 
The role that the immune system plays in resisting or eradicating formation and progression of cancers 
is still unresolved. The long-standing theory of immune surveillance proposes that cells are constantly 
monitored by the immune system which is responsible for the recognition and elimination of early 
stage cancer cells. The development of solid tumours suggests that these have managed to evade 
immune surveillance and therefore prevent eradication. 
The role of the immune system in the development of cancers appears to be validated by the increase 
in certain cancers in individuals that are immunocompromised 1. Recently there is increased evidence 
from genetically engineered mice and from clinical epidemiology suggesting that the immune system 
operates as a significant barrier to tumour formation and progression 1.  
Exposure of immune deficient mice to carcinogens found that tumours arose more frequently and/or 
more rapidly in the immune deficient mice compared with their immunocompetent controls. In 
particular, deficiencies in the development or function of CD8+ cytotoxic T lymphocytes (CTLs), CD4+ 
helper T cells, or natural killer (NK) cells each led to increases in tumour incidence 1. Mice with 
immunodeficiencies of both T cells and NK cells were even more susceptible to cancer development. 
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The results indicated that both the innate and adaptive immune system contribute to immune 
surveillance and are involved in tumour eradication 1. 
Transplantation experiments have also shown that cancer cells that have developed in 
immunodeficient mice are inefficient at initiating secondary tumours in synergistic immunocompetent 
hosts, whilst cancer cells from immunocompetent hosts are equally efficient at initiating transplanted 
tumours in both types of host 1. These results would suggest that highly immunogenic cancer cell 
clones are routinely eliminated from immunocompetent hosts leaving behind weakly immunogenic 
variants that grow and generate solid tumours 1. This can occur in both immunodeficient and 
immunocompetent hosts. In immunodeficient hosts highly immunogenic cancer cells are not depleted 
and these can develop into solid tumours along with the weakly immunogenic cancer cells 1. 
Epidemiological studies also support the existence of an antitumoral immune response in some forms 
of cancer 1. In patients with colonic and ovarian cancers that have high levels of CTLs and NK cells 
prognosis is improved when compared to patients with tumours lacking such abundance of killer 
lymphocytes 1. Additionally, some immunosuppressed organ transplant recipients have been seen to 
develop donor-derived cancers that were potentially held in check by a fully functional immune 
system in the donor 1.     
Tumour-host immunological interactions are complex. Highly immunological cancer cells may evade 
immune destruction through the disablement of immune components that have been produced to 
eliminate them 1. Cancer cells may paralyse infiltrating CTLs and NK cells by secreting transforming 
growth factor β (TGF-β) or other immunosuppressive factors 1. Other mechanisms also include the 
recruitment of inflammatory cells that are actively immunosuppressive such as regulatory T cells and 
myeloid-derived suppressor cells (MDSCs) which both suppress the action of cytotoxic lymphocytes 1. 
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1.2 Colorectal Cancer 
 
1.2.1 Epidemiology 
 
Colorectal cancer (CRC) is the third most common cancer in the developed world and the 4th most 
common cancer in the UK. The World Health Organisation (WHO) estimates that there are 
approximately 1 million new cases and 500,000 deaths annually worldwide 2. The lifetime incidence 
of CRC is 5% however both incidence and mortality have been found to be decreasing 2-4. At the time 
of diagnosis approximately 20-25% of patients with CRC will have already developed metastatic 
disease of which the most common site of metastasis is the liver 5. This is likely attributable to tumour 
spread via the portal system 6-8. Approximately 50% of patients will develop liver metastases during 
Hallmarks of cancer 
Resisting cell death 
Sustaining proliferative 
signalling 
Evading growth 
suppressors 
Enabling replicative 
immortality 
Activating invasion and 
metastasis 
Inducing angiogensis 
Reprogramming of energy 
metabolism 
Avoiding immune 
destruction 
Figure 1 Hallmarks of cancer adapted from Hanahan and Weinberg 1 
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their disease course 9. The natural history of metastatic disease is variable however without treatment, 
patients will have a median survival of less than 12 months 9,10.  
Of the patients that develop metastatic disease these can be classified into the following groups 
regarding treatment: resectable disease, unresectable disease or disease that can become resectable 
after initial treatment and downstaging of tumour 11. Of the 20-25% patients that are found to have 
metastatic colorectal cancer at the time of diagnosis, only 20% of patients will have liver metastases 
(CRLM) that are considered amenable to resection whilst the majority (80%) of patients have disease 
which is initially considered unresectable 12.  
Chemotherapy is a key treatment in the management of patients with CRLMs. It is used in patients 
with both disease that is considered resectable and unresectable. The aim of this treatment in patients 
with initially unresectable disease is to down-stage the tumour to enable curative resection. Standard 
chemotherapy regimens in the UK include 5-fluorouracil (5-FU)/leucovorin plus irinotecan (FOLFIRI) 
or oxaliplatin (FOLFOX). These regimens are successful in facilitating resection in 7 - 40% of patients 
that initially have unresectable disease 13.  
As well as chemotherapeutic agents, biological agents have also been developed based on our greater 
understanding of the biology of colorectal cancer (CRC). Two agents targeting two mechanisms: 
angiogenesis and epidermal growth factor have been developed. These are bevacizumab 
(angiogenesis), cetuximab and panitumumab (epidermal growth factor). The addition of these 
biological agents to established chemotherapy regimens improves response rates and can increase 
the number of candidates suitable for surgical resection 14.   
Although progress has been made in the development of effective agents in the treatment of 
metastatic colorectal cancer, survival remains stubbornly low. Patients not eligible to undergo curative 
resection will have a median survival of between 16- 24 months 15. Given that surgical resection gives 
the greatest probability of cure, the need for the development of further agents remains.  
22 
 
1.2.2 Risk factors 
 
Most CRC cases are sporadic however genetic and environmental factors are also important. There is 
no single risk factor that accounts for most cases of colorectal cancer, they are several that are either 
unmodifiable or modifiable and they often co-exist and interact. Unmodifiable risk factors include 
male sex, increasing age, inflammatory bowel disease as well as family history of disease. Modifiable 
risk factors include smoking, alcohol excess, increased dietary red meats, obesity and diabetes 16-22. 
The relative risk of developing colorectal cancer is higher in patients with one or more first-degree 
relative affected by the disease and in patients with inflammatory bowel disease 23,24.   
The other risk factors are more common and are also modifiable. These represent a greater proportion 
of disease burden for the population despite having lower relative risks compared to those of having 
a first-degree relative with the disease and a diagnosis of inflammatory bowel disease 25.   
Colorectal cancer has a significant heritable component with up to 35% risk potentially attributable to 
heritable factors 26. Hereditary forms of colorectal cancer such as familial adenomatous polyposis and 
hereditary non-polyposis colon cancer are determined by known genetic abnormalities but only 
account for less than 5% of colorectal cancers 27. Other than these well-known hereditary forms of 
colorectal cancer, genetic factors that determine the risk of disease development are poorly 
understood.  
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1.2.3 Molecular mechanisms of CRC pathogenesis 
 
One of the key aspects of the formation of CRC is the progression of normal glandular epithelial cells 
into invasive adenocarcinomas, which occurs following an accumulation of acquired and epigenetic 
changes 28. Fearon and Vogelstein proposed the polyp to cancer sequence in 1988 when describing a 
tumour progression model including a stepwise progression from the formation of benign neoplasms 
to the progression to more histologically advanced neoplasms and finally transformation into invasive 
carcinomas 29.  
With an increased understanding of the molecular pathogensis of CRC this initial model has been 
revised numerous times. Now it is also recognised that serrated polyps have the potential for 
malignant transformation as well as the tubular and tubulovillous adenomas that were initially 
described 30,31. Pre-malignant serrated polyps occur more frequently in the proximal colon and are 
associated with CpG island methylator phenotype (CIMP) which is recognised by having a high 
frequency of aberrantly methylated CpR dinucleotides. Conventional tubular adenomas are more 
commonly initiated by inactivation of the biallelic inactivation of the tumour-suppressor gene APC and 
to display chromosomal instability (CIN) recognised by aneuploidy and gains and losses of large 
portions of whole chromosomes. In addition, BRAF mutations, are more commonly found in tumours 
arising from the serrated pathway.  
1.2.4 Epidemiology 
 
Colorectal cancer is the third most common cancer worldwide and is the fourth most common cancer 
cause of cancer death with an estimated 1.4 million cases and 693,900 deaths in 2012 32,33. Its 
incidence increases with increasing age with a median age at diagnosis of 67 years in men and 71 years 
in women 34.  It is most prevalent in the western world such as in Europe, North America and Australia 
whilst its prevalence is less in Africa and Asia 33. The incidence of the disease is increasing in certain 
countries which have historically had a low-risk such as Kuwait and Israel in Western Asia, and the 
Czech Republic and Slovakia in Eastern Europe 35. Trends of the disease in high-risk countries have 
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been variable over the past 20 years with a gradual increase in incidence in countries such as Finland 
and Norway; a stable incidence in France and Australia, and a decreasing incidence in the USA 33. The 
reduction in colorectal cancer incidence seen in the US is confined to patients under the age of 50 and 
is attributed to increased screening for the disease and removal of pre-cancerous lesions 36. The 
increase in incidence seen in countries such as Kuwait, Israel, Czech Republic and Slovakia may reflect 
an increased prevalence of risk factors for the development of colorectal cancer such as an unhealthy 
diet, smoking and obesity, factors attributed to a western lifestyle 35.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Estimated age-standardised colorectal cancer incidence for men in 2008. Data from Globocan 2008 32 
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1.2.5 Prognosis 
 
The prognosis of colorectal cancer has improved steadily over time and in high income countries such 
as the USA, Canada and several countries in western Europe the 5-year survival has reached almost 
65%, whilst remaining less than 50% in low income countries 37,38. When colorectal cancers are 
detected early at a localised stage the 5-year survival rate is 90.3%. Once it has spread to regional 
lymph nodes or adjacent organs the 5-year survival reduces to 70.4%. By the time colorectal cancer 
has metastasised to distant organs such as the liver and lungs the 5-year survival rate drops to 12.5% 
34.   
 
1.2.5 Classification of colorectal cancer 
 
Colorectal cancers are classified according to the local depth of invasion (T stage), involvement of 
lymph nodes (N stage), and presence of distant metastases (M stage) (Table 1.1). These stages are 
combined to give the patient and overall disease stage defined as per Table 1.2. This provides the basis 
for decision on treatments to be given 39. 
Despite providing guidance on patient treatment and giving information with regards to prognosis the 
response of patients to treatment and their outcome is not predicted. In patients with stage III disease 
and stage II disease with additional risk factors for disease, adjuvant chemotherapy is recommended, 
however not all of these patients will benefit from this 25.   
 
 Definition 
T stage  
Tx No information available for local tumour infiltration 
Tis Tumour restricted to mucosa, no infiltration of lamina muscularis mucosae 
T1 Infiltration through lamina muscularis mucosae into submucosa, no infiltration into lamina 
muscularis propria 
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T2 Infiltration into but not beyond lamina muscularis propria 
T3 Infiltration into subserosa or non-peritonealised pericolic or perirectal tissue, or both; no 
invasion of serosa or into neighbouring organs 
T4a Infiltration of serosa 
T4b Infiltration of neighbouring organs 
N Stage  
Nx No information about lymph node involvement available 
N0 No lymph node involvement 
N1a Cancer cells detectable in 1 regional lymph node 
N1b Cancer cells detectable in 2-3 regional lymph nodes 
N1c Tumour satellites in subserosa or pericolic or perirectal fat tissue, regional lymph nodes not 
involved 
N2a Cancer cells detected in 4-6 regional lymph nodes 
N2b Cancer cells detected in 7 or more regional lymph nodes 
M stage  
Mx Information on metastatic spread not available 
M0 No distant metastases 
M1a Metastasis to one distant organ or distant lymph nodes 
M1b Metastasis to more than one distant organ or set of distant lymph nodes or peritoneal 
metastasis 
Table 1.1 Classification of colorectal cancer according to tumour depth (T stage), lymph node involvement (N stage) and 
presence of metastasis (M stage). Adapted from the TNM Classification of malignant tumors, 7th edition 39  
 
 
 
Overall disease stage T stage N stage M Stage 
Stage 0 Tis N0 M0 
Stage 1 T1/2 N0 M0 
Stage 2 
 
2a 
2b 
2c 
T3/4 
 
T3 
T4a 
T4b 
N0 
 
N0 
N0 
N0 
M0 
 
M0 
M0 
M0 
Stage 3 Any N positive M0 
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3a 
 
 
3b 
 
 
 
3c 
 
T1-T2 
T1 
 
T3-4a 
T2-3 
T1-2 
 
T4a 
T3-T4a 
T4b 
 
N1 
N2a 
 
N1 
N2a 
N2b 
 
N2a 
N2b 
N1-N2 
 
M0 
M0 
 
M0 
M0 
M0 
 
M0 
M0 
M0 
Stage 4 
 
4a 
4b 
Any 
 
Any 
Any 
Any 
 
Any 
Any 
M positive 
 
M1a 
M1b 
Table 1.2 Colorectal cancer stage according to the Union Internationale Contre le Cancer classification 39 
 
1.2.6 Pathogenesis of colorectal cancer 
 
The pathogenesis of colorectal cancer is heterogeneous. The molecular mechanisms are clinically 
important as they are related to patient prognosis and patient response to treatment 40. 
1.2.6.1 The adenoma carcinoma sequence 
 
Colorectal cancer develops over several years and often arises from pre-malignant lesions, most 
commonly from pre-malignant dysplastic adenomas. Mutations of the tumour suppressor antigen 
presenting cell (APC) gene occur early in the process of cancer formation and occur in the majority of 
adenomas 25. The adenoma-carcinoma sequence (Figure 1.2) is further developed through mutations 
activating the KRAS oncogene and mutations inactivating the tumour suppressor gene, p53 28. These 
typical mutations are often accompanied by chromosomal instability through changes in chromosome 
number and structural changes 41. 
28 
 
 
 
 
 
 
 
 
 
Sporadic cancers however do not all have these characteristic gene mutations and develop through 
different pathways and events. Cancers like these include those that have developed from serrated 
precursor lesions. These are often characterised by the CIMP phenotype and activating mutations of 
the BRAF oncogene 42. 
1.2.6.2 Hereditary colorectal cancer 
 
Hereditary colorectal cancer accounts for up to 5% of all colorectal cancers 27. The two most common 
forms are familial adenomatous polyposis coli (FAP) and hereditary non-polyposis colon cancer 
(HNPCC). Both of these are inherited in an autosomal dominant fashion. HNPCC associated cancers 
show evidence of mismatch repair deficiency and have a high level of microsatellite instability 27. FAP 
on the other hand follow the typical adenoma-carcinoma sequence 27.  
 
 
Mucosa 
Submucosa 
Muscularis Propria 
Normal 
Colon 
Hyperproliferative 
epithelium 
Adenoma Carcinoma 
APC 
mutation 
KRAS 
mutation 
p53 mutation 
Figure 1.4 Representative diagram of the adenoma-carcinoma sequence in the development of colorectal cancer 
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1.2.7 Markers of prognosis 
 
1.2.7.1 Microsatellite instability 
 
Microsatellites are a type of simple DNA sequence repeat. Microsatellite instability (MSI) is a unique 
molecular alteration induced by deficiencies in the DNA mismatch repair system characterised by 
unstable microsatellites that have variable lengths 43. The MSI phenotype is one of the main molecular 
subtypes of colorectal cancers and accounts for 12-20% of colorectal cancers in Western countries 
and 6-13% colorectal cancers in Eastern countries 43. Hereditary colorectal cancers such as hereditary 
non-polyposis coli that are caused by germline mutations in mismatch repair genes have a high level 
of microsatellite instability (MSI-H) 43. These cancers account for up to 5% of all colorectal cancers. 
Patients with sporadic colorectal cancers with an MSI-H phenotype account for up to 15% of all 
colorectal cancers 43. Patients with the MSI-H phenotype have a better prognosis compared to patients 
with microsatellite stability 25. The MSI-H phenotype also gives an indication of patient response to 
treatment with chemotherapy as these patients have been shown not to benefit from adjuvant 
chemotherapy treatment with 5-fluorouracil but have an improved response to chemotherapy that is 
irinotecan based 44.  
1.2.7.2 Immune response in colorectal cancer 
 
Patients with a high level of microsatellite instability have an associated high level of tumour-
infiltrating lymphocytes. This is likely to occur due to the deficiency of mismatch repair genes and the 
production of antigens that are subsequently induced, leading to activation of the hosts immune 
response 44. Patients with tumour infiltration with CD45R0-positive and CD3-positive lymphocytes 
were found to have a better prognosis regardless of cancer stage compared to those with low 
lymphocyte infiltration, who had a poorer prognosis 45.   
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1.2.7.3 KRAS mutation 
 
KRAS is the human homolog of the Kirsten rat sarcoma 2 virus oncogene. This encodes a small GTP-
binding protein that acts as a self-inactivating signal transducer by cycling from GDP to GTP bound 
states in response to the cell surface receptor EGFR. Activation of EGFR stimulates the RAS/RAF/MAPK, 
STAT and PI3K/AKT pathways. Together these pathways are involved in the regulation of cellular 
proliferation, adhesion, angiogenesis and survival 46.  Anti-EGFR targeted treatments include 
cetuximab and panitumumab. The KRAS oncogene can harbour oncogenic mutations in between 30% 
and 50% of colorectal cancers and is a marker of poor prognosis when present as well as a sign of 
resistance to treatment with EGFR inhibitors 46.   
1.2.8 Diagnosis of colorectal cancer 
 
Patients with symptoms concerning for colorectal cancer are referred on a ‘two-week’ basis in the UK. 
Symptoms concerning for this diagnosis include an unexplained change in bowel habit; rectal bleeding, 
a palpable mass and anaemia as well as taking in to consideration patient age and comorbidities. 
Patients with a suspected diagnosis of colorectal cancer are offered either a CT colonography or an 
optical colonoscopy to confirm the diagnosis. Although histological diagnosis is desirable, if a lesion 
that is highly suspicious for malignancy is seen on imaging from CT colonography then histology is not 
essential prior to surgery. Only in cases of rectal tumours when surgery may result in the formation of 
a permanent stoma or an ultra-low anterior resection, or if neo-adjuvant treatment is being planned 
47. 
1.2.9 Staging of disease 
 
Assessment of local extent of colon cancer is assessed using computed tomography (CT). This imaging 
allows clinicians to assess the extent of spread in relation to the bowel wall and adjacent organs. This 
imaging also is key to planning surgical resection and can guide neo-adjuvant treatment in patients 
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that have very locally advanced disease or if their disease is initially not considered to be resectable 
47. 
1.2.10 Metastatic colorectal cancer 
 
At the time of diagnosis approximately 20% of patients will present with distant metastatic disease 48. 
Colorectal cancers most commonly metastasize to the liver, as well as to the lungs and peritoneum. It 
is therefore important to perform imaging of the liver and routine imaging with a CT scan incorporating 
the chest, abdomen and pelvis is usually sufficient, however further characterisation can be 
performed with magnetic resonance imaging for liver lesions that are equivocal on CT scanning 47. 
Patients that present with metastatic colorectal cancer can be divided into three groups: patients with 
surgically resectable disease, patients that can become resectable following initial treatment and 
those are not resectable. Only 10-20% of patients with metastatic colorectal liver metastases are 
candidates for surgical resection, with the vast majority presenting with liver metastases that are not 
amenable to resection 14. Patients treated with chemotherapy that are subsequently able to undergo 
surgical resection have long-term survival rates that are comparable to those patients that are 
considered resectable initially 14. This has led to an increased use of chemotherapy and biological 
agents in the treatment of metastatic colorectal cancer with a subsequent increase in the numbers of 
patients now considered suitable to undergo surgical resection.   
1.2.11 Management of patients with metastatic colorectal cancer  
 
Patients with a diagnosis of colorectal cancer are managed by multi-disciplinary team that includes 
surgeons, oncologists, gastroenterologists, radiologists, pathologists as well as specialist nurses. In 
patients without metastatic disease the multi-disciplinary team assess in the first instance whether 
the tumour is able to be surgically resected and subsequently an assessment is made as to whether 
there they should receive chemotherapy post-operatively. 
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1.2.11.1 Surgery 
 
Surgery can be performed to cure patients with colorectal cancers. This can be performed in open 
surgery or can be undertaken in a minimally-invasive way using laparoscopy (key-hole surgery). The 
benefits of laparoscopic surgery include a faster return of bowel function, shorter stay in hospital as 
well as a reduced requirement for a blood transfusion. It does however take longer to perform surgery 
and is more expensive than traditional open surgery. Despite these differences both approaches 
achieve the same long-term results 49. During surgery to remove colon cancer the tumour as well as 
surrounding lymph nodes are taken. The extent of surgery is determined by the location of the tumour 
in the colon and the associated blood vessels that supply the area of colon in which it is situated. 
Difficulties in deciding who is suitable to undergo surgical resection remain in clinical practice. The 
criteria for resectability are not standardised and are related to the experience of the surgeon and the 
multi-disciplinary team. Current guidelines state that resection should be considered for solitary 
metastases and metastases confined to the liver parenchyma 13. The remaining liver needs to be 
healthy and there must be a sufficient volume remaining post-resection to avoid post-hepatectomy 
liver failure (approximately 25%) 50. Extra-hepatic disease is no longer an absolute contra-indication 
for resection over colorectal liver metastases. It is also possible to perform multiple hepatic resections, 
providing that there is sufficient remaining healthy liver with evidence of a similar survival benefit to 
that of primary hepatic resection 51,52. Contraindications to surgery include unresectable extra-hepatic 
disease, extensive hepatic tumour burden or if a patient is not fit enough to undergo the procedure 
14.     
1.2.11.2 Adjuvant treatment 
 
The risk of disease recurrence in patients with stage III colorectal cancers is between 15-50% 25. It is 
therefore recommended that all these patients receive chemotherapy following their surgery 
(adjuvant chemotherapy), providing they do not have any contra-indications to this. Fluorouracil is the 
mainstay of chemotherapy treatment and has been shown to reduce recurrence rates by 17% and to 
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improve overall survival by 13-15% 53. In combination with oxaliplatin, the 5-year disease free survival 
and overall survival improved by 5.9% and 2.5% respectively 54. 
1.2.11.3 Chemotherapy 
 
Most patients that present with colorectal liver metastases may present with extensive disease which 
may initially not be considered resectable. This group of patients will receive systemic chemotherapy, 
either given with palliative intent or as a neo-adjuvant treatment with the aim of downsizing tumour 
burden and converting patients to operable disease. Standard chemotherapy regimens for patients 
with colorectal liver metastases are FOLFOX) or FOLFIRI. These chemotherapy regimens can help 
facilitate resection in up to 40% of patients 13. FOLFOX has been shown to reduce the size of liver 
metastases by more than half in 59% of patients treated whilst facilitating curative resection in 38% 
of patients 55. A recent randomised trial has found an increased conversion rate to resectability and 
increased overall survival following treatment with FOLFIRINOX (5-fluorouracil/leucovorin, oxaliplatin 
and irinotecan) chemotherapy compared with other regimes in patients with initially unresectable 
metastatic colorectal cancer 56.   
In patients with resectable metastatic disease, chemotherapy is helpful as it can reduce the incidence 
of disease relapse through the eradication of occult disease 14. The recent EORTC 40983 trial that 
compared patients treated with both neo-adjuvant and adjuvant chemotherapy with FOLFOX4 
chemotherapy to those undergoing surgery alone, found that there was an improvement in 
progression free survival in those treated with chemotherapy but ultimately no improvement in long-
term survivorship between the two groups 57.   
1.2.11.4 Biological treatment 
 
An increased understanding of the biology of colorectal cancer has led to the development of 
biological therapies targeting angiogenesis and epidermal growth factor receptors. The addition of 
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these agents along with standard chemotherapy regimens aim to increase the number of patients that 
are eligible for surgery.  
1.2.11.5 Anti-angiogenesis agents 
 
The addition of bevacizumab to first and second line chemotherapy in the treatment of metastatic 
colorectal cancer has been shown to improve both progression-free and overall survival 14. Due to 
concerns with regards to wound healing complications, data on its peri-operative use is limited. 
1.2.11.6 Anti-epidermal growth factor receptor agents 
 
Cetuximab and panitumumab are active in patients with metastatic colorectal cancer as single-line 
agents as well as in combination with chemotherapy. These agents’ activity is confined to patients 
with RAS wild-type tumours. Several randomised trials have evaluated the effects of cetuximab in 
patients with unresectable colorectal liver metastases. These found, to varying degrees, an increase 
in resection rates with an overall resection rate across these trials of 60-79% 58-61.  
1.2.11.7 Other treatments for colorectal liver metastases 
 
Radiofrequency ablation (RFA), selective internal radiation therapy (SIRT) and stereotactic ablative 
radiotherapy (SABR) are other modalities that can be utilised in the treatment of unresectable liver 
metastases. RFA is a localised thermal treatment technique that is designed to induce tumour 
destruction by heating the tumour tissue to temperatures exceeding 60°C 62. This is a well-accepted 
and documented treatment for patients with inoperable colorectal liver metastases. SIRT involves 
embolising radiolabelled spheres (SIR-Spheres) into the arterial supply of the liver 63. SABR is a non-
invasive, ablative treatment approach for patients with liver metastases that are ineligible for 
resection or thermal ablation. It delivers extremely high biological doses of radiation to limited liver 
volumes with high precision and in few fractions which minimises normal tissue toxicity and maximises 
local control 64. 
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1.2.11.8 Multi-disciplinary team approach to the management of colorectal liver metastases 
 
The management of patients with cancer is addressed by multiple specialists given their complex 
needs. The management of patients with metastatic colorectal cancer is undertaken by colorectal 
multi-disciplinary teams including a specialist hepatobiliary team that can provide the additional 
expertise for patients with liver metastases. The team comprises colorectal and hepatobiliary 
surgeons, oncologists, diagnostic and interventional radiologists, histopathologists and nurse 
specialists. Regular MDT discussions take place to ensure optimal treatment choices are made over 
their disease course and to review opportunities for potentially curative resection of their disease 
during their treatment 14. Throughout the patient journey, nurse specialists are key to providing them 
with support, advice and information. 
 
1.3 Oncolytic virotherapy 
 
1.3.1 Introduction 
 
Oncolytic virus (OV) immunotherapy utilises viruses that replicate within tumour cells naturally or are 
modified to selectively replicate within tumour cells. It has long been recognised that viruses have the 
ability to kill cancer cells and recently clinical trials have shown evidence of therapeutic benefit in 
patients with multiple tumour types 65-67. The increase in interest in oncolytic viruses is a consequence 
of increased understanding of tumour and viral biology, tumour immunology and molecular genetics.  
Following a successful phase III clinical trial the first oncolytic virus was approved for use in clinical 
practice in the United States in the treatment of patients with advanced melanoma with further 
development of oncolytic virotherapy anticipated based on the success of this 67. 
Viruses share several properties including a genetic element consisting of single- or double-stranded 
DNA or RNA and are able to infect host cells and replicate. The result of viral infection varies depending 
on the interaction between the virus and host immune system, the pathogenicity of virally encoded 
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genes and the ability of the virus to replicate. An increased understanding of cell entry, viral 
replication, immune response and lytic versus latent infections has increased the interest in using 
these viruses in the treatment of human diseases. OVs differ from traditional vaccines in that they 
directly infect and lyse tumour cells. They do not require defined antigens to be included in the vector 
as dying tumour cells may release tumour-associated antigens (proteins derived from tumour cells 
that can be recognised by the immune system) with a resultant induction of the host immune 
response. OVs also provide additional danger signals (nuclear and cytosolic proteins) that are released 
by cells during injury or necrosis and which stimulate both the innate and adaptive immune system, 
promoting an efficient anti-tumour immune response 68.  
The mechanism by which anti-tumour activity is mediated by OVs is not completely understood. Two 
distinct mechanisms are thought to contribute to this; these are, selective replication within and lysis 
of tumour cells in situ and activation of systemic anti-tumour immunity 68.  
Oncolytic viruses have the ability to enter both normal and cancer cells, however abnormalities in 
cancer cell response to stress, cell signalling and homeostasis allow the virus to preferentially replicate 
within them 1. Mechanisms by which viruses are detected and cleared from cells can also be aberrant 
in cancer cells, resulting in increased viral replication. An example of one such mechanism is protein 
kinase R (PKR); this is a critical factor involved in clearing intracellular viral infections. The absence of 
this protein in some cancer cells results in increased viral replication following infection. There is 
variation between cancer types and this difference has an effect on the activity of oncolytic viruses. 
The response of the immune system to oncolytic virus also plays a role in its efficacy however there is 
a balance between the promotion of an immune response versus the neutralising effect of host 
antiviral responses following infection. Viruses are able to help promote an immune response against 
cancer cells by allowing tumour antigen presentation during active viral infection; conversely, 
neutralising host antiviral responses can dampen the viral effect and block replication with a resultant 
reduction of viral infection in tumour cells.  The outcome of infection is determined by the balance of 
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these pathways 68. The activation of systemic immunity towards cancer cells results in effects at both 
the primary tumour as well as distant sites of metastatic disease.  
Many viruses have been proposed as vectors for oncolytic virus immunotherapy. However, two 
viruses, T-VEC (modified herpes simplex virus) and H101 (modified adenovirus) have been approved 
for clinical use in the United States and China respectively.  
1.3.2 Mechanism of oncolytic virus activity 
 
The majority of OVs directly lyse and kill cancer cells. Cell entry of virus, replication and cell response 
to viruses determine the efficiency of this 69. The ability to lyse cancer cells is also dependent on the 
type of virus, virus concentration, tropism and susceptibility of cancer cells to the different modes of 
cell death 68. 
Normal cells have various signalling pathways that detect and clear viral particles. These pathways can 
be stimulated by release of interferons, or through the activation of toll-like receptors (TLRs). These 
are present on the cell surface as well as within cells and are pattern recognition receptors that 
become activated in response to pathogen-associated molecular patterns (PAMPs) that are common 
to viruses. Stimulation of TLRs leads to the activation of the host cell antiviral response as well as the 
systemic innate immunity 68. Host factors involved in clearance of oncolytic virus include tumour 
necrosis factor (TNF) associated factor 3 (TRAF), interferon (IFN) related factors 3 and 7 and retinoic 
inducible gene 1 (RIG1). These stimulate the JAK (Janus Kinase) – STAT (signal transducer and 
activation of transcription) pathway that coordinates antiviral activity in cells that are infected. There 
is a resultant reinforcement of interferon release and this activates PKR activity. PKR is an intracellular 
protein that when activated stops protein synthesis within the cell, promotes cell death and viral 
clearance. As cancer cells are abnormal they may have aberrant interferon pathway signalling and PKR 
activity which prevents viral clearance 68. 
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Various viruses are also able to block apoptosis through the manipulation of aberrant signalling 
pathways within tumour cells (Figure 1.3). Replication of most oncolytic viruses results in cell death 
with a subsequent elimination of cancer cells and initiation of a systemic immune response 68. 
 
 
 
Figure 1.3 Promotion of viral spread and immune evasion by oncolytic virus in cancer cells. Once a cell detects viral presence 
a signalling cascade through several interferons (IFN) elements, janus kinase (JAK), signal transducer and activation of 
transcription (STAT), and interferon regulatory factor 9 (IRF9) leads to a programmed transcriptional pathway that leads to 
a reduction in viral spread and targets infected cells for apoptosis or necrosis. Local interferon produced by the innate immune 
response can also result in antiviral activity through the interferon receptor (IFN receptor). Type I IFNs signal through the JAK-
STAT pathway which results in the upregulation of cell cycle regulators protein kinase R (PKR) and interferon regulatory factor 
7 (IRF7). These limit viral spread through binding to viral particles and triggering type 1 IFN pathways that lead to abortive 
apoptosis and alerting the immune system to the presence of viral infection. Cancer cells may downregulate key parts of the 
type 1 IFN signalling pathway with a resultant limitation in the pro-apoptotic effects. The figure demonstrates the areas that 
vaccinia virus affects these pathways to prevent elimination and to promote viral spread. Figure adapted from Kaufmann et 
al 68. 
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1.3.2.1 Initiation of systemic anti-tumour immunity by oncolytic virotherapy 
 
Following oncolysis, tumour cells release tumour associated antigens. These are then able to promote 
an adaptive immune response that mediates an anti-tumour effect at distant tumour sites. Following 
oncolytic cell death tumour cells also release viral PAMPs as well as danger associated molecular 
patterns (DAMPs) such as heat shock proteins (HSPs), high mobility group box 1 proteins (HMGB1), 
calreticulin, adenosine triphosphate (ATP), and uric acid. They also release cytokines that promote the 
maturation of antigen presenting cells such as dendritic cells. These cytokines include type 1 
interferons, tumour necrosis factor-α (TNF- α), interferon gamma (IFN-γ) and interleukin-12 (IL-12) 68. 
These then activate CD4+ and CD8+ T cell responses. CD8+ T cells can develop into cytotoxic effector T 
cells that move to areas of tumour growth and mediate anti-tumour immunity following recognition 
of tumour antigens 68. As viruses induce a natural immune response from the host, this can result in 
oncolytic virus clearance by neutralising antibodies and through cytotoxic T-cell mediated immune 
response. 
Release of tumour associated antigens in combination with cytokines and DAMPs can be beneficial in 
the generation of an immune response against cancer cells. This is particularly important in the 
generation of an anti-cancer immune response to tumours that are distant to the site of virus 
administration 68. The innate immune response can also be activated by Type 1 interferons and DAMPs 
as they directly activate natural killer cells. Natural killer cells target cancer cells as these cells have a 
downregulation of major histocompatibility complex (MHC) class 1 expression. There is a balance to 
the effect of the activation of NK cells, whilst these are able to target cancer cells as described they 
can also eliminate virally infected cells, with a subsequent reduction in viral efficacy 68. The factors 
influencing the balance between immune-mediated clearance of virus and the induction of anti-
tumour immunity are incompletely understood. 
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Figure 1.4 Induction of the immune system by oncolytic virus. Following infection of cancer cells by oncolytic virus 
endoplasmic reticulum and genotoxic stress occurs within the infected cells. Reactive oxygen species and antiviral cytokines 
are produced and then released from the infected cells with subsequent initiation of the immune system. Immune cells such 
as antigen presenting cells, CD8+ T cells and natural killer cells are stimulated. Oncolysis of the infected cancer cell occurs and 
this causes a release if viral progeny, pathogen associated molecular patterns (PAMPs), which include: viral capsids, viral 
proteins and viral DNA/double stranded or single stranded RNA; danger associated molecular patterns (DAMPs) which include 
heat shock proteins (HSP), high mobility group box 1 protein (HMGB1), calreticulin, adenosine triphosphate (ATP) and uric 
acid; and tumour associated antigens/ neoantigens. PAMPs and DAMPs stimulate the immune system through the activation 
of Toll-like receptors. Antigen presenting cells take up and tumour associated antigens and neoantigens which also stimulates 
the immune system whilst the release of viral progeny acts to spread viral infection further. These events stimulate the 
immune system to act against cancer cells infected with virus and to generate immune responses to tumour associated and 
neo-antigens which may be displayed on cancer cells that are not infected by oncolytic virus. Figure adapted from Kaufman 
et al 68. 
 
1.3.2.2 Overcoming cancer-mediated immune evasion 
 
Tumour cells have developed the ability to evade the immune system in several ways. These include 
the expression of immune inhibitory receptors on cell surfaces that inactivate effector immune cells. 
These inhibitory receptors secrete factors that promote the recruitment of immune suppressive cells, 
these factors include IL-10, TGF-β as well as indoleamine-2,3-dioxygenase (IDO). The immune 
suppressive cells that are recruited as a result include tumour associated macrophages and MDSCs.  
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In order to overcome inhibitory responses OVs modify the inhibitory environment through several 
mechanisms that alter the cytokine milieu as well as the type of immune cells present in the tumour 
microenvironment. These changes result in increased recognition of tumour cells by the immune 
system as well as eradication of these cells. They can also increase spread of tumour-associated 
antigens 68. In the presence of DAMPs and following engagement of TLRs there is an increased level of 
type 1 interferons and other inflammatory mediators with a resultant increase in systemic immunity 
against cancer cells. 
The lysis of cancer cells can lead to the expression of previously concealed antigens, termed neo-
antigens. The expression of these leads to their detection by antigen presenting cells, triggering an 
immune response against these new antigens. If T-cell clones are generated then these may be able 
to kill antigen-expressing cells that were not originally infected by the virus 68. 
1.3.3 Factors affecting oncolytic virus spread 
 
Barriers that reduce the spread of OVs include elevated interstitial pressures, dense connective tissue, 
necrotic tissue, calcification, and reduced vasculature 70. In an attempt to overcome these physical 
barriers, the majority of clinical trials utilising OVs have opted to administer them intratumorally. In 
clinical practice intratumoral administration of OV is limited as it is only applicable to those tumours 
that are accessible to injection with OV. However, the phase III clinical trial of talimogene 
laherparepvec (T-VEC) did demonstrate that a systemic anti-tumour response could be generated 
from the injection of an index tumour with distant sites of non-injected disease responding to 
intratumoral OV adminsitartion, therefore overcoming physical barriers 67.  
The size of tumours as well as the heterogeneity of the tissue can also affect viral biodistribution 70. 
Oncolytic viruses have the ability to infect cancer-associated fibroblasts (CAFs), however infection of 
these does not result in viral replication. The infection of these fibroblasts can therefore reduce 
delivery of oncolytic virus to cancer cells 71.  
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1.3.4 Oncolytic virus development 
 
As viruses are live, the approach to tumour cell targeting as well as the attenuation of viral 
pathogenesis are important considerations in OV development. It is desirable for OVs to have limited 
viral immunogenicity whilst maintaining tumour cell killing with subsequent immune activation. 
Recombinant engineering has permitted the development of effective oncolytic virus strategies. 
1.3.4.1 Cancer cell targeting of oncolytic viruses 
 
Many oncolytic viruses have a natural tropism for aberrant cell surface proteins that are expressed on 
cancer cells. Examples of these include intracellular adhesion molecule 1 (ICAM-1) and decay 
accelerating factor (DAF) for coxsackie virus and the herpesvirus entry mediator (HVEM) and nectins 
for the entry of herpes simplex virus into cancer cells 72-74.  
Oncolytic viruses can also be engineered so that they target specific cell surface receptors that are 
expressed on cancer cells. For example, a measles virus has been engineered to target certain tumours 
that express the tumour antigen carcinoembryonic antigen (CEA). The virus has been engineered to 
express a single-chain antibody that recognises expressed CEA 75. Another OV adenovirus that is 
currently being investigated in clinical trials has been engineered to target integrins that are highly 
expressed on the surface of ovarian cancer cells 76.   
1.3.4.2 Utilising aberrant signal pathways in cancer for oncolytic virotherapy 
 
Several molecular targets promote virus accumulation and replication within cancer cells. There is 
frequent overexpression of the B cell lymphoma (BCL) cell survival proteins. One of these proteins 
(BCL-XL) is targeted by Newcastle Disease virus as its expression prevents apoptosis, enabling viral 
replication and spread 77.  
The RAS signalling pathway is another pathway that has been targeted in OV therapy (Figure 1.5). The 
RAS signalling pathway is involved in the regulation of several aspects of carcinogenesis including 
resistance to cell death and cell proliferation. This has been targeted by the OVs vaccinia virus and 
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reovirus as these have a natural selectivity for cancer cells with an over-active pathway 78,79. In healthy, 
normal cells, there is activation of the PKR pathway following viral entry. Once activated this pathway 
inhibits protein translation and prevents the production of virus particles halting viral spread 68. Cancer 
cells that have a RAS transformation do not activate the PKR pathway and this results in cell infection 
by OV and subsequent replication, leading to oncolysis ultimately 68. Vaccinia virus depends on 
epidermal growth factor receptor (EGFR)-induced RAS signalling for viral replication. This virus 
encodes ligands that trigger EGFR signalling and in cancer cells that over-express EGFR there is 
increased viral infection through the EGFR-induced RAS signalling pathway 78.  
Cancer cells can also have defects in their antiviral defences through type 1 interferon signalling. Type 
1 interferons are essential in antiviral responses in healthy cells through the promotion of host 
immune response against the virus and through the reduction of cellular proliferation and activation 
of the apoptotic protein p53. In many cancers this pathway is inactivated through the reduction of 
type 1 interferons or by limiting signalling via reduced receptor expression or through alteration of 
downstream signalling. Oncolytic viruses therefore have an increased specificity for cancer cells and 
in cells in which the type 1 interferon response is limited (as in normal healthy cells) there is viral 
clearance through interferon-mediated responses 68. 
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Figure 1.5 Targeting of the Ras signalling pathway by oncolytic vaccinia virus. In cancer cells regulation of cell cycle and 
cellular proliferation are disrupted. This promoted viral replication and encourages oncolytic virus-induced cell death. 
Increase in the GTPase Ras blocks protein kinase R (PKR) and can facilitate oncolytic virus replication through the inhibition 
of apoptosis in Ras-mutant cancer cells. In the cell nucleus there is a resultant decrease in the cell cycle regulators p16 and 
retinoblastoma which renders cancer cells more susceptible to oncolytic vaccinia virus. Figure adapted from Kaufman et al 
68. 
 
1.3.4.3 Limiting the viral pathogenesis of oncolytic viruses 
 
As oncolytic viruses are live particles they have the potential to be able to cause host toxicity and even 
latent disease and subsequent chronic infection. The potential pathogenicity is dependent on the 
virus, natural or engineered attenuation factors and the host immune response. Most oncolytic 
viruses utilise attenuated vectors or less virulent strains of virus to limit patient toxicity 68. 
Talimogene leherperecvec (T-VEC) is an example of an engineered attenuated virus. Herpes simplex 
virus is known to cause neurovirulence and latent infection. The viral gene product ICP34.5 mediates 
toxicity as it counteracts the type 1 interferon response and antagonises PKR signalling in non-dividing 
cells 80. 
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Vaccinia virus has also been attenuated to limit its activity to cancer cells. In non-attenuated vaccinia 
virus infections, the viral protein vaccinia growth factor (VGF) is secreted and acts on the host EGFR 
activating the RAS signalling pathway. This activation results in increased production of thymidine 
kinase through increased cell proliferation. Thymidine Kinase helps to promote viral replication 81. 
Deletion of VGF results in attenuation of vaccinia virus, permitting cell replication in cells with aberrant 
EGFR-RAS signalling such as rapidly proliferating cancer cells 81. 
Vaccinia virus can also be attenuated through the deletion of the B18R protein that is responsible for 
blocking type 1 interferon signalling 82. This results in the susceptibility of normal healthy cells to the 
host type 1 interferon response with subsequent limitation of the viral infection. As cancer cells 
commonly disrupt the type 1 interferon pathway in order to evade the immune system they are 
susceptible to viral infection and oncolysis. B18R deletion may also increase vaccinia virus activity as 
type 1 interferons produced as a consequence of viral infection are not blocked by the B18R protein 
83. 
1.3.4.4 Stimulation of the immune system by oncolytic viruses 
 
Stimulation of the immune system by OVs to clear tumour is a key aspect of the anti-cancer effects of 
oncolytic viruses. Several approaches have been utilised to stimulate this anti-tumour response in 
oncolytic virotherapy including the viral expression of pro-inflammatory cytokines or T-cell co-
stimulatory molecules such as with the vaccinia virus JX-594 that expresses granulocyte macrophage 
colony stimulating factor (GMCSF), promoting robust T cell responses 84. An oncolytic adenovirus that 
expressed heat shock protein 70 (HSP70) has been used to increase antigen presentation. This is 
because HSP70 increases the delivery of proteins to proteases with a resultant increase in protein 
breakdown and processing 85. In the use of herpes simplex virus as an oncolytic virus such as with T-
VEC there has been a deletion of the ICP47 protein. This protein acts to block the function of the 
transporter associated with antigen processing. The action of this protein results in a reduced 
presentation of infected cells to CD8 T cells 86. 
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1.3.4.5 Limiting viral clearance by the host immune system 
 
Whilst activation of the immune system is an important aspect of creating a host immune response 
towards cancer cells, there is a balance at play as the same immune response can result in rapid 
clearance of virus from the host and a subsequent reduction in its efficacy. Through vaccination or 
naturally, we become exposed to oncolytic viruses and generate neutralising antibodies, thus 
generating cellular immunity against those that we have been exposed to.  
One mechanism by which this can be overcome includes the utilisation of various serotypes of virus. 
It is possible to switch serotypes between administration for certain viruses such as adenovirus and 
vesicular stomatitis virus (VSV) which prevent the development of neutralising antibodies 68. Other 
ways that this can be overcome include covalent conjugation with polyethylene glycol of the viral coat 
and polymer coating to reduce binding of antibodies to viruses and subsequent neutralisation 87,88. 
Another approach is to alter the hosts immune response towards oncolytic viruses. Pre-clinical studies 
have shown a reduced oncolytic viral neutralisation through the dampening of the host immune 
system with cyclophosphamide. Pre-treatment with cyclophosphamide prior to oncolytic virotherapy 
with measles virus and VSV resulted in a reduction of host circulating antiviral antibodies 89. 
1.3.4.6 Improving oncolytic virus tumour infiltration  
 
As well as trying to limit oncolytic virus neutralisation and elimination following administration 
strategies have been sought to optimise their distribution and bioavailability. In an attempt to improve 
viral penetrance proteolytic enzymes have been applied to tumours prior to treatment with oncolytic 
virus to break-down the extracellular matrix that poses a barrier to oncolytic virus treatment 90,91. 
Oncolytic viruses have also been engineered so that they express proteolytic enzymes such as 
hyaluronidase with studies showing an increased efficacy of virus expressing proteolytic enzyme 
compared with parental oncolytic virus alone 92.  
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1.3.5 Oncolytic viruses in clinical development 
 
There are currently two oncolytic viruses that have been approved for clinical use. These include the 
FDA and NICE approved herpes simplex virus T-VEC, and the Chinese approved adenovirus H101. 
Several oncolytic viruses are discussed below before focusing more closely on the use of vaccinia virus 
as an oncolytic virotherapy. 
1.3.5.1 Adenovirus 
 
Adenovirus is a non-enveloped double-stranded DNA virus with a 35Kb genome. Due to its large 
genome it is able to tolerate multiple engineering modifications. Most of the population will have had 
exposure to the virus and will therefore be seropositive for virus exposure.  
Adenovirus enter the cell using the coxsackie-adenovirus receptor before being trafficked to the cell 
nucleus where it expresses its early genes required for viral propagation. These early genes encode 
the proteins E1A and E1B that target the tumour suppressor gene p53 and retinoblastoma associated 
protein, promoting cell-cycle entry. In healthy cells targeting of these host cell cycle regulators results 
in abortive apoptosis and viral clearance 68.  
Treatment with adenoviruses have resulted in very few adverse events. Coupled with its safety profile, 
the relative ease with which it is possible to modify its genome without adversely affecting its 
infectivity have made them a good virus for development. Adenoviruses have been engineered to 
target cell surface receptors that are upregulated on cancer cells. A modification to the adenovirus 
Ad5/3-Δ24 enabled cell entry through binding of cell receptors αvβ3 and -5 as well as through the 
binding of the coxsackie-adenovirus receptor (CAR). This modification is beneficial in the treatment of 
ovarian cancer where the expression of the CAR receptor is variable and the expression of the 
receptors αvβ3 and -5 is high 93,94. Further adenovirus modifications include the combining of 
serotypes termed ‘mosaics’. CD46 is expressed on normal cells and prevents complement recognition 
and elimination. Cancer cells can also express this in order to prevent recognition and elimination by 
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complement. One adenovirus serotype, Ad35 gains cell entry through the binding of CD46 95. A mosaic 
adenovirus has been developed with the CAR-binding sequence of Ad5 replaced with the CD46 binding 
of Ad35, this modification enhances the cytocidal effect of the oncolytic adenovirus in cancers with a 
low expression of CAR 96. 
The adenovirus H101 has a deletion in the portion of E1B that inactivates p53. This adenovirus has 
been approved for clinical use in the treatment of nasopharyngeal cancers in China. In a phase III 
clinical trial of patients with advanced squamous cell carcinoma of the head and neck or oesophagus, 
it was found that combination treatment with H101, cisplatin and 5-FU showed a higher rate of 
response compared with treatment by cisplatin and 5-FU alone. The trial also demonstrated a good 
safety profile of the virus with feverish symptoms, injection site reactions and flu-like symptoms being 
the main adverse reactions reported. No survival data was reported in this study 97. Following 
publication of the results of this clinical trial the virus was approved for clinical use in China. 
1.3.5.2 Herpes Simplex Virus 
 
Another oncolytic virus that has been approved for clinical use is the herpes simplex virus, T-VEC. HSV-
1 is a member of the alphaherpesvirus family. It is a double stranded DNA virus and has a larger 
genome than that of adenovirus at 152kb. HSV-1 replicates in cell nuclei however its replication does 
not result in mutations of the host cell DNA (insertional mutagenesis). Its large genome and lack of 
insertional mutagenesis make HSV-1 an excellent oncolytic virus candidate, it can however cause skin 
lesions in patients as well as causing infection of peripheral nerves and latent infection. 
T-VEC contains deletions of the neurovirulence genes ICP34.5, which results in better cancer 
selectivity of the virus and reduced infection of neurons. It also has an ICP47 deletion which usually 
acts to inhibit antigen presentation. The deletion of ICP47 leads to the presentation of antigens by 
both normal cells and cancer cells, leading to immune-mediated killing of cancer cells whilst leading 
to containment of the infection in healthy tissues. The ICP47 deletion also causes early activation of 
US11 which blocks PKR phosphorylation and prevents cancer cells from undergoing abortive apoptosis 
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once infected which increases the therapeutic activity of T-VEC 98. As well as these deletions, T-VEC 
has had GM-CSF inserted in place of the ICP34.5, improving the induction of anti-tumour immunity. 
T-VEC has been evaluated in clinical trials for several types of cancer including melanoma, pancreatic 
cancer as well as head and neck cancers. T-VEC was assessed in phase II clinical trial on patients with 
unresectable melanoma. Patients were treated with intratumoral virus followed by a further injection 
3 weeks later and 2weekly injections subsequent to this until a maximal clinical response or tolerated 
dose was reached or until disease progressed. This phase II study found an objective response rate 
with T-VEC treatment of 26%. As well as this the virus was well tolerated with flu-like symptoms being 
the predominant side effect reported. A phase III prospective, randomised, clinical trial then followed 
in which 436 patients with advanced, unresectable melanoma were treated with intratumoral viral 
injection. The trial found that 16.3% of patients treated with T-VEC responded to treatment with the 
virus within 12 months of commencing treatment and maintained a response for 6 months 
subsequent to that. This was in comparison to the other arm of the study in which patients were 
treated with GM-CSF alone. In this group of patients 2.1% of participants achieved a durable response. 
This was found to be statistically significant 67. There was an objective response rate of 26.4% in 
patients treated with T-VEC whilst a complete response rate of 10.9% was also noted and there was 
also an increased median overall survival when compared to patients treated with GM-CSF alone 67. 
Following the success of this clinical trial T-VEC was approved for use in the treatment of melanoma 
by the FDA in the United States and subsequently by NICE who have also approved the use of T-VEC 
for treating inoperable metastatic melanoma. 
1.3.5.3 Vaccinia virus 
 
Vaccinia virus belongs to the poxviridae family. Poxviruses are large enveloped viruses with a linear 
double stranded DNA genome 99. Vaccinia has an approximate 190kb genome and is a large and 
complex virus of which there are many strains. The central genomic region is highly conserved 
amongst poxviruses; however, the terminal regions encode viral factors that modulate the immune 
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response or affect host ability to produce an antiviral response 99. Unlike many other viruses no specific 
host-cell receptor for virus binding and entry have been identified for vaccinia virus 100. It replicates 
entirely in the cell cytoplasm of infected cells and therefore the risk of viral integration into host 
chromosomes does not occur. With regards to the treatment of cancer, oncolytic vaccinia virus is a 
promising candidate and has been shown to replicate and lyse cancer cells within 72hrs of infection 
101. It also has a broad tumour tropism and is stable in the bloodstream enabling treatment of distant 
metastases. It also spreads rapidly within tumours, whilst having a large transgene-encoding capacity 
78,101. Vaccinia virus also has an established safety profile in humans given its use in the smallpox 
vaccination process 102. 
There are four forms of vaccinia virus that are produced during the life-cycle of the virus. These include 
the intracellular mature virion (IMV), intracellular enveloped virion (IEV), cell-associated enveloped 
virion (CEV) and the extracellular enveloped virion (EEV) 81. Assembly of these virions takes place in 
cytoplasmic ‘factories’ and these involve the use of non-infectious precursors called crescents 103. The 
IMV consists of single lipid bilayer and is the most abundant form of vaccinia virus. Cells infected by 
vaccinia virus produce IMVs in the cell cytoplasm and these become wrapped virions following the 
acquisition of two extra membrane envelopes derived from the trans Golgi network or from the 
endosome. Microtubules then transport these to the cell surface where they fuse with the cell 
membrane, acquiring an additional membrane and becoming EEVs 99. These can transform into EEV 
as a result of exiting cytoplasmic crescents via microtubules and undergoing additional modifications 
including the addition of an extra membrane 81. The EEV differs in that it expresses fewer viral antigens 
on its surface whilst also incorporating host cell proteins, which enables it to evade the host immune 
response 104. This ability to limit its exposure to the host immune response facilitates its arrival at the 
target tumour 104.  
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1.3.5.3.1 Cell entry and replication of vaccinia virus  
 
The mechanism of cell entry for vaccinia virus is not completely understood. A number of pathways 
and cell signalling factors have been shown to contribute to its entry into cancer cells. Cell entry of 
vaccinia virus can vary depending on the strain of vaccinia. Entry can occur through direct fusion with 
the plasma membrane or through endocytic routes.  
1.3.5.3.2 Direct fusion to the plasma membrane 
 
With regards to cell entry via direct fusion to the plasma membrane, 4 proteins are responsible for 
the attachment of the mature virion (MV). These proteins include H3, A27, and D8 that bind to 
glycosaminoglycans on the cell surface; and protein A26 that binds with the extracellular matrix 
protein laminin and mediates viral binding independent of glycosaminoglycans 105. Extracellular 
enveloped virion (EEV) binding moieties have not been identified. Once MV and EEV have attached to 
the plasma membrane an 11 protein entry fusion complex completes the fusion of vaccinia virus to 
the plasma membrane 106. As well as this EFC, it has been reported that tumour necrosis factor 
associated factor 2 (TRAF2) which is a cytoplasmic adapter protein, facilitates entry of vaccinia virus 
via direct fusion at the plasma membrane 107. 
1.3.5.3.3 Endocytosis 
 
Endocytosis appears to be the predominant mechanism for cell entry by vaccinia virus. The advantage 
of endocytosis in cell entry is that there is no evidence of virus presence on the host plasma membrane 
and this avoids an immune mediated reaction. The enclosure of activated viral proteins within 
endocytic vesicles also protect them from neutralisation by the host immune circulating antibodies 
108. A low pH, commonly found within the tumour microenvironment has also been shown to facilitate 
endosomal mediated entry of vaccinia viruses 109. MVs and EEVs utilise micropinocytosis, an endocytic 
process dependent on actin that is mediated by tyrosine kinases, to gain entry into tumour cells 109. 
MVs utilise their ubiquitously expressed surface phosphatidylserine (PS) reported to target the MV 
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producing vaccinia virus for apoptosis. This results in MVs being mistaken for apoptotic debris and is 
taken up by tumour cells 110. It is thought that PS enables viral entry due to the presence of EGF-like 
domains present within PS receptors. These domains are thought to interact with EGFRs present on 
the cell surface with subsequent induction of blebbing (detachment of a patch of cell membrane from 
the surface of the cell) 110. The induction of blebbing leads to cytoskeletal rearrangements that lead to 
the accumulation of actin and this enables the blebs to retract further leading to the formation of out-
pocketings. These go on to form the macropinosome. These move deeper into the cytoplasm and the 
pH lowers within becoming more acidic. This change in pH as well as other cues prepare the virus for 
its deposition into the host cytoplasm 110. 
1.3.5.3.4 Factors promoting vaccinia virus entry into cells 
 
It has been shown that vaccinia utilises a pH dependent route to enter into cells. To confirm this Villa 
et al. utilised two drugs to raise the pH of the endosome through the inhibition of vacuolar-ATPase. 
This enzyme is responsible for generating the acidic pH in early endosomes. The study found that 
inhibition of vacuolar-ATPase resulted in compromised delivery from early to late endosomes 105. The 
study also noted that when vaccinia virus was in an environment with a low pH it was able to partially 
overcome the inhibitory effects of these drugs, thus indicating that the pH surrounding the endosome 
plays a part in vaccinia virus entry 105. 
Hypoxia and low oxygen tension have also been shown to be factors that affect vaccinia virus cell 
entry. In the presence of vascular endothelial growth factor (VEGF-A), a pro-angiogenic growth factor 
that is induced by hypoxic conditions, expression in tumours was shown to increase viral 
internalisation into tumour cells through the Akt pathway 111. Inhibition of the Akt pathway was shown 
to reduce viral cell entry however it did not completely reduce vaccinia virus internalisation, indicating 
that other pathways and mechanisms are likely to be involved also 111. 
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1.3.5.4 Vaccinia virus oncolytic virotherapy 
 
Vaccinia virus is the most well-studied of the poxvirus family. It exhibits a wide range of tropism in 
both normal and cancerous mammalian cells. In its use as an oncolytic virus, vaccinia has been 
attenuated to improve its selectivity for infection of cancer cells. Several versions are currently in use 
in clinical trials. Genetic modifications of vaccinia virus include thymidine kinase (TK) gene deletion. 
TK is an essential enzyme for pyrimidine synthesis, and its deletion ultimately results in selectivity of 
virus replication in cells with high nucleotide pools, such as rapidly dividing cancer cells 112.  In studies 
in which there has been a VACV double deletion (vvDD), VGF is also deleted, leading to further 
attenuation and dependence on the cell cycling status of target cancer cells. VGF is expressed early in 
VACV infection and is secreted as a ligand of EGFR to stimulate adjacent quiescent cells; it therefore 
impacts upon the spread of infection within normal tissues 113. Despite this deletion causing a 
decreased pathogenicity of VACV, its ability to replicate within and destroy cancer cells is not affected 
114.  
1.3.5.4.1 JX-594 
 
The first VACV to be tested in phase I clinical trials was pexastimogene devacirepvec (Pexa-Vec, JX-
594). Derived from the Wyeth vaccinia strain this oncolytic virus has a TK deletion as well as having 
the immunomodulatory gene encoding for GM-CSF and β-galactosidase, with the aim of stimulating 
the immunotherapeutic effects of the virus as well as stopping the intra-tumoral (IT) vascular supply 
66,115,116. In a phase I clinical trial JX-594 was given intratumorally to 14 patients with primary or 
metastatic liver tumours. This was an open-label, phase I dose-escalation trial with patients receiving 
one of four intratumoral doses of JX-594 (1x108 pfu, 3x108 pfu, 1x109 pfu and 3x109 pfu) every 3 weeks. 
All patients experienced grade I – III flu-like symptoms, four developed transient dose-related 
thrombocytopenia whilst two developed Grade III hyperbilirubinaemia at the highest dose. The 
maximum tolerated dose of JX-594 was therefore determined as 1x109 pfu. The trial also showed 
evidence of dissemination of virus in the blood through infection of distant tumour sites that were not 
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injected. 10 of the 14 patients underwent radiographic evaluation of their disease following injection 
with JX-594, and this showed that three had had a partial response to treatment, 6 had stable disease 
whilst one had progressive disease (according to response evaluation criteria in solid tumours 
(RECIST)) 66. Mastrangelo et al. also administered JX-594 intratumorally in the treatment of patients 
with incurable melanoma 117. Patients were given twice-weekly intratumoral injections of escalating 
dose from 1x104 up to 2x107 pfu/lesion for 6 weeks. Viral treatment was well tolerated with patients 
experiencing low-grade flu-like symptoms lasting less than 24 hours. Of the seven patients that were 
involved in the trial, two with the largest tumour burden did not respond to treatment with vaccinia 
virus. Three patients had a mixed response with treated tumours and some distant tumours regressing 
whilst other distant ones progressed. One patient had a partial response with regression of injected 
and uninjected dermal tumours. This patient went on to have disease resected and was subsequently 
rendered disease free. One patient developed a complete response to treatment with vaccinia virus 
117. A phase II dose-ranging study was conducted to evaluate the safety and anti-tumour efficacy of JX-
594 at high dose (1x109 pfu) vs low dose (1x109 pfu) in patients with hepatocellular carcinoma 118. Virus 
was administered intratumorally and was well tolerated at both doses. Patients received intratumoral 
JX-594 at three time-points: day 1, 15 and 29. 30 patients were enrolled and randomised to either arm 
of the study. Based on the modified response evaluation criteria in solid tumours (mRECIST) following 
magnetic resonance imaging four patients responded to treatment with one complete response and 
3 partial responses, whilst 10 patients had stable disease. Responses to treatment were also seen in 
both injected and non-injected tumours. The overall survival was significantly longer in the high-dose 
arm compared with the low dose arm (14.1 months vs 6.7 months, HR: 0.39, P=0.02), whilst the overall 
survival was 9 months for the whole cohort 11. Another phase IIb clinical trial in patients with 
hepatocellular carcinoma who had failed sorafenib treatment was completed and did not reach its 
primary endpoint of prolonging overall survival in patients treated with JX-594 compared with best 
supportive care 119. Heo et al. conducted a pilot study exploring the safety and efficacy of JX-594 
treatment followed by sorafenib in 3 patients with hepatocellular carcinoma. In all three patients 
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sequential treatment was well tolerated, resulted in reduced tumour perfusion and was associated 
with objective tumour responses on MRI scanning according to the Choi criteria 120. A phase III trial is 
currently underway comparing the treatment of hepatocellular carcinoma with Pexa-Vec and 
sorafenib to sorafenib treatment alone. 
Breitbach et al conducted a phase I dose-escalation trial of a single intravenous infusion of JX-594 in 
23 patients with other advanced solid tumours refractory to treatment 121. Tumours included lung, 
colorectal, melanoma, thyroid, gastric and mesothelioma. Patients were treated in one of six dose 
cohorts ranging from 1x105 to 3x107 pfu/kg. JX-594 delivery, gene expression and replication in solid 
tumours was assessed. Safety, pharmacokinetics and antitumour activity were evaluated. The 
treatment was well tolerated, and dose escalation proceeded without dose limiting toxicities. As with 
other trials assessing JX-594 the most common adverse effects were low grade flu-like symptoms 
lasting up to 24hrs. Neutralising antibodies to vaccinia were detectable in 6 patients at baseline and 
developed in all patients treated at a high concentration of the virus by day 15. Despite this there was 
no correlation between neutralising antibody titres whether raised at baseline or induced, and JX-594 
replication, safety or anti-tumour activity. Biopsies were assessed 8-10 days post infusion of JX-594. 
87% of patients treated with a high dose of virus (>1.5x107 pfu/kg) had biopsies that were positive for 
JX-594 on immunohistochemical and quantitative polymerase chain reaction (qPCR) analysis 
compared to those treated at lower doses with no detection of virus on biopsies 121.  
Park et al conducted a phase Ib clinical trial with JX-594 in patients with colorectal cancer 122. In this 
clinical trial 15 patients with treatment refractory colorectal cancer were treated with two-weekly 
intravenous administration of JX-594. The purpose of this study was to establish the maximum 
tolerated dose following intravenous administration with doses of 1x106, 1x107 and 3x107 pfu/kg 
administered. In this trial no dose-limiting toxicity was reported, and the maximum tolerated dose 
was not reached. Common side effects of systemic virus administration were low grade flu-like 
symptoms which lasted less than 24 hours. Following intravenous administration plaque forming units 
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were detectable in the patient circulation up to 2 hours following the first cycle and up to 30 minutes 
following the 4th cycle of virus administration. Of the 15 patients treated in this trial ten had 
radiologically stable disease 122.   
1.3.5.4.2 Oncolytic vaccinia viruses in clinical trials 
 
Other strains of VACV currently in clinical trials include GLV-1h68 and a double deleted VACV (vvDD). 
GLV-1h68 has been attenuated by the deletion of viral TK gene F14.5L, J2R and the haemagglutinin 
gene A56R 123,124. Despite these deletions the virus remains highly tumour selective and has been 
shown to exhibit higher oncolytic efficacy than the parental Lister strain of virus and has been shown 
to cause efficient regression and in some cases, eradication of tumour in nude mice bearing several 
solid tumours including colorectal tumours 123. It is believed that activation of innate immunity and 
infiltration of immune cells at tumour sites play a role in this effect.  
The double-deleted VACV (vvDD) has both TK and VGF genes deleted, increasing replication selectivity 
in cancer cells. In pre-clinical work involving mice with paediatric solid tumours this virus inhibited 
tumour growth and prolonged survival 125. 
1.3.5.4.3 Oncolytic vaccinia virus in combination treatment 
 
Most cancer therapies rely on the use of multiple agents in conjunction with one another. One such 
example is the use of the FOLFOX and FOLFIRI regimens that are used in the treatment of patients 
with colorectal cancer. These combine several chemotherapy agents such as leucovorin, 5-FU, 
oxaliplatin and irinotecan and have both been shown to improve 5-year survival of patients compared 
with 5-FU alone 54. 
Similarly, it has been demonstrated that there is a superior effect when oncolytic virotherapy is used 
in combination with traditional therapies. An example of this includes the treatment of patients with 
advanced hepatocellular carcinoma. JX-594 oncolytic vaccinia virus was combined with Sorafenib, 
which is a small-molecule multikinase inhibitor with antiproliferative and antiangiogenic effects. The 
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combination of these two agents was found to induce tumour necrosis in patients and limit disease 
progression, whilst use of the virus alone did not achieve such results 120. Based on these results a 
phase III trial is currently underway comparing combination treatment with sorafenib monotherapy. 
A similar result from combination treatment was seen in patients with renal cancer. In a single patient 
with a prognosis of less than 6 months, repeated JX-594 administration followed by treatment with 
sunitinib (small-molecule VEGF inhibitor) resulted in complete tumour response with a prolonged 
disease free survival 120.   
 
1.3.5.5 Vaccinia virus encoding a fusion suicide gene (FCU1) 
 
For many years 5-FU has been the principle active agent to treat colorectal cancer and is still included 
in chemotherapy regimens for the treatment of colorectal liver metastases. 5-FU is able to exert a 
bystander effect through passive diffusion into and out of cells, resulting in a bystander effect. Its 
cytotoxicity is determined by its conversion into 5-fluorouridine triphosphate (5-FUTP) and 5-fluoro-
deoxyuridine monophosphate (5-FdUMP). 5-FUTP inhibits RNA synthesis whilst 5-FdUMP inhibits 
thymidylate synthase which is responsible for the conversion of deoxyuridine monophosphate into 
thymidine monophosphate which is a key molecule in DNA synthesis (Figure 1.6). 5-FU can also be 
directly incorporated into cell RNA, interfering with RNA transcription, and less often it can be 
incorporated into DNA, inhibiting replication 126,127.  
Systemic toxicity of 5-FU lead to the development of new approaches aiming to concentrate it within 
tumour tissue. One such technique is suicide gene therapy that results in the intracellular conversion 
of non-toxic prodrugs into potent chemotoxins delivered by oncolytic viruses directly to the cancer 
cells. One example of this type of suicide gene therapy is the incorporation of the fusion suicide gene 
(FCU1). This suicide gene is derived from a fusion of the Saccharomyces Cerevisiae cytosine deaminase 
(CDase), an enzyme that is present in fungi and bacteria but absent from mammalian cells, that 
deaminates cytosine to uracil. It is also derived from the uracil phosphoribosyltransferase (UPRTase) 
58 
 
enzyme derived from Escherichia Coli which converts 5-FU into the toxic metabolite 5-fluorouridine 
monophosphate (5-FUMP). The fusion suicide gene has been shown to efficiently catalyse 5-FC into 
its toxic metabolites 5-FU and 5-FUMP 127. This strategy of suicide gene therapy also generates a 
bystander effect as the generation of 5-FU from infected cells is able to diffuse into non-infected cells, 
unlike some other prodrug systems that require gap junctions 128.  
 
 
Figure 1.6 5-fluorouracil metabolism and effects 
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1.3.5.5.1 Pre-clinical use of fusion suicide gene using an adenovirus vector 
 
Erbs et al first assessed the fusion suicide gene using a replication-deficient adenovirus to transduce 
tumour cells 129. The study found that in vitro the FCU1 gene maintained equivalent effects of UPRTase 
compared with the gene originating from Saccharomyces cerevisiae, whilst its CDase effects were 
higher compared to the original Escherichia Coli gene. Tumour cells that were transduced with 
adenovirus encoding the FCU1 gene were more sensitive to 5-FC, therefore requiring lower 
concentrations compared to adenovirus expressing the original CDase gene alone. The study also 
found an increase in the bystander effect in cells treated with adenovirus expressing FCU1 compared 
to virus expressing either the UPRTase gene or the CDase gene. In vivo testing also found that tumour 
growth was reduced following intra-tumoral injection of adenovirus expressing FCU1 followed by 
intravenous administration of 5-FC. There was a statistically significant suppression of tumour growth 
in BALB/c nude mice that were implanted with SW480 and LoVo colorectal cancer cell lines. 4 weeks 
following injection both SW480 and LoVo tumours were between 50 and 65% smaller compared with 
controls, however relatively large doses of 5-FC were required to achieve these results. The results of 
this study suggested that the use of an oncolytic virus to deliver FCU1 suicide gene therapy was 
potentially an effective candidate for cancer gene therapy strategies 129. 
1.3.5.5.2 Delivery of FCU1 using non-replicative vaccinia virus 
 
In an attempt to improve the efficacy of the FCU1/5-FC strategy Erbs et al. assessed a propagation-
deficient vaccinia virus 127. In this study the Modified vaccinia virus Ankara (MVA) was used as a vector 
for gene therapy. This virus was chosen due its safety profile, it is also non-propagative in animal and 
mammalian cells but viral infection results in rapid replication of viral DNA and therefore amplification 
of the FCU1 transgene. This study demonstrated the ability of the MVA vector to transduce a variety 
of tumour cells including colorectal cell lines. During in vivo experiments, nude mice with colorectal 
tumours (LoVo) were treated with a single intratumoral injection of MVA-FCU1, given in combination 
with oral 5-FC administration. The conversion of 5-FC to 5-FU was evaluated. After a single dose of 5-
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FC the highest levels of 5-FU in tumours were reached at 3-8 days following infection, whilst 5-FU was 
still present within tumour tissues up to 14 days afterwards. The level of 5-FU detected within treated 
tumours was equivalent to the level achieved with 5-FU administered systemically at 20-fold the 
maximum tolerated dose, furthermore the serum 5-FU level following treatment with MVA-FCU1 was 
undetectable, resulting in tumour killing without systemic toxicity. In comparison with his initial study 
Erbs found that the vaccinia virus vector was able to suppress tumour growth at relatively lower doses 
of 5-FC whereas no reduction in tumour growth was seen using the adenovirus vector 127.  
1.3.5.5.3 VV-FCU1   
 
Foloppe et al. first used a replication competent Copenhagen strain vaccinia virus expressing the 
transgene FCU1 in the pre-clinical setting (Figure 1.7) 130. Due to the efficient replication, cell lysis and 
spread of vaccinia virus as well as its broad host range and safety record in human use it was deemed 
to be an excellent candidate to use. The vaccinia virus was of the Copenhagen strain and was 
attenuated, having had a TK deletion. As a result, the virus was less pathogenic than wild-type vaccinia 
whilst preserving its ability to infect and replicate in cancer cells due to its dependence on host cell 
nucleotides. The study found VV-FCU1 in the presence of 5-FC mediated anti-tumour effects in vitro 
and in vivo in a murine model of a human colorectal cancer (nude mice with subcutaneous LoVo 
tumours). In vitro experiments found that there were increased levels of UPRTase and CDase levels at 
a multiplicity of infection (MOI) of 0.0001 in VV-FCU1 treated cells in comparison with those that had 
previously been treated with the MVA virus expressing FCU1 at an MOI of 0.01. The study found that 
the combination of VV-FCU1 and 5-FC resulted in greater toxicity to human cancer cell lines compared 
with virus alone, whilst the addition of 5-FC to cells treated with virus not encoding the FCU1 gene did 
not increase the toxicity to these cell lines. These results reinforced the theory that the enhanced 
killing by the combination of 5-FC and VV-FCU1 was due to the expression of FCU1 and its ability to 
convert 5-FC to 5-FU. In vivo experiments were also conducted in nude mice bearing subcutaneous 
LoVo colorectal tumours. VV-FCU1 was injected intravenously or intratumorally in these mice and they 
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received oral 5-FC at 7-days post virus administration for 3 weeks. Both routes of administration 
showed a significant reduction in tumour growth compared with controls. The same was also found 
in a model of liver metastasis. There were no adverse events noted following viral treatment in vivo, 
however some did develop cutaneous lesions that healed over 6 weeks 130. This study demonstrated 
the potency of the Copenhagen strain VV-FCU1/ 5-FC system as a cancer gene therapy and provided 
further evidence to support the use of this in translational models. 
 
Figure 1.7 Schematic representation of VV-FCU1 by Foloppe et al 130. Thymidine kinase (TK) has been deleted and in its 
place of the new virus contains the fusion suicide gene (FCU1) under the control of the p11k7.5 promoter.  
 
1.4 Summary 
 
Oncolytic viruses are a developing field of anti-cancer agents that have multi-modal action and recent 
advances have seen the licensing of two such viruses, an adenovirus and herpes simplex virus for 
clinical use in patients. Vaccinia virus is an oncolytic virus that lends itself to oncolytic virotherapy due 
to its broad tissue tropism, large transgene encoding capacity, its ability to spread in the blood as well 
as its excellent safety profile in human use.  
The immune-mediated effects of oncolytic virotherapy are an important aspect of treatment as they 
prime the host to act against tumour cells. The benefit of this is that this enables the host immune 
system to recognise tumour associated antigens at other sites of disease and to create an immune 
response against these, preventing the development of metastases.  
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Vaccinia virus encoding the fusion suicide gene is a promising candidate for patients with colorectal 
cancer and liver metastases. The ability of the virus to convert non-toxic fluorocytosine into its active 
metabolite 5-fluorouracil lends itself to the treatment of these cancers as this is one of the 
predominant chemotherapy agents used in the treatment of patients with colorectal cancer that has 
metastasised to the liver. 
1.5 Hypothesis 
 
We hypothesise that VV-FCU1 is an effective oncolytic virotherapy that effectively kills colorectal 
cancer cells through its modes of action. 
The objectives of this study were: 
• To evaluate the effects of VV-FCU1 on immortalised colorectal cancer cell lines as well as in 
human tissue through the development of an organotypic culture model in our laboratory 
• Assess the immunogenicity of vaccinia virus in the treatment of colorectal cancers through 
the assessment of mode of cell death and through the identification of markers of immune 
cell death 
• To use a precision cut tumour slice model to investigate methods of enhancing oncolytic 
virotherapy in solid tumours 
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Poxvirus Study 
type 
Tumour site Administration Phase Status and 
outcomes 
National 
clinical trial ID 
Pexa-Vec 
(JX-594) 
Clinical Colorectal cancer IV 1 Completed. No 
dose-limiting 
toxicities reached, 
maximum tolerated  
NCT01469611 
Clinical Colorectal cancer IV 1 Completed. Repeat 
IV injections were 
well tolerated. No 
dose limiting 
toxicities noted 
NCT01380600 
Clinical Solid tumours IV 1 Completed. JX-594 
infects, replicates 
and expresses 
transgene products 
in dose-related 
fashionand is 
tumour selctive 
NCT00625456 
Clinical Colorectal cancer IV 1/2ab Completed. Results 
not published 
NCT01394939 
Clinical Colorectal cancer IV 1b Completed. 
Maximum tolerated 
dose not reached, 
multiple injections 
well tolerated  
NCT01469611 
GLV-
1h68/GL-
ONC1 
Clinical Solid tumours IV 1 Completed. Well 
tolerated with 
minimal toxicity 
NCT00794131 
GLV-1h68 Pre-
clinical 
Colorectal IV  Inhibited primary 
tumor growth and 
metastatic lesion 
formation; disrupted 
tumor vasculature 
NA 
VV-FCU1 Pre-
clinical 
Colorectal cancer IV/IT  Significant reduction 
in tumour growth of 
colon tumours and 
liver metasatases 
with both IV and IT 
administration 
compared with 
controls 
NA 
Table 1.3 A summary of clinical and pre-clinical trials using oncolytic vaccinia virus in the treatment of colorectal cancer 
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Chapter 2 – Materials and methods  
 
2.1 Cell lines, treatment and media 
 
2.1.1 Vaccinia Virus 
 
Vaccinia viruses (Copenhagen strain) used in this study were supplied by Transgene SA, France. Details 
are listed in Table 2.1 below: 
Table 2.1 Vaccinia viruses supplied by Transgene SA, France and storage conditions 
Reagent Supplier Storage conditions 
VVTK-I4L-/GFP Transgene SA, France Stored at -80°C in aliquots at 
2.5x109 pfu/mL 
VVTK-I4L-/FCU Transgene SA,France Stored at -80°C in aliquots at 
2.3x108 pfu/mL 
 
2.1.2 Cell culture media 
 
All cell culture media used in this study are displayed in Table 2.2 along with their supplier and 
supplements. Working cell culture medium was prepared in the same way but supplemented with 
10% fetal bovine serum (FBS). 
Table 2.2 Cell culture media and additional supplements used in experiments 
Medium Supplements Supplier 
L-15 Medium 
(Liebowitz) 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin 
(Sigma, UK), 2mM L-Glutamine (Sigma, UK) and 10% FBS (Life 
Technologies, UK) 
Sigma (UK) 
McCoys 5A 
(modified) 
Medium 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin 
(Sigma, UK), 2mM L-Glutamine (Sigma, UK) and 10% FBS (Life 
Technologies, UK) 
Thermofisher 
(UK) 
Dulbecco’s 
Modified Eagle’s 
Medium 
(DMEM) 
100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin 
(Sigma, UK), 2mM L-Glutamine (Sigma, UK) and 10% FBS (Life 
Technologies, UK) 
Sigma (UK) 
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RPMI-1640 100 U/mL penicillin (Sigma, UK), 100µg/mL streptomycin 
(Sigma, UK), 2mM L-Glutamine (Sigma, UK) and 2% FBS (Life 
Technologies, UK) 
Sigma (UK) 
 
2.1.4 Cell lines 
 
All cell lines were recently purchased from the American Type Culture Collection (ATCC, USA). No cell 
line validation was required. The cells were adherent lines that were maintained at 37°C in an 
atmosphere of 5% CO2 within an incubator. All cell culture work was carried out under sterile 
conditions in a laminar flow biosafety cabinet class II (Kendro, UK). Tissue culture flasks and other 
plasticware was provided by Nunc. Mycoplasma testing was carried out regularly using the 
MycoAlertTM Mycoplasma Detection Kit (Lonza, UK). 
Table 2.3 Cell lines used in tissue culture experiments 
Cell line Cell culture medium Tissue Type Source 
HT29 McCoys (Modified) 5A 
Medium 
Human colorectal 
adenocarcinoma 
ATCC, USA 
SW620 L-15 Medium Human colorectal 
adenocarcinoma 
ATCC, USA 
HCT116 McCoys (Modified) 5A 
Medium 
Human colorectal 
carcinoma 
ATCC, USA 
 
2.2 Tissue Culture 
 
2.2.1 Passaging of adherent cells 
 
Tissue culture flasks were removed from incubation conditions (37°C, 5% CO2). Media was removed 
from each flask and the cell layer was washed with Hanks’ Balanced Salt Solution (Sigma, UK) before 
being discarded. Cells were then detached using Trypsin-EDTA (1x) solution (Sigma, UK) for 5-10 
minutes in incubation conditions. Once detached cells were transferred into a universal tube and 
culture media was added to disperse cells. The universal tube was then centrifuged at 1500rpm for 3 
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minutes after which the supernatant was discarded, leaving a cell pellet. This was re-suspended in 
culture media and the cells were split. These were then added to a new flask containing fresh culture 
medium and placed in incubation conditions. To set up cells for an experiment, re-suspended cells 
were counted to enable seeding at an appropriate cell concentration. 
2.2.2 Calculating cell number 
 
A 1:10 dilution of cell suspension (10µL) in trypan blue (90µL) (Sigma, UK) was made and 10µL of the 
mixture was pipetted onto a haemocytometer. Trypan blue can only penetrate dead cells as it is 
membrane impermeable, therefore live cells remain unstained. Only live cells were counted in the 
four corners of the haemocytometer.  
The following formula was used to determine the cell number: 
Mean number of cells/quadrant x dilution factor (10) x chamber depth (104) 
2.2.3 Cryopreservation of cells 
 
Cells were harvested in culture medium and centrifuged at 1500rpm for 3 minutes. The supernatant 
was removed, and the cell pellet re-suspended in medium containing 50% cell culture medium, 40% 
FBS (Life Technologies, UK) and 10% dimethyl sulphoxide (DMSO) (Sigma, UK). The cell suspension was 
transferred to sterile cryovials and stored down at -80°C in a cryo-freezing container before being 
transferred to liquid nitrogen for storage. 
2.2.4 Revitalisation of cryopreserved cell lines 
 
Cryovials containing cells were removed from liquid nitrogen storage and thawed in a water bath for 
30 seconds to 1 minute. Cell suspension was then transferred to a universal tube containing 10mL of 
warmed culture medium and was centrifuged at 1500rpm for 3 minutes. Supernatant was then 
discarded leaving behind a cell pellet. This was re-suspended in media and transferred in to a tissue 
culture flask before being placed in an incubator at 37°C, 5% CO2. 
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2.3 Evaluation of cell line treatment with vaccinia virus 
 
2.3.1 Calculating the amount of virus needed for specific multiplicity of infection (MOI) 
 
MOI is the ratio of virus particles to the number of cells in a defined area. The number of virus particles 
that enter cells at a particular time is a statistical process as some cells will absorb varying amounts of 
virus particles or not absorb them at all. 
To calculate the number of vaccinia virus needed, the following calculations were performed: 
Number of cells/well x required MOI = volume of virus required (pfu/well) 
Volume of virus required (pfu/well) ÷ virus stock concentration = µL/well virus needed 
2.3.2 Cell Titre 96® Aqueous non-radioactive cell proliferation (MTS) assay 
 
The cell titre 96® aqueous non-radioactive cell proliferation (MTS) assay (Promega, UK) contains an 
MTS tetrazolium compound and an electron coupling reagent (PES). PES is chemically stable enabling 
its combination with MTS to form a stable solution. MTS is then bio-reduced by cellular oxidoreductase 
enzymes into a coloured formazan product, directly proportional to the number of living cells in 
culture. 
100µL cells were seeded in a 96-well plate at the required seeding density and left in culture media 
for 24 hours at 37°C, 5% CO2. This ensured that cells were 80% confluent in culture. After 24 hours 
supernatant was aspirated from each well and replaced with 100µL of diluted vaccinia virus in growth 
medium and left for a specified period of time in incubation conditions. Cell titre 96® aqueous one 
solution reagent (Promega, UK), diluted in RPMI media at a ratio of 1:10 was added to all wells in the 
96-well plate. Plates were incubated for up to 1 hour before being placed in the Varioskan® Flash plate 
reader (Thermo Scientific, UK) and the Optical Density (OD) absorbance readings measured 
(wavelength 492 nm). Data were then analysed. The average OD of background control was subtracted 
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from the average OD of samples from each treatment. The percentage of cell survival was then 
calculated relative to untreated cells: 
% survival = av. OD cells treated with virus at specified MOI ÷ av. OD un-treated samples x 100 
2.3.3 Immunogenic cell death (ICD) – determinants and markers 
 
All cell lines were plated in 6-well plates at specified seeding densities and were incubated at 37°C 5% 
CO2 overnight. Cells were then treated with either vaccinia virus, heat inactivated vaccinia virus or 
were left untreated. Mitoxantrone was used as a positive control for ICD. Treatment was left on cell 
lines for 24, 48 and 72 hours respectively. Supernatants were initially taken off from each cell line and 
reserved, these were then retained for HMGB1 ELISA (Sandwich-enzyme immunoassay, IBL 
international, Switzerland) (see later). Cells were washed with PBS (Fisher Scientific, UK), once 
removed PBS wash was retained in a falcon tube. Accutase (Thermofisher Scientific, UK) was used to 
dissociate adherent cells, removed and the wells were once again washed with PBS. Accutase, 
adherent cells and PBS wash was taken up and pipetted into the same falcon tube as the initial wash. 
Suspension was spun, re-suspended in PBS (Fisher Scientific, UK) and 100µL of cells were aliquoted 
into a 96-well plate with each well corresponding to a specific antibody per treatment for each of the 
three cell lines.  Cells were incubated for one hour with primary antibodies (see Table 2.4 below). Cells 
were then washed, and secondary antibodies (Table 2.4) were added for a further 30 minutes to non-
labelled primary antibodies. Cells were washed once again and then analysed by flow cytometry using 
a MACSQUANT Analyzer and MACSQuantify software (Miltenyi Biotec, UK). 
Table 2.4 Primary and secondary antibodies used in the assessment of immunogenic cell death 
Primary antibodies 
Name Supplier Dilution 
Rabbit polyclonal antibody to calreticulin Abcam, UK 1:100 
Rabbit monoclonal antibody to HSP70 Abcam, UK 1:100 
Rabbit polyclonal antibody to FAS Abcam, UK 1:20 
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Rabbit IgG monoclonal-isotype control  Abcam, UK 1:3000 
Anti-human CD274 (PD-L1, B7-H1) purified eBioscience, UK 1:50 
Anti-human HLA-A , B, C PE  Biolegend, UK 1:10 
Anti-human CD80 PE eBioscience, UK 1:10 
Secondary antibodies 
Name Supplier Dilution 
Goat anti-mouse IgG Alexa Fluor® 546 Life Technologies, UK 1:200 
Goat anti-rabbit IgG Alexa Fluor® 488 Life Technologies, UK 1:200 
 
Table 2.5 Cell viability staining kit used in the assessment of immunogenic cell death 
Cell viability staining Supplier 
Live/Dead fixable violet dead cell 
stain kit 
Invitrogen 
 
2.3.4 High mobility group box 1 protein (HMGB1) – enzyme linked immunosorbent assay (ELISA) 
 
ELISA was used for the quantitative determination of HMGB1 protein from supernatants collected and 
stored during initial experiments for assessment of ICD in cell lines. Supernatants and standards were 
added to the relevant wells of a 96-well plate coated with purified anti-HMGB1 antibody. The plate 
was incubated at 37°C 5% CO2 overnight. Enzyme conjugate was then added for 2 hours followed by a 
wash. The plate was then incubated with a colour substrate solution for 30 minutes at room 
temperature before a stop solution was added. The optical density was then measured at 450nm using 
a Variaskan® flash plate reader (Thermo Scientific, UK) to determine HMGB1 concentration.  
2.3.5 Phycoerythrin (PE) Annexin V apoptosis detection 
 
Apoptosis is a normal physiological process which occurs in maintenance of tissue homeostasis. 
Apoptosis is characterized by certain morphologic features that include the loss of plasma membrane 
asymmetry and attachment, condensation of the cytoplasm and the nucleus, and internucleosomal 
cleavage of DNA. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
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translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing PS to the 
external cellular environment. Annexin V is a 35-36kDa calcium dependent phospholipid binding 
protein that has a high affinity for PS. Annexin V may be conjugated by fluorochromes, retaining its 
binding affinity to PS and enabling flow cytometric analysis of cells that are undergoing apoptosis. 7-
amino-actinomycin D (7-AAD) is a dye which allows identification of early apoptotic cells. Cells with 
intact membranes are not permeable to the dye whereas dead and damaged cells are permeable to 
it. This allows the distinction to be made between cells in early apoptosis, late apoptosis and necrosis. 
All three colorectal cancer cell lines were plated in 6-well plates and incubated overnight at 37°C 5% 
CO2. Cells were treated with VV, heat inactivated VV, cisplatin (positive control) or were left untreated 
in media and left for 24, 48 and 72 hours respectively. At each time-point cells were dissociated using 
Accutase (Thermofisher Scientific, UK) and spun down to create a cell pellet. Supernatant was then 
discarded, and cells were re-suspended in Annexin V binding buffer (BD Biosciences, UK) and 100µL 
aliquots were pipetted into 96-well plates. 5µL of 7-AAD and PE Annexin V were added to each well 
before subsequently analysing them by flow cytometry using a MACSQUANT Analyzer and 
MACSQuantify software (Miltenyi Biotec, UK).   
2.3.6 Autophagy detection 
 
When subjected to certain conditions that threaten survival, eukaryotic cells employ a lysosome 
mediated pathway for digesting their own cellular contents. This process is known as autophagy. 
Various constituents of the cytoplasm such as organelles and proteins are sequestered into double-
membraned autophagosomes. Autophagosomes subsequently fuse with lysosomes and their 
contents are degraded. Autophagy plays a variety of important roles including tumour suppression, 
cellular differentiation and regulation of innate and adaptive immunity.  
Cyto-ID® (Enzo Life Sciences, UK) is a 488nm-excitable green fluorescent detection reagent that 
becomes brightly fluorescent in vesicles produced during autophagy enabling detection of autophagy 
in live cells using flow cytometry. 
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Rapamycin is a lipophilic macrolide antibiotic that is used as an inhibitor of the mammalian target of 
Rapamycin (mTOR) and is a well-established inducer of autophagy in a wide range of cells. mTOR is a 
serine/threonine kinase, important in the control of cell growth, proliferation and survival. mTOR 
inhibits autophagy by phosphorylating proteins encoded by autophagy-related genes (Atgs). 
Rapamycin forms a complex with the intracellular Rapamycin receptor, immunophilin FK506-binding 
protein 12 (FKBP12), which interacts specifically with the TOR proteins and inhibits signalling to 
downstream targets. Rapamycin induced autophagy is characterized by the accumulation of 
autophagic vacuoles and the stimulation of autophagic flux. 
All HCT116, HT29 colorectal cancer cell lines and B16F10 mouse melanoma cells were plated in a 6-
well plate and incubated overnight at 37°C 5% CO2. Cells were treated with VV, rapamycin positive 
control or left untreated in media following 24 hours of incubation. After 72 hours’ treatment cells 
were detached using Accutase (Thermofisher Scientific, UK) and centrifuged at 1000rpm for 5 minutes 
to create a pellet. Cells were then washed and resuspended in 1x Assay Buffer (Enzo Life Sciences, UK) 
and were collected by centrifugation once more. Cells were then resuspended in 250µL of 1x Assay 
Buffer (Enzo Life Sciences, UK) and 250µL of Cyto-ID® green (Enzo Life Sciences, UK) was added to each 
sample and mixed. Samples were incubated for 30 minutes at 37°C in the dark. After 30 minutes cells 
were collected by centrifugation and re-suspended in 500µL of 1x Assay Buffer (Enzo Life Sciences, 
UK) before being analysed by flow cytometry using a MACSQUANT Analyzer and MACSQuantify 
software (Miltenyi Biotec, UK). 
2.3.6 Western Blotting for protein detection in cell lysates 
 
 2.3.6.1 Lysate preparation and protein separation using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Colorectal cancer cell lines treated with VV or untreated controls were washed with PBS (x2) (Fisher 
Scientific, UK) and then lysed using 250µL cold radioimmunoprecipitation (RIPA) buffer (Life 
Technologies, UK) and with Halt™ protease and phosphatase inhibitor cocktail mix 1:100 (Life 
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Technologies, UK). Following 5 minutes of gentle shaking on ice, cell lysates were sonicated for 15 
seconds (x3). Sonicated lysates were then centrifuged at 13,000 rpm for 5 minutes at 4°C before 
transferring supernatants into fresh eppendorfs and storing down at -80°C. 
Total protein in the lysate was determined using Pierce™ bicinochoninic acid (BCA) Protein Assay Kit 
(Life Technologies, UK) by following the manufacturer’s protocol. 25µL samples or albumin containing 
standards were added in duplicate to a 96-well plate prior to the addition of 200µL working reagent 
for 30 minutes at 37°C. The reaction product was measured at 562nm using a Variaskan® flash plate 
reader (Thermo Scientific, UK). The protein concentration was then interpolated from the standard 
curve produced. 
To ensure uniform protein loading, samples were diluted in RIPA buffer (Life Technologies, UK) to the 
required concentration. 31µL of diluted lysate, 4µL of NuPAGE® sample reducing agent (Life 
Technologies, UK) and 10µL NuPAGE® LDS loading buffer (Life Technologies, UK) was mixed before 
being placed on a heating block at 90°C for 5 minutes. The XCell Surelock™ Mini-Cell Electrophoresis 
apparatus (Life Technologies, UK) was assembled according to the manufacturer’s instructions. 40µL 
of lysate samples were loaded onto a NuPAGE® 4-12% Bis-Tris protein gel, 1.0mm, 10 well (Life 
Technologies, UK). 5µL of BLUeye pre-stained protein ladder (10-245kDa, Geneflow, UK) was also 
loaded onto the gel. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping gene 
which is constitutively expressed in cells, was used as a loading control to ensure equivalent protein 
loading of all samples. Samples were run in NuPAGE® 3-(N-morpholino) propansulfonic acid (MOPS) 
sodium dodecyl sulfate (SDS) running buffer (Life Technologies, UK) that was diluted 1:20 in water. 
Electrophoresis was carried out at 180V for 60 minutes using a PowerPac (Bio-Rad, UK).        
2.3.6.2 Protein transfer, blocking, antibody probing and band detection 
 
Proteins from the gel were transferred to a nitrocellulose membrane by electroblotting at 20 volts for 
7 minutes using the iBlot® gel transfer device (Life Technologies, UK). The membrane blot was 
incubated for 1 hour at room temperature in blocking buffer (PBS 0.1% Tween 20) (Sigma, UK) 
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containing 5% milk powder, and left on a roller. Primary antibody (Table 2.6) was then added and left 
at 4°C overnight on a rotating plate. The membranes were then washed (x3) with PBS 0.1% Tween 20 
(Sigma, UK) before the secondary antibodies (Table 2.7) were added for a further hour and left to 
incubate on a rotating plate at room temperature for 1 hour. Membranes underwent a further three 
washes with PBS 0.1% Tween 20 (Sigma, UK). The blot was then covered in SuperSignal® West Pico 
chemiluminescent substrate or SuperSignal® West Femto maximum sensitivity substrate (Life 
Technologies, UK) for up to 5 minutes. Following exposure to substrates the protein bands were 
visualised using the ChemiDoc-It2 imager (UVP, UK). Direct comparison of the protein bands was 
confirmed by comparison to the BLUeye prestained protein ladder (Geneflow, UK). The blot was then 
returned to PBS 0.1% Tween 20. 
Table 2.6 Primary antibodies used in western blotting 
Primary antibodies Molecular 
weight (KDa) 
Dilution Supplier 
Purified mouse anti-RIP antibody 74 1 in 1000 BD biosiences, UK 
Rabbit polyclonal anti-RIP3 antibody 57 2.5 in 1000 Abcam, UK 
Rabbit polyclonal PARP antibody 116 and 89 1 in 1000 Cell Signalling, UK 
Mouse monoclonal anti-GAPDH antibody 35.9 1 in 2000 Origene, USA 
RIP and PARP controls 
Jurkat apoptosis cell extracts (untreated or 
treated with etoposide) 
116 and 89 N/A Cell signalling, UK 
NIH 3T3 cell lysate 74 N/A ATCC, UK 
 
Table 2.7 Secondary antibodies used in western blotting 
Secondary antibodies Dilution Supplier 
Goat anti-mouse IgG 1 in 1000 Origene, USA 
Donkey anti-rabbit IgG 1 in 5000 Fitzgerald, UK 
Goat anti-rabbit IgG 1 in 2000 Cell Signalling, USA 
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2.3.6.3 Membrane stripping and antibody re-probing 
 
15mL of Restore™ PLUS stripping buffer (Fisher Scientific, UK) was added to the blot and left on a 
rocker for 10 minutes before washing (x3) in PBS 0.1% Tween 20 for 5 minutes. They were then 
blocked using non-fat milk 5% with TBS 0.1% tween-20. Membranes were incubated overnight at 4°C 
with purified mouse GAPDH 2D9 monoclonal antibody (Insight Biotechnology, UK) to detect GAPDH. 
The membranes were then washed again 3 times for 5 minutes using TBS 0.1% tween and incubated 
for an hour with goat anti-mouse IgG Horseradish Peroxidase (HRP) (Insight Biotechnology, UK). 
Membranes were then washed, and bands were detected as previously described. 
  
2.4 Organotypic culture 
 
2.4.1 Tissue collection and preparation 
 
Ethical approval was obtained for the ‘Evaluation of the effects of treatment on cancer tissue’ 
12/LO/1661. Written consent was obtained from patients undergoing hepatic resection at the Royal 
Surrey County Hospital, Guildford. 
Tumour samples were collected at the time of surgical resection from the Royal Surrey County 
Hospital, Guildford. At the time of surgical resection 8mm punch biopsies (Kai Medical Europe, 
Germany) were taken from tumours and transported in a sterile container on ice to the laboratory. 
To enable slicing of tumour cores, a 4% agarose (Sigma, UK) solution was made in advance and stored 
at 4°C. At the time of receipt of tumour this was heated in a microwave until liquid and then placed 
into a water bath at 42°C. Tumour cores were embedded in agarose within a 6-well plate and allowed 
to set on ice for 10-20 minutes. Once set, the agar was cut into the shape of a cube containing the 
tumour core. This was removed from the 6-well plate and fixed onto a metallic support block using an 
ethyl cyanoacrylate-based glue (Carl Roth, Germany). This was allowed to set on ice for 5-10 minutes. 
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Whilst the glue was setting the Leica VT1200 s vibrating microtome (Leica Microsytems Ltd, UK) was 
calibrated and set up to move at a speed of 0.4mm/s, oscillation 3.0mm and slice thickness 300µM. 
The decision to slice the tissue at 300µm intervals was based on existing literature regarding the use 
of organotypic cultures as well as our experience in cutting tumours. Whilst thinner slices can be 
procured we found that the cutting of tissue cores at this thickness was less consistent. The metallic 
support block and embedded tissue were then inserted into a purpose built media tray within an ice 
tray with DMEM (supplemented with 10% FBS and 100 U/mL penicillin (Sigma, UK), 100µg/mL 
streptomycin (Sigma, UK)) within, submerging the embedded tissue. Having already been calibrated 
consecutive 300µm slices were produced until the tumour was completely sliced or until the agar 
mould gave way and the tissue was no longer fixed in place (Figure 2.1).  
Slices were then transferred onto Millipore® Millicell® cell culture inserts (Sigma, UK) within a 6-well 
plate. 1mL of either media alone or containing virus at desired MOI was added to the bottom of these 
wells with an additional 250-500µL being placed within the insert containing the tissue slice. Once 
treated the tissue was placed inside an incubator at 37°C, 5% CO2 and placed onto a rotating tissue 
slice incubation unit (Alabama Research & Development, USA). 
After a defined period, tissue slices were removed from culture conditions and fixed in 10% formalin 
(Sigma, UK). They were then transferred to the University of Surrey, vet school pathology lab and were 
processed in an automated Sakura Tissue-Tek VIP6 (Sakura Finetek Europe B.V., Netherlands) tissue 
processing machine and left overnight. Following processing tissue slices were placed in a Sakura 
Tissue-Tek TEC (Sakura Finetek Europe B.V., Netherlands) paraffin embedding machine and were 
manually embedded within cassettes. 
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2.4.2 Calculating the amount of virus needed for specified concentration in tissue slices 
 
A plaque-forming unit (pfu) is a measure of the number of virus particles capable of forming plaques 
per unit volume.  It is a functional measurement rather than a measurement of the absolute quantity 
of particles: viral particles that are defective or which fail to infect their target cell will not produce a 
plaque and thus will not be counted. 
To calculate the number of virus particles required the following calculations were performed: 
Desired virus concentration/Stock concentration of virus x 1000µL = volume of virus particles required 
per ml 
Vol. of treatment per tissue slice = 1.5ml/slice 
Vol. virus required/ml x 1.5ml/slice = pfu required/experiment 
 
A B C D 
E F G H 
Figure 2.1 Workflow demonstrating retrieval of surgical specimen to production of organotypic cultures ready for incubation. 
A: Operating theatres; B: Liver containing large tumour; C: internal view of incised tumour with evidence of 8mm punch biopsy 
taken from within; D: tissue fixed in agarose in agarose; E: agarose attached to mounting plate in preparation for slicing; F: 
image of vibratome machine used to slice tumour; G: Mounted tumour tissue undergoing slicing in vibratome; H: tissue slices in 
media following slicing 
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2.4.3 Enzymatic staining - Detection of virus presence, cell proliferation and apoptosis by enzymatic 
immunohistochemistry (IHC) staining 
 
Visualisation of virus presence, evidence of apoptosis and cell proliferation was assessed using IHC. 
Firstly, paraffin embedded tissue slices were deparaffinised in three 5-minute washes in 100% xylene 
(Sigma, UK) for 5 minutes. They were then washed in 100% ethanol (Fisher Scientific, UK) twice. 
Following washes in ethanol the tissue slices were placed in 0.3% methanol/hydrogen peroxide 
(Sigma, UK) for 20 minutes, blocking endogenous peroxidases. Tissue slices were then rehydrated in 
70% and 50% ethanol (Fisher Scientific, UK) before being rinsed in distilled water for 5 minutes. 
Antigen retrieval was performed to break methylene bridges formed during tissue fixation, exposing 
antigenic sites for antibody binding. This was done by placing tissue into boiling 0.01M citrate buffer 
pH6.0 for 12 minutes. Slices were subsequently left to cool down for 1 hour. Slides were washed in 
distilled water for 3 minutes followed by two 3-minute washes in phosphate buffered saline (PBS) 
(Fisher Scientific, UK).   
Tissue slices were blocked by the addition of 2.4% horse serum in 1% PBS/BSA (Vector Laboratories, 
UK) in a moist chamber for 15 minutes. This was tapped off and Avidin D (Vector Laboratories, UK) 
was added to tissue slices and left for 15 minutes before the slices were washed three times in PBS 
(Fisher Scientific, UK). Biotin (Vector Laboratories, UK) was then added to the tissue slices and left for 
15 minutes before being tapped off. The desired primary antibody was then applied to each of the 
tissue slices (100µL/slice) and the slices were left overnight at room temperature in a moist chamber. 
The dilutions at which antibodies were used was determined through previous optimisations in the 
laboratory. Optimisation was performed for the following newly acquired antibodies: anti-GFP, anti-
VV as well as anti-HMGB1 antibodies.  Three further washes with PBS (Fisher Scientific, UK) were 
performed before the addition of Universal secondary antibody (Vector Laboratories, UK) for 30 
minutes to rabbit monoclonal or polyclonal antibodies. These slices were then washed with PBS 
(Fisher Scientific, UK) before adding Vectastain R.T.U ABC reagent (Vector Laboratories, UK). This was 
left for 30 minutes before slices were once again washed with PBS (Fisher Scientific, UK). For slices to 
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which a goat polyclonal primary antibody was added these were washed three times in PBS before 
adding ImPRESS™anti-goat HRP reagent (Vector laboratories, UK) and leaving for 30 minutes before 
washing with PBS. 
DAB peroxidase substrate solution (Vector Laboratories, UK) was added to each of the sections for 3-
10 minutes. Sections were then rinsed in distilled water before being counterstained by Haematoxylin 
QS (Vector Laboratories, UK) for up to 45 seconds. They were then immediately rinsed and placed in 
running water for 5 minutes.  
Tissue was then dehydrated in a series of 50%, 70%, 100% ethanol (Fisher Scientific, UK) and in three 
changes of 100% xylene (Sigma, UK). Slices were left to dry completely before being mounted with 
Vector mounting media (Vector Laboratories, UK) and a glass coverslip (VWR International). Slides 
were left to set until dry before being assessed under a light microscope. 
Table 2.8 Primary antibodies used for immunohistochemical staining 
Primary antibody Description Dilution Source 
Anti-Ki67 (ab16667) Rabbit monoclonal 1:100 Abcam, UK 
Cleaved Caspase 3 (Asp175) Rabbit monoclonal 1:50 Cell signalling Technology®, USA 
Anti-green fluorescent protein (ab6673) Goat polyclonal 1:2000 Abcam, UK 
Anti-Vaccinia virus (ab35219) Rabbit polyclonal 1:6000 Abcam, UK 
Anti-HMGB1 antibody (ab79823) Rabbit monoclonal 1:400 Abcam, UK 
   
2.4.4 Quantification of 3,3′-Diaminobenzidine (DAB) immunohistochemical staining 
 
Evaluation of immunohistochemical staining was performed using the open resource digital image 
analysis software, ImageJ. The IHC profiler application developed by Varghese et al 131 enables 
automated digital IHC analysis for unbiased, quantitative assessment of antibody staining intensity in 
tissue sections.  To create this programme the authors adopted the spectral deconvolution method 
of DAB/haematoxylin colour spectra by using optimised optical density vectors of the colour 
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deconvolution plugin for separation of the DAB colour spectra. The plugin has been assessed on 
thousands of scored DAB stained IHC images. A comparison study between use of the plugin and 
manual analysis resulted in an 88.6% match with a statistical significance of P<0.0001 131. 
IHC staining was performed as outlined in materials and methods. Using the Zeiss Primo Star 
microscope digital images were taken at three random areas of each DAB stained tissue slice and 
analysed using the IHC profiler application for Image J. The percentage of highly positive DAB 
staining for each digital image was calculated using the software and then an average reading was 
taken per tissue slice. 
 
2.5 Evaluation of VACV in organotypic culture 
 
2.5.1 Detection of virus presence in 300µm tissue slices by confocal microscopy 
 
Following treatment of tissue with virus containing GFP, slices were fixed in 4% formalin solution 
(Sigma, UK) and left overnight. The following day tissue slices were washed with two washes in PBS 
(Fisher Scientific, UK) for 5 minutes each. Tissue was then blocked with Tris-buffered saline (Sigma, 
UK) with 0.2% Tween-20 (Sigma, UK) and 1% FBS (Life Technologies, UK) for 15 minutes. TOPRO®-3 
nuclear stain (Life Technologies, UK), diluted 1:400 in 1% PBS/BSA, was added and tissue was left for 
30 minutes. Tissue slices were then mounted onto Dako slides (Dako, UK) and Vectashield hard set 
mounting medium (Vector laboratories, UK) was added and a cover slip placed on top. Tissue was then 
taken to the confocal microscope (Nikon A1M confocal laser scanning microscope for assessment. 
2.5.2 Detection of virus presence in paraffin embedded 4µm tissue slices by confocal microscopy 
 
Paraffin embedded tissue slices, treated with virus containing GFP, were deparaffinised in three 5-
minute washes in 100% xylene (Sigma, UK) for 5 minutes. They were then washed in 100% ethanol 
(Fisher Scientific, UK) twice. Following washes in ethanol the tissue slices were placed in 0.3% 
methanol/hydrogen peroxide (Sigma, UK) for 20 minutes, blocking endogenous peroxidases. Tissue 
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slices were then rehydrated in 70% and 50% ethanol (Fisher Scientific, UK) before being rinsed in 
distilled water for 5 minutes. 
Slides were then air dried before the addition of TOPRO®-3 nuclear stain (Life Technologies, UK), 
diluted 1:400 in 1% PBS/BSA. This was left for 30 minutes. Following this, Vectashield hard set 
mounting medium (Vector laboratories, UK) was added and a cover slip placed on top. Tissue was then 
taken to the confocal microscope (Nikon A1M) for assessment. 
2.5.3 Enzymatic assays 
 
FCU1 activity was assessed in treated organotypic cultures through the measurement of 5-FC and 5-
FU as substrates. Organotypic cultures were left untreated, treated with media 100µM 5-FC (Abcam, 
UK) treated with virus alone or treated with virus and 100µM 5-FC. 5-FC was added at 48 hours 
following infection with VV-FCU1. At 24-hour time intervals 50µL supernatant was taken and frozen 
up to 96 hours following treatment. The samples were then transported on ice to Transgene 
laboratories in France where high performance liquid chromatography (HPLC) was performed. After 
thawing the frozen supernatant samples 5-FC and 5-FU were separated isocratically using HPLC 
(Hewlett Packard HP 1100 liquid chromatograph with UV detection at 260nm and 280nm). A Supelco 
supelcosil LC-18-S (5µm packing; 4.6 x 250mm) column and a guard cartridge (10 x 3 mm; Varian, Les 
Ulis, France) with a flow rate of 1ml min-1. The mobile phase was 20mM KH2PO4, 5mM 
tetrabutylammoniumsulfate, 5% methanol adjusted to pH5 with potassium hydroxide.    
 
2.5.4 Focused ultrasound delivery and cavitation detection 
 
Ultrasonic exposures were carried out using the System for Acoustic Transfection (SAT) chamber. This 
system was based on prior design 132 but modified to allow a decrease in the exposure area for the 
prepared tumour slices. Tumour slices and treatment agents were contained in a sonolid assembly 
that consisted of a 35mm cell culture dish (µ-dish) (Ibidi, Germany) fitted to a polydimethylsiloxane 
(PDMS) lid (Dow Corning, USA). Details of the construction and assembly are the same as in Carugo et 
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al. except that for this experiment a 12mm Millipore® Millicell® cell culture insert (Sigma, UK) was 
inserted between the cell culture dish and the sonolid. The sonolid was sealed over the cell culture 
dish with Millipore® Millicell® cell culture insert (Sigma, UK) within it ensuring that no air pockets were 
within the assembly (Figure 2.2). 
The sonolid was held in the SAT by a circular bracket in the pre-focal region of 40mm radius, 120mm 
radius of curvature, 1.1MHz center frequency ultrasound transducer (Sonic Concepts, USA), such that 
the incident pressure field was focussed on the Millipore® Millicell® cell culture insert. The transducer 
drive signal path consisted of a waveform generator (Agilent Technologies, UK), low-pass filter (Mini-
Circuits, UK) and power amplifier (E&I Ltd, USA). 
When the cell culture plate inserts, culture dishes and sonolids were in the ultrasound chamber they 
were exposed to 1.1MHz, 150mV, 40 cycles at 10ms pulse duration for 20 seconds in total. These 
conditions were kept constant throughout the experiment. 
 
 
Figure 2.2 Schematic representation of instrument set up and organotypic culture position for exposure to cavitational 
ultrasound. Set up based on previous published work by Carugo et al. 132. Following preparation of organotypic cultures these 
were then placed inside a 12mm Millipore® Millicell® cell culture insert fixed within a cell culture dish. The cell culture insert 
was then submerged in the desired treatment with or without 50µL SonoVue microbubbles. This was sealed with a Sonolid, 
ensuring that there were no bubbles within the set up. This was then placed into supporting apparatus and submerged in the 
SAT chamber above the ultrasound transducer and exposed to ultrasound frequency as described. 
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2.5.5 Experimental protocol 
 
Prepared tumour slices were placed within 12mm Millipore® Millicell® cell culture inserts (Sigma, 
UK) within a cell culture disc. The cell culture insert containing the tissue slice was filled with 850µL 
of the desired treatment: 
1. DMEM alone 
2. DMEM plus 50µL SonoVue microbubbles (Bracco Imaging, France) 
3. Vaccinia Virus (Transgene, France) in media plus 50µL SonoVue microbubbles (Bracco 
Imaging, France) 
Tissue slices were completely submerged within the cell culture insert.  The sonolid was attached as 
described and the dish was then taken for ultrasound application in the SAT. 
Following treatment exposure, tissue slices were removed from the SAT apparatus and transferred 
onto Millipore® Millicell® cell culture inserts (Sigma, UK) within a 6-well plate. 1mL 10% FBS DMEM 
media was added to the bottom of these wells with an additional 250-500µL being placed within the 
insert containing the tissue slice. The tissue was then placed inside an incubator at 37°C, 5% CO2 and 
placed onto a rotating tissue slice incubation unit (Alabama Research & Development, USA). 
 
2.6 Statistical Analysis 
 
All statistical calculations were performed using GraphPad Prism Version 7.04 software. Two-way 
analysis of variance (ANOVA) with Bonferroni correction was performed for multiple comparisons. In 
the assessment of immunogenic cell death two-way ANOVA was also performed for the comparison 
of multiple means with the Tukey post-hoc test or the Bonferroni correction. Results are shown in 
graphs with error bars shown. For all tests, a 5% significance level was used. Therefore, the following 
symbols were used in figures to show the level of significance: *p<0.05; **p<0.01; ***p<0.001 and 
****p<0.0001 
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Chapter 3 – Evaluation of the effects of oncolytic vaccinia virus in 
colorectal cancer cell lines 
 
3.1 Introduction 
 
Colorectal cancer (CRC) is the fourth most common cancer in the UK. At the time of diagnosis 
approximately 20% of patients will present with distant metastatic disease 48. Only 10-20% of patients 
with metastatic colorectal liver metastases are candidates for surgical resection, with the vast majority 
presenting with liver metastases that are not amenable to resection 14. This group of patients will 
receive systemic chemotherapy, either given with palliative intent or as a neo-adjuvant treatment with 
the aim of downsizing tumour burden and converting patients to operable disease. Fluorouracil is the 
mainstay of chemotherapy treatment and has been shown to reduce recurrence rates by 17% and to 
improve overall survival by 13-15% 53. A novel approach to the treatment of metastatic colorectal 
cancer is with oncolytic virotherapy. This utilises viruses that have the ability to replicate within 
tumour cells naturally or are modified to selectively replicate within tumour cells. It has long been 
recognised that viruses have the ability to kill cancer cells and recently clinical trials have shown 
evidence of a therapeutic benefit in patients with multiple tumour types 65-67.  Following oncolysis, 
tumour cells release tumour associated antigens. These are then able to promote an adaptive immune 
response that mediates an anti-tumour effect at distant tumour sites. Following oncolytic cell death 
tumour cells also release viral PAMPs as well as danger associated molecular patterns (DAMPs) such 
as heat shock proteins (HSPs), high mobility group box 1 proteins (HMGB1), calreticulin, adenosine 
triphosphate (ATP), and uric acid. They also release cytokines that promote the maturation of antigen 
presenting cells such as dendritic cells. Release of tumour associated antigens in combination with 
cytokines and DAMPs can be beneficial in the generation of an immune response against cancer cells. 
This is particularly important in the generation of an anti-cancer immune response to tumours that 
are distant to the site of virus administration 68.  
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Vaccinia virus is one such form of oncolytic virus. It belongs to the Poxviridae family and is the most 
well studied virus in this family having been utilised as a vaccine during the eradication of smallpox. 
With regards to the treatment of cancer, oncolytic vaccinia virus is a promising candidate and has been 
shown to replicate and lyse cancer cells within 72hrs of infection 101. It exhibits broad tumour tropism 
and is stable in the bloodstream enabling treatment of distant metastases. It also spreads rapidly 
within tumours, whilst having a large transgene-encoding capacity 78,101. Vaccinia virus has an excellent 
safety profile in humans given its use in the smallpox vaccination process 102. In its use as an oncolytic 
virus, vaccinia has been attenuated to improve its selectivity for infection of cancer cells. Several 
versions are currently in use in clinical trials, the most prominent of which is JX-594. Most cancer 
therapies rely on the use of multiple agents in conjunction with one another. Similarly, it has been 
demonstrated that there is a superior effect when oncolytic virotherapy is used in combination with 
traditional therapies. For many years 5-FU has been the principle active agent to treat colorectal 
cancer and is still included in chemotherapy regimens for the treatment of colorectal liver metastases. 
Due to the systemic toxicity of 5-FU experienced by patients new approaches have been made aiming 
to concentrate it within tumour tissue, therefore limiting these side effects. One such technique is 
suicide gene therapy. This technique converts a non-toxic pro-drug into potent chemotoxins delivered 
by vaccinia viruses directly to the cancer cells. One example of this type of suicide gene therapy is the 
incorporation of the fusion suicide gene (FCU1). Vaccinia virus encoding the fusion suicide gene has 
been shown to be a promising candidate for patients with colorectal cancer and liver metastases in in 
vitro and in vivo studies 130.  
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3.1.1 Aims 
 
The aim of this chapter was to determine if colorectal cancer cell lines were susceptible to the 
oncolytic vaccinia viruses VVTK-I4L-/GFP and VVTK-I4L-/FCU. Furthermore, we wanted to assess the 
mode of cell death if susceptibility to treatment was demonstrated to assess if cell death was 
immunogenic. 
In order to assess this the following experiments were performed: 
1. Infection of 3 representative colorectal cancer cell lines with vaccinia virus and assessment of 
oncolysis by Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation Assay (MTS assay) to 
validate previous findings 
2. To determine the primary mode of cell death induced by oncolytic vaccinia virus by 
phycoerythrin (PE) Annexin V apoptosis detection and western blotting 
3. To determine if there was evidence of immunogenic cell death through the detection of 
determinants and markers of immunogenic cell death using flow cytometry and by enzyme 
linked immunosorbent assay (ELISA) 
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3.2 Results 
 
3.2.1 Susceptibility of colorectal cancer cell lines to Vaccinia Virus 
 
The first step in this experiment was to confirm the susceptibility of colorectal cancer cell lines to 
vaccinia virus. Three standard colorectal cancer cell lines were selected to assess this, these were 
HT29, HCT116 and SW620 colorectal cell lines. To assess the susceptibility of each of these, cells were 
plated on a 96-well plate and were then treated with serial dilutions of vaccinia virus at multiplicity of 
infection (MOI) ranging from 1x10-6 up to an MOI of 1 for up to 72 hours (Figure 3.1). Cells lines were 
treated with media alone as a comparative negative control. Cell survival was then analysed using an 
MTS assay as described in methods. 
The response to vaccinia virus infection varied in this panel of colorectal cell lines. MTS assay (see 
methods) was used to assess for a reduction in cell proliferation. Both the HCT116 and SW620 cell 
lines demonstrated a reduction in cell proliferation using this assay following treatment with vaccinia 
virus. At the highest MOI in these experiments, less than 25% of cells remained viable after 72 hours 
of incubation with virus. Using the MTS cell proliferation assay, the HT29 cell line did not demonstrate 
any reduction in cell proliferation following 72 hours of treatment. At the maximum MOI of 1, more 
than 90% of these cells treated with vaccinia virus appeared to remain viable according to the results 
of the assay (Figure 3.1). 
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Figure 3.1 Cell proliferation assay at 72 hours following treatment of colorectal cancer cell lines with oncolytic vaccinia 
virus. Cells were plated on 96-well plates at a set seeding denisty. Oncolytic vaccinia virus was added to wells at varying MOIs 
and incubated for up to 72 hours. MTS assay was performed to assess for effects of vaccinia virus on HCT116, SW620 and 
HT29 colorectal cancer cell lines. A minimum of three experimental repeats were performed in each cell line. 
 
3.2.2 Assessment for presence of vaccinia virus through expression of green fluorescent 
protein in cell lines using fluorescent microscopy 
 
As one form of the vaccinia virus used in our experiments encoded green fluorescent protein (GFP) 
this enabled us to assess for viral presence through its expression using simple fluorescent microscopy 
in the first instance. 
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We plated each of the 3 cell lines in 6-well plates and treated them with serial dilutions of vaccinia 
virus and these were incubated for up to 72 hours. At each 24-hour interval the cell lines were assessed 
using a fluorescent microscope to assess for expression of GFP as a marker of vaccinia virus presence 
on the plate. Over 72 hours each cell line was found to have increasing expression of GFP on 
fluorescent microscopy suggesting proliferation of vaccinia virus (figure 3.2). 
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Figure 3.2 Evidence of viral infection in tissue culture using immunofluorescence. Visualisation of GFP expression through 
immunofluorescence in colorectal cancer cells treated with oncolytic vaccinia virus expressing green fluorescent protein over 
72 hours at varying MOIs. Images shown for HCT116 and HT29 colorectal cancer cell lines with comparative panel of images 
for comparison between 24 and 72 hours of treatment. A minimum of three experimental repeats were performed in each 
cell line 
 
Having confirmed virus presence in tissue culture experiments through the expression of GFP using 
immunofluorescence, it was unclear as to why these MTS results were seen in the HT29 colorectal 
cancer cell line. The immunofluorescent images obtained also demonstrated an apparent increased 
expression of GFP over time as with the other cell lines, suggestive of viral replication in this cell line 
(Figure 3.2). As there was evidence of increasing GFP expression in the HT29 colorectal cancer cell line 
under direct visualisation, but there was no evidence of reduced cell proliferation with MTS assay we 
wanted to further assess this cell line for evidence of any vaccinia virus effects in the treated cell line 
prior to progressing with further experiments. To do this we utilised PE annexin V to assess for 
evidence of cell death. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing PS to the 
external cellular environment. Annexin V is a 35-36kDa calcium dependent phospholipid binding 
protein that has a high affinity for PS. Annexin V may be conjugated by fluorochromes, retaining its 
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binding affinity to PS and enabling flow cytometric analysis of cells that are undergoing apoptosis. 7-
amino-atinomycin (7-AAD) is a dye which allows identification of early apoptotic cells. Cells with intact 
membranes are not permeable to the dye whereas dead and damaged cells are permeable to it. This 
allows the distinction to be made between cells in early apoptosis, late apoptosis and necrosis and 
would give us the information required to assess for an effect of vaccinia virus on the HT29 cell line. 
HT29 cells were treated in the same way as with previous experiments with the same range of MOI 
(1x10-6 to 1) of vaccinia virus. The results of this experiment demonstrated an increase in cell death of 
this colorectal cancer cell line when treated with oncolytic vaccinia virus (Figure 3.3). At the maximum 
MOI of 1, less than 20% of cells were alive after 48 hours. This finding therefore confirmed that all 
three colorectal cancer cell lines intended for use in further experiments were susceptible to 
treatment with oncolytic vaccinia virus. 
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Figure 3.3 Evidence of cell death in HT29 cells following treatment with vaccinia virus. PE annexin V assay assessing cell 
survival in HT29 colorectal cancer cells treated with oncolytic vaccinia virus at 72 hours with varying MOIs. 
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3.2.3 Control experiments 
 
To confirm that these were accurate results secondary to vaccinia virus infection control experiments 
were performed on all three cell lines. Vaccinia virus expressing GFP was first heat inactivated at 70°C 
for 10 minutes based on preliminary experiments (Figure 3.4) 
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Figure 3.4 Effects of vaccinia virus following heat inactivation. Heat inactivation of virus and percentage cell survival based 
on MTS assay. SW620 cell lines were treated with vaccinia virus expressing GFP at an MOI of 1, that had been heat inactivated 
at varying temperatures for varying times. The lowest temperature and duration of heating were chosen for further 
experiments. We therefore heat inactivated the virus at 70°C for 10 minutes. Immunofluorescent image also taken following 
heat inactivation of virus at 70°C for 10 minutes with no GFP expression following this mode of inactivation. Two experimental 
repeats were performed. 
 
Untreated cells in media and heat inactivated virus were used as negative controls, whilst cisplatin 
was used as a positive control, having been previously shown to have a cytotoxic effect in colorectal 
cancer cell lines. The results from our control experiments demonstrated that there was no reduction 
in cell survival in colorectal cancer cell lines left in media and also treated with heat inactivated 
vaccinia virus over 72 hours. The cisplatin positive control did cause a reduction in cell survival and 
this was less marked than for cells treated with virus (Figure 3.5). 
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Figure 3.5 Effects of vaccinia virus and positive and negative controls on colorectal cancer cell lines. Control experiments 
assessing cell survival following treatment with virus, cisplatin, heat inactivated vaccinia virus and colorectal cancer cells left 
in media alone. Results obtained using MTS cell proliferation assay. Three experimental repeats were performed in this 
experiment. 
 
3.2.4 Comparison of effects of VV-GFP and VV-FCU1 
 
As we were provided with two types of vaccinia virus, one encoding GFP, and the other encoding the 
fusion suicide gene FCU1 required for pro-drug activation, we wanted to assess that the effects of 
both types of virus to ensure that they were similar and to exclude any interference of results by GFP 
or FCU1. To do this we therefore performed comparative MTS assays using both forms of virus and 
our colorectal cancer cell lines. 
Figure 3.6 shows the MTS assays used to assess cell viability in two of three of our colorectal cancer 
cell lines SW620 and HT29. Both cell lines were treated with both forms of vaccinia virus as described 
in methods and left to incubate for 72 hours. The results of our experiments demonstrated that both 
types of vaccinia exerted similar effects on our colorectal cell lines. This confirmed that the effects 
that were demonstrated in our tissue culture experiments was due to vaccinia virus rather than GFP 
or FCU1. 
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Figure 3.6 Effects of both forms of vaccinia virus used in our experiments on colorectal cancer cell lines. Control experiment 
comparing the effects of VV-FCU1 and VV-GFP on colorectal cancer cell lines. Tissue culture was performed as described in 
methods. Cells were treated with virus for 72 hours. Three experimental repeats were performed. 
 
3.2.5 Determination of mode of cell death 
 
The mechanism of tumour cell death is poorly understood following treatment with vaccinia virus. 
Several modes of cell death have been implicated to varying degrees. These include apoptosis, 
necrosis, necroptosis and autophagy 133. Vaccinia virus strain also is a factor in the type of cancer cell 
death that occurs 133. 
We first wanted to assess for evidence of apoptotic cell death. Characteristics of cells undergoing 
apoptosis includes chromatin condensation, DNA fragmentation and membrane blebbing 134. This 
form of cell death occurs in all normal tissues, causing a silent death where phosphatidylserine (PS) is 
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expressed on the cell surface as a signal attracting antigen presenting cells (APCs). There are two main 
pathways of apoptosis: the extrinsic and intrinsic pathways. The extrinsic pathway is ligand 
dependent. Tumour necrosis factor alpha (TNF α) and Fas ligand (Fas L) bind to their respective 
receptors, leading to the recruitment and activation of caspase 8 by dimerization. Activation of 
caspase 8 results in cleavage of executioner caspses 3 and 7 and this results in target cell degradation. 
Mitochondrial stress and damage results in the release of cytochrome C from mitochondrial pores. 
This results in the formation of an apoptosome with caspase 9 as well as adaptor protein apoptotic 
protease-activating factor-1 (APAF1). This leads to cleavage and recruitment of executioner caspases 
and to apoptotic cell death 135. 
Poly (ADP-ribose) polymerase (PARP) detects and repairs breaks in DNA. This is a target of the 
executioner caspases and undergoes proteolysis prior to the onset of apoptosis. Cleavage of PARP at 
the execution stage of apoptosis is one of the hallmarks of apoptosis. 
Firstly, we looked for evidence of apoptotic cell death using the PE Annexin V assay. This assay was 
carried out as outlined in methods. All three colorectal cancer cell lines were treated for a 72-hour 
time course (Figure 3.7). In order to validate results of treatment with vaccinia virus, cells were also 
treated with comparative controls. These controls included: no treatment, heat inactivated vaccinia 
virus and cisplatin treatment. Over 72 hours there was an increase in Annexin V and 7-amino-
actinomycin D (7-AAD) following treatment of all three colorectal cell lines with vaccinia virus (Figure 
3.7). These results are consistent with cell death being predominantly apoptotic as the binding of 
annexin V to externalised phosphatidylserine indicates the presence of apoptosis, whilst 7-AAD 
staining is indicative of cell death, with early apoptotic cells excluding this dye and late apoptotic cells 
staining positively when the dye passes into the nucleus and bind to DNA. 
Our results showed an increase in apoptosis in the three colorectal cancer cell lines treated with virus 
over the 72-hour time course, with the percentage of apoptosis increasing in a time-dependent 
manner. In the untreated and heat inactivated virus negative control groups there was very little cell 
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death over 72 hours compared with virus and cisplatin treatment (Figure 3.7). The cisplatin positive 
control group did show an increase in cell death over 72 hours, however this was less than virus 
treatment. 
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Figure 3.7 Assessment of mode of cell death in colorectal cancer cell lines treated with vaccinia virus compared with 
controls. FACS plots for SW620, HT29 and HCT116 cell lines treated with vaccinia virus and controls at 72 hours. Flow 
cytometry performed as outlined in methods. Two experimental repeats were performed. 
 
These findings suggest that treatment with this strain of vaccinia virus resulted in apoptotic cell death 
in these three colorectal cancer cell lines. To further assess for apoptotic death western blotting was 
performed as described in methods. Poly (ADP-ribose) polymerase (PARP) is a 116kDa polymerase 
that appears to be involved in DNA repair in response to stress 136. PARP can be cleaved and is one of 
the main targets of caspase-3 which is one of the key mediators of apoptotic cell death in vivo 137. 
Given the initial results of the PE annexin V assay which indicated apoptotic cell death in treated 
colorectal cancer cell lines we anticipated that our western blot would result in reduced presence of 
the 116kDa PARP band. HCT116, HT29 and SW620 colorectal cancer cell lines were treated with 
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vaccinia virus, with control cells left untreated. Jurkat cells were treated with 25µM etoposide as 
recommended by the manufacturer as a positive control. 
In the HCT116 colorectal cancer cell line treated with vaccinia there was a reduction in the 116kDa 
band on western blotting compared with untreated controls over 72 hours suggesting cleavage of 
PARP and indicating apoptotic cell death (Figure 3.8). In the SW620 cell line at 72 hours post treatment 
there was a reduction in the 116kDa band in comparison with untreated control which also indicated 
apoptotic cell death. There did not appear to be any obvious reduction in this band in the HT29 cell 
line over 72 hours when compared with untreated controls (Figure 3.8). 
For two of the three cell lines used in this experiment the western blotting results supported the 
findings from the initial experiment with PE annexin V suggesting that the primary mode of cancer cell 
death following treatment with vaccinia was apoptosis. 
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Figure 3.8 Assessment of apoptotic cell death in colorectal cancer cell lines treated with vaccinia virus using western 
blotting. Western blotting assessing for PARP cleavage in colorectal cancer cell lines treated with oncolytic vaccinia virus. All 
three cell lines were treated for 72 hours as outlined in methods. Western blotting performed as described in methods. In 
HCT116 colorectal cell line there was an apparent reduction in PARP bands at 24, 48 and 72 hours in virus treated cells (VV) 
compared with untreated controls (UT). There was reduction in PARP at 72 hours in the SW620 colorectal cell line treated 
with VV compared to control however this was not evident at earlier time points. There was no reduction in PARP bands at 
any time points in the HT29 cell line. Positive controls are also displayed and performed as per manufacturers advice. GAPDH 
bands were measured to assess the amount of protein in each well and to validate findings. 
 
As other forms of cancer cell death have been implicated with oncolytic vaccinia virus, further 
experiments were undertaken to see if other modes of cell death were also occurring. Necrotic cell 
death is induced by external factors such as toxins, infection and trauma. This type of cell death is 
morphologically characterised by cellular swelling, rupture of plasma membranes and loss of 
cytoplasmic contents 138. Whilst necrosis has long been viewed as non-programmed cell death its 
execution has been shown to be controlled by specific signal-transduction pathways and catabolic 
mechanisms. This form of programmed necrotic cell death is termed necroptosis. Necroptosis is 
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induced by TNF signalling involving the receptor-interacting protein (RIP) family. Following inhibition 
of apoptosis by the caspase inhibitor activation of RIP1 and RIP3 kinase leads to mitochondrial 
instability and death 138. When RIP1 and RIP3 kinase become phosphorylated this leads to the 
generation of the necrosome, a molecular complex that initiates necroptosis 138.  This leads to 
phosphorylation of mixed lineage kinase domain-like (MLKL) pseudokinase with a resultant influx of 
calcium into the cell. This results in cellular swelling and plasma membrane rupture, releasing 
intracellular components. This mode of cell death has been identified as the predominant mode of 
ovarian cancer cell death following treatment with vaccinia virus by Whilding et al. 133. To assess for 
programmed necrosis in colorectal cancer cell lines we performed western blotting specifically looking 
for an increase in RIP1 and RIP3 kinase bands that would be an indication of necroptotic cell death in 
our colorectal cancer cell lines. 
All three colorectal cancer cell lines were treated with vaccinia virus over a 72-hour time-course as in 
previous experiments. Western blotting was undertaken as outlined in methods. The results from our 
experiments showed reducing RIP1 and RIP3 bands compared to untreated negative controls, rather 
than an increase in these bands as would be expected in necroptosis (figure 3.9). These results indicate 
that there is no evidence of necroptotic cell death in colorectal cancer cells treated with vaccinia virus. 
For positive controls 3T3 cells were treated with cytochrome C as per manufacturers 
recommendations. These positive controls showed an increase in RIP1 and RIP3 bands compared with 
untreated controls. The results of our experiment indicated that cell death in our three colorectal 
cancer cell lines was not necroptosis. 
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Figure 3.9 Assessment of necroptotic cell death in colorectal cancer cell lines treated with vaccinia virus. Western blotting 
assessing for increase in RIP1 and RIP3 bands in colorectal cancer cell lines treated with oncolytic vaccinia virus. All three cell 
lines were treated for 72 hours as outlined in methods. Western blotting performed as described in methods. There was no 
obvious increase in RIP1 and RIP3 bands for all three colorectal cancer cell lines treated with oncolytic vaccinia virus 
throughout the time course compared with untreated controls. Positive controls are also displayed and performed as per 
manufacturers advice. GAPDH bands were measured to assess the amount of protein in each well and to validate findings. 
 
The results of these experiments suggested that the predominant mode of cell death in colorectal 
cancer cells treated with oncolytic vaccinia virus was apoptosis. Apoptosis is classified as a type 1 
programmed cell death 138. Although this has been historically considered to be non-immunogenic 
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several studies have shown that oncological treatments such as irradiation and other agents such as 
doxorubicin can trigger immunogenic apoptosis 138,139. 
3.2.6 Assessment of immune mediated cell death 
 
We then wanted to assess if cell death in colorectal cancer cell lines treated with oncolytic vaccinia 
virus was immune mediated. We decided to assess a panel of DAMPs that are markers of immune 
mediated cell death. These DAMPs included: high-mobility group box 1 protein (HMGB1), calreticulin 
(CRT), and heat shock protein 70 (HSP70). We also decided to look for other proteins that are 
determinants of immune mediated cell death. These included CD80, human leukocyte antigen (HLA), 
programmed death ligand 1 (PD-L1) and first apoptosis signal receptor (FAS). CD80 is a protein found 
on dendritic cells, activated B cells and monocytes that provides a costimulatory signal required for T 
cell activation. HLA is a gene that encodes the major histocompatibility complex proteins in humans 
and is responsible for the regulation of the immune system. PD-L1 is a transmembrane protein that 
plays a role in immunosuppression after it binds to its receptor PD-1 found on activated T cells, B cells 
and myeloid cells. Expression of PD-L1 may result in immune evasion by cancers and inhibit response 
to treatment with oncolytic viruses. FAS is a death receptor on the cell surface that leads to apoptotic 
cell death. 
Flow cytometry and ELISA were performed as described in methods to assess for immunogenic cell 
death in the three colorectal cancer cell lines. Mitoxantrone an anthracycline, was used as a positive 
control as this has been proven to induce immunogenic cell death 140. Negative controls included heat 
inactivated virus, as used in previous experiments as well as those left untreated. Cells were left for 
72 hours before being analysed. 
In the HCT116 colorectal cancer cell line there was an increase in calreticulin over 72 hours following 
treatment with vaccinia virus compared with controls. This was statistically significant at the 72-hour 
time-point (p=0.0002) (Figure 3.10). There was also an increase in HMGB1. This also increased over 
the 72-hour time point and was more marked in cells treated with virus compared with controls. At 
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72 hours the difference in HMGB-1 level was statistically significant in the cells treated with virus 
compared with all other controls (VV vs UT p=0.0002; VV vs HI p=<0.0001; VV vs MTX p=<0.0001) 
(Figure 3.10). There was no significant increase in HSP70, FAS, PD-L1 or MHC following treatment with 
vaccinia. 
As there was an increase in both HMGB1 and calreticulin the results of these experiments suggested 
that cell death in HCT116 colorectal cell lines treated with oncolytic vaccinia virus may be 
immunogenic. 
HCT116
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Figure 3.10 Markers of immunogenic cell death in HCT116 colorectal cancer cell lines treated with vaccinia virus. Flow 
cytometry and ELISA performed as described in methods. Cells were treated for up to 72 hours and were assessed for markers 
and determinants of immunogenic cell death at 24-hour intervals. Mitoxantrone (MTX) was used as a positive control. 
Negative controls were heat inactivated virus (HI) and untreated cells (UT). VV = vaccinia virus. Graphs represent pooled data 
from two independent experimental repeats. Statistical analysis using two-way ANOVA. Statistical level of significance: 
*p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
 
In the SW620 colorectal cancer cell line there was an increase in HSP70 over 72 hours following 
treatment with vaccinia virus compared with controls, although this peaked at 48 hours. The increase 
in this marker was found to be significant compared to heat inactivated virus and to positive controls 
treated with mitoxantrone (p=0.03) (Figure 3.11). There was an increase in FAS over 72 hours also and 
once again this was maximal at the 48-hour time point. There was a statistically significant increase in 
FAS in cells treated with vaccinia virus compared with heat inactivated virus (p=0.04), but no 
significant increase compared with other controls (Figure 3.11).  There was also an increase in HMGB1 
over 72 hours. This increased over the 72 hours and was more marked in cells treated with virus 
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compared with controls. At 72 hours the difference in HMGB-1 level was statistically significant in the 
cells treated with virus compared with all other controls (VV vs UT p=0.001; VV vs HI p=0.0004; VV vs 
MTX p=0.04) (Figure 3.11). There was no significant increase in CRT, PD-L1 or MHC following treatment 
with vaccinia. 
There was an increase in 3 of the 7 markers that were assessed. This was most marked however in the 
case of HMGB1 with a gradual increase over the 72 hours. It was also significant compared with all 
other controls.  The results from this cell line suggest that cell death following treatment with oncolytic 
vaccinia virus may be immunogenic. 
 
SW620 
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Figure 3.11 Markers of immunogenic cell death in SW620 colorectal cancer cell lines treated with vaccinia virus. Flow 
cytometry and ELISA performed as described in methods. Cells were treated for up to 72 hours and were assessed for markers 
and determinants of immunogenic cell death at 24-hour intervals. Mitoxantrone (MTX) was used as a positive control. 
Negative controls were heat inactivated virus (HI) and untreated cells (UT). VV = vaccinia virus. Graphs represent pooled data 
from two independent experimental repeats. Statistical analysis using two-way ANOVA. Statistical level of significance: 
*p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
 
In the HT29 colorectal cancer cell line there was an increase in CRT, HSP70 and MHC over 72 hours 
following treatment with vaccinia virus compared with controls. The increase in these markers were 
not statistically significant when compared to controls (Figure 3.12). At 48 hours there was an increase 
in CD80 in cells treated with vaccinia virus and this was significantly raised compared with all other 
controls (p=0.01), this did not continue to 72 hours (Figure 3.12). As with the previous cell lines there 
was an increase in HMGB1 over 72 hours. This increased over the 72 hours and was more marked in 
cells treated with virus compared with controls. At 72 hours the difference in HMGB-1 level was 
statistically significant in the cells treated with virus compared with negative controls but not 
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compared with positive controls (VV vs UT p=0.01; VV vs HI p=0.02) (Figure 3.12). There was no 
increase in FAS, PD-L1 or MHC following treatment with vaccinia virus. 
There was a significant increase in 2 of the 7 markers of immunogenic cell death that were assessed. 
Once again this was most marked in the case of HMGB1 with a gradual increase over the 72 hours.  
The results from this cell line suggest that cell death following treatment with oncolytic vaccinia virus 
may be immunogenic. 
 
HT29 
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Figure 3.12 Markers of immunogenic cell death in HT29 colorectal cancer cell lines treated with vaccinia virus. Flow 
cytometry and ELISA performed as described in methods. Cells were treated for up to 72 hours and were assessed for markers 
and determinants of immunogenic cell death at 24-hour intervals. Mitoxantrone (MTX) was used as a positive control. 
Negative controls were heat inactivated virus (HI) and untreated cells (UT). VV = vaccinia virus. Graphs represent pooled data 
from two independent experimental repeats. Statistical analysis using two-way ANOVA. Statistical level of significance: 
*p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
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3.3 Discussion 
 
We initially set out to see if three colorectal cancer cell lines that had been shown to be susceptible 
to treatment by other forms of oncolytic vaccinia virus such as JX-594 were susceptible to the vaccinia 
virus used in our experiments. As with JX-594 our oncolytic vaccinia virus was genetically modified to 
improve its tolerability and effectiveness compared with naturally occurring vaccinia virus. Deletion 
of thymidine kinase ensures that virus replicates specifically in tumour cells rather than in healthy 
cells. We initially confirmed viral presence and replication through direct immunofluorescence in 
tissue culture over 72 hours. This preliminary information indicated that the virus was replicating over 
the course of the experiment as GFP appeared to be increasing over time. To quantify the effects of 
VV-GFP we then performed MTS proliferation assays. The result from our three colorectal cell lines 
was mixed as two of the three lines (HCT116, SW620) treated with vaccinia showed an obvious 
reduction in cell proliferation following treatment for 72 hours at relatively low MOIs whilst a third 
cell line (HT29) did not. This finding contrasted with the increased visualisation of GFP under direct 
immunofluorescence in our preliminary experiment. The results of the MTS assay may be attributable 
to overseeding of the well plate with a resultant high readout due to the reduction of MTS by 
mitochondrial reductase in the HT29 cell line. The result could also be a product of the cell line being 
contaminated or contamination of any of the constituents of tissue culture during cell passage. As is 
known with immortalised cell lines, after serial passaging the resultant cell lines over time develop 
changes so that they differ from their original cell precursor. If this has happened with the HT29 cell 
lines in this case then there could be a change in the behaviour of these cells and a resultant resistance 
to infection by vaccinia virus compared with the other two colorectal cancer cell lines which were 
assessed in the same way. To further assess the HT29 cell line we then performed a cell death assay 
using PE annexin V. The results from this experiment found that treatment of HT29 with VV-GFP did 
result in cell death. These findings reassured us that the virus was having an effect in this cell line as 
suggested by the increased GFP expression under direct immunofluorescence and in contrast to MTS 
results. It is not clear why the MTS assay result did not show a reduction in cell proliferation in the 
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HT29 cell line. This could potentially have been due to over-seeding of the cells in tissue culture 
compared with other studies however, the cells were always assessed pre-treatment and 80% 
confluence was visually confirmed, as with the other cell lines. Once treated the cells also appeared 
to be decimated by the vaccinia virus at 72 hours. Figure 3.13 demonstrates the change in appearance 
of HT29 cell lines using grey scale microscopy following treatment with VV-GFP at an MOI of 1 at 24 
and 72 hours for comparison. The images are in clear contrast with one another as after 72 hours the 
treated HT29 cells are condensed and aggregated compared with the appearance at 24 hours. They 
were also no longer attached to the base of the well-plate. As the results of PE annexin V testing 
showed evidence of cell death in keeping with other published studies utilising the HT29 cell line 
treated with other types of oncolytic vaccinia virus, we decided to include the cell line in further 
experiments 78,141. This cell line could be further investigated through lower well-plate seeding, a 
longer incubation period with virus, or even a shorter exposure to MTS. If these results still did not 
show infectivity of virus then further interrogation into reasons for resistance could be assessed.  
 
Figure 3.13 Appearances of HT29 cell line following treatment with VV-GFP at MOI 1 at 24 and 72 hours. 
 
Once we had confirmed susceptibility of these cell lines to vaccinia virus we then went on to assess 
for the mode of cell death. This was assessed using PE annexin V to assess for apoptosis and necrosis 
as well as western blotting, looking again at apoptosis but also necroptosis. Our experiments found 
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that the predominant mode of cell death in these treated colorectal cancer lines was apoptosis. The 
type of cell death is thought to be important with regards to immunogenicity and the influence on 
immune cells in the tumour microenvironment. Apoptosis has historically been considered to have 
been non-immunogenic, however some anti-cancer agents have been shown to trigger immunogenic 
apoptosis 138. Immunogenicity of oncolytic viruses is beneficial as it can result in the release of tumour 
associated antigens which are then able to promote an adaptive immune response that mediates an 
anti-cancer effect at distant sites of disease. This has clinical implications for the delivery of oncolytic 
viruses and could result in the systemic administration of OVs to treat tumours rather than depending 
on intratumoral administration which can limit their application in certain circumstances. Mode of cell 
death was also investigated using flow cytometry for autophagy. Results from our experiments did not 
show that there was any evidence of autophagy in our three-tested colorectal cancer cell lines (data 
not shown). 
To assess if apoptotic death was immunogenic in our treated cell lines we performed flow cytometry 
and ELISA to assess for a panel of markers and determinants of immunogenic cell death as described 
earlier in this chapter. The results of all three colorectal cancer lines treated with oncolytic vaccinia 
virus were variable however each cell line was noted to have an increase in certain markers and 
determinants of immunogenic cell death. In the HCT116 cell line there was a statistically significant 
increase in calreticulin and HMGB1 compared with controls over 72 hours. In the SW620 cell line there 
was an increase in HSP70 and FAS over 72 hours that peaked at 48 hours but was statistically 
significant compared with controls. As with the HCT116 cell lines there was a statistically significant 
increase in HMGB1 over 72 hours compared with controls. In the treated HT29 cell line there was a 
significant increase in CD80 compared with controls at 48 hours and as with the other two cell lines 
there was a significant increase in HMGB1 expression over 72 hours. Treatment of all three cell lines 
with vaccinia virus consistently resulted in significant increases in HMGB1 expression. These results 
indicate that treatment with vaccinia virus results in apoptotic cell death that is immunogenic in these 
colorectal cancer cell lines. In its use with other cancer cell lines such as melanoma vaccinia virus was 
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seen to induce a higher expression of calreticulin as well as HMGB1 142. HMGB1 can cause additional 
immunogenic effects so that virally induced cell death can influence immune infiltration in tumours to 
attract immune cells and stimulate them 142. Oncolytic viruses appear to be type II inducers of 
immunogenic cell death, selectively targeting the endoplasmic reticulum. They are able to induce 
immunogenic apoptosis by altering homeostasis of the endoplasmic reticulum and triggering stress 
143. In our experiments vaccinia virus was not able to induce a full picture of immunogenic cell death, 
however a mixed type of cell death was seen and this has been shown to be more immunogenic than 
apoptosis alone by other groups 142. 
3.4 Conclusion 
 
Our work has demonstrated that oncolytic vaccinia virus successfully infects and kills colorectal cancer 
cells through a mixed pattern of cell death that is predominantly apoptotic but that is also necrotic. 
This mixed pattern of apoptotic and necrotic cell death has been indicated to be more immunogenic 
than apoptosis alone by other groups 142. We have also found that when infected with vaccinia virus 
colorectal cancer cell lines there was an increase in the expression of some of the markers of 
immunogenic cell death. 
Given the excellent ties with our surgical colleagues at the Royal Surrey County Hospital NHS Trust we 
wanted to assess the effects of VV-GFP and VV-FCU1 in human tissue. We planned to do this using 
excess tissue taken at time of surgery in patients undergoing curative liver resections for metastatic 
colorectal cancer. Moreover, we aimed to assess the pro-drug activation model in human tissue as 
this had previously been described by Foloppe et al. in a colorectal xenograft model in nude mice 130. 
We hoped to develop an organotypic culture method in our laboratory that would enable us to do 
this. 
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Chapter 4 – Development of an organotypic culture model and 
evaluation of the use of oncolytic vaccinia virus in colorectal cancer 
 
4.1 Introduction 
 
Tumours have been appropriately described as pathological organs consisting of cancerous cells and 
stromal tissue supporting these. The stroma of tumours consists of an extracellular matrix made up of 
proteoglycans, hyaluronidase, fibrous proteins and stromal cells. These stromal cells include 
fibroblasts and adipocytes (mesenchymal supporting cells) as well as immune cells and cells of the 
vascular system. Peptide factors such as growth factors, cytokines, chemokines and antibodies are 
also located here. As tumours develop, changes also take place to the stroma and in later stages of 
tumour development the stroma is more supportive of tumour progression than in the early stages of 
cancer 144. The ability to predict tumour response to treatment is difficult. Whilst molecular and 
genetic profiling drives the evolution of personalised anti-cancer therapy, the presence of a molecular 
biomarker does not always translate into a successful clinical outcome 145. An example of this in 
colorectal cancer is the epidermal growth factor (EGFR) inhibitors cetuximab and pantimumab that 
are approved for use in patients with wild-type KRAS but result in clinical benefit in up to 20% of 
patients 145. The ability to identify drug sensitivity to treatment and give an indication of clinical benefit 
would be a valuable tool in the treatment of cancers. The ability to conserve the heterogeneity of 
tumours in vitro would therefore aid the ability to effectively predict tumour response to treatment. 
4.1.2 2D monolayers of tumour cells 
 
Following dissociation this model requires tumours to be adherent to the culture dish. Two types of 
monolayer cultures exist, these include primary cell cultures and immortalised cancer cell lines. 
Primary cultures taken from tumours are more heterogeneous and are therefore more likely to be 
representative of the primary tumour but are limited in their proliferative capacity when compared to 
cancer cell lines. Immortalised cancer cell lines such as those used in tissue culture experiments are 
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clonal outgrowths from a primary tumour. The benefits of 2D models are that they are easy to handle, 
have a homogeneous character and result in limitless growth which allow a high throughput for 
experiments. The immortalisation of cancer cell lines is often inefficient owing to the inability of cells 
to adhere to tissue culture plates as well as their proliferative ability. This results in clonal outgrowth 
and as such these cell lines do not represent the heterogeneity of the primary tumour. These cell lines 
have been shown to have genetic, epigenetic and gene expression differences to the in vivo tumours 
from which they were derived 146,147.  
4.1.3 3D culture models 
 
3D culture systems are a more faithful representation of in vivo tumours as cell to cell interactions can 
occur in these systems. 3D culture systems have been developed so that they are able to grow for 
many passages. This has been established through the embedding of stem cells into a 3D matrix and 
exposure to tissue-specific exogenous growth factors as well as growth factors endogenously 
produced by the stem cell microenvironment and surrounding mesochyme 146. They then organise 
into epithelia of their organ of origin. Similarly, tumour cells have been cultured into spheroid 
structures termed ‘organoids’. This technique has demonstrated long-term expansion ex-vivo of 
tumour cells that maintain the heterogeneity of the original tumour and organoids have been 
developed for several tumour types including colorectal and pancreatic cancers 148.  
Limitations of the 3D culture system include the necessity for a collagen gel for culturing as can 
complicate potential drug screening and also make culturing more labour intensive than the 2D model 
of culture. Organoids that are developed from stem cells also lack the heterogeneity and 
microenvironment of tissue in vivo. This can be addressed through the addition of patient co-cultures 
taken from normal tissue adjacent to the tumour containing stroma. The same method can be adapted 
for cell cultures through the addition of fibrobalsts, endothelial cells and immune cells enabling 
interaction between tumour cells and the stromal cells of the tissue microenvironment 146. The 
generation of organoids takes several weeks which reduces their utility in directing personalised 
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therapy for patients as this would be required in a much shorter time frame 146. Despite this 3D models 
are valuable tools in the development of anti-cancer therapeutics however they lack the complexity 
of the tumour microenvironment and are lacking in any vasculature. 
4.1.4 Patient derived xenografts 
 
Patient derived xenografts are developed from patient tumours that are implanted on immune 
deficient mice. These tumours retain the heterogeneity of the original tumour as the tissue is 
implanted without the necessity for dissociation, they also retain the original tumours characteristics 
such as histological features and metastatic behaviour 146. This model has been used for drug 
screening, the discovery of biomarkers as well as pre-clinical evaluation as in the case of the vaccinia 
virus used in our experiments 130. Systematic analysis of xenografts allow biobanking of genomically 
well-defined tumours and these are useful for developing new biomarkers and individual treatment 
strategies for patients 149. 
As with the other methods described there are also limitations to this technique. These include 
variable engraftment success rates, with highly aggressive tumours having the highest engraftment 
rate thereby potentially skewing the variation of tumours that are seen compared to the population 
146.  These models also take a long time to generate and this results in a relatively low throughput as 
well as being expensive to run 146. Another limitation is due to the necessity for these xenografts to be 
implanted into immunocompromised host animals which makes the evaluation of tumour 
immunology as well as immunotherapeutic agents difficult. As a result, other models are required to 
assess immunotherapies. 
4.1.5 Organotypic cultures 
 
Precision-cut tumour slices or organotypic cultures are a potentially more complete 3D representation 
of the tumour microenvironment in vitro as they do not necessitate excessive manipulation of tissues. 
These slices capture the architecture, heterogeneity and native cellular elements of the tumour of 
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interest rather than surrounding tumour with artificial matrices. Organotypic culture was initially 
reported in chick embryo cardiac tissue and rat brain tissue in 1957 and 1962 respectively 150,151. Tissue 
is taken from tumour tissue and is quickly sliced using a vibratome before being placed in optimal 
culture conditions. It is important that this process occur in a short period of time after tissue 
collection to minimize tissue distortion and to preserve native morphology and architecture for further 
analysis.  
Several studies have assessed the use of organotypic cultures. Van der Kuip et al utilised organotypic 
cultures to assess anti-cancer drugs in a breast cancer model. Using this method fresh primary breast 
tumour tissue was taken at the time of surgical resection, in organ transportation medium on ice. 
5mm tissue cores were prepared under a sterile hood using a hand-held coring tool. 200µm tissue 
slices were prepared in cold PBS using a Krumdieck precision cutting tissue slicer. These slices were 
then submerged in 1ml supplemented mammary epithelial growth medium and incubated in 24-well 
plates at 37C 5%CO2 on a shaking platform at 150 rpm. Medium was changed after 24 hours and was 
performed for an additional 72 hours. This study found that 88% (22/25) of breast tumour samples 
were viable with three cases being unsuccessful due to a lack of transportation medium in one 
instance, contamination of the tissue in a second instance and finally due to the tumour being 
mucinous and difficult to slice. Cell viability was assessed using three-coloured immunofluorescence 
with living cells detected using tetramethylrhodamine methyl ester (TMRM), picogreen and SYTO®63. 
Through immunofluorescent assessment of live and dead cells as well as IHC analysis found them to 
be viable for 4 days when comparing morphology to the paraffin embedded original tumour tissue. In 
this study there was at least a 3 hour gap between the tissue being resected and preparation of the 
organotypic cultures. The same method also proved effective when assessing treatment of these 
breast cancer derived organotypic cultures with Taxol 152. 
Zimmerman et al assessed human precision-cut liver tumour slices as a patient-individual predictive 
test system for oncolytic measles virus 153. The aim of this study was to evaluate the use of the 
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precision cut liver slice model as a predictive test system for the effectiveness of different measles 
vaccine viruses in primary or secondary liver tumours. Samples were obtained from 20 patients and 
were transported in ice-cold William’s E medium and transported directly to the laboratory where the 
slicing procedure started within 1 hour. 8mm cores were produced using a special coring device. The 
tissue was sliced using the Krumdieck tissue slicer as in the study by Van der Kuip, and these were 
between 200 and 300µm thickness. After slicing, samples were washed with supplemented and 
oxygenated William’s E medium and placed in 12-well plates. Slices were cultivated in 2ml WEGG 
medium in 80% oxygen, 5% CO2 at 37C with gentle shaking. In this study slices were infected one day 
following slicing with virus and left for 1 hour before virus was removed and replaced with fresh 
culture medium. Precision cut tumour slices were cultured for up to 5 days in 12-well plates. The study 
found that the slices created demonstrated heterogeneity in terms of the tissue composition as well 
as the viability of the slices, although it did not address the variability of tissue slice viability any further 
than this. The study did confirm that the oncolytic measles virus used did successfully infect 
organotypic cultures. Using confocal microscopy, the study was also able to demonstrate evidence of 
measles virus infection in a colorectal liver metastasis model, although the depth of penetrance was 
not described, and the amount of infection was not quantified. This study utilised the confocal 
microscope to determine the success of infection and to help determine whether further analysis 
should be undertaken on the treated tumour slices. 
Vaira et al. 154 adapted their methods and incorporated the use of the vibratome VT1200 which was 
able to cut tumour cores at a defined thickness at a micrometre level, whilst also being able to cut 
tumour slices in 20-40 seconds. The machine also minimises the vertical deflection of the blade, 
therefore preserving the integrity of delicate specimens. Vaira et al assessed tissue viability in 
organotypic cultures from tumours that had just been resected, they excluded any patients that had 
received neoadjuvant chemotherapy or radiotherapy. Organotypic cultures were cultured on 
Millipore inserts for up to 120 hours using 1ml of Ham-F12 media, with media being changed every 2 
days. Tissue slices were harvested from baseline, every 24 hours up to 120 hours. This was done in 
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duplicate with one slice being snap-frozen for qPCR and the other being formalin fixed for IHC 
evaluation. IHC evaluation was assessed using an automated image analysis system. The study found 
that the general architecture including epithelial structures and their spatial relationships to stroma 
was confirmed up to 120 hours. Ki67 staining was used to assess proliferative activity and they did not 
see a significant decrease up to the 120 hour timepoint although there was a gradual decline in this. 
The study showed that tissue slices were viable for up to 120 hours, however there was a steep 
decrease in the viability from 72 hours onwards compared with the earlier timepoints. This study 
assessed the effects of small-molecule targeted therapy with the PI3K inhibitor LY294002 and found 
a partial dose-response relationship following treatment. The study concluded that organotypic 
culture was a reproducible method for testing therapeutic agents 154. 
Preserving tissue slices for a prolonged period of time is a key factor and requires optimisation of 
culture conditions. Tissue slices have been cultured floating freely in media or on membrane supports. 
Membrane supports are porous and keep the tissue slice still during culture. This prevents it from 
moving around the culture dish which could potentially damage the tissue slice and affect the tissue 
architecture in comparison with the original tumour. When culture plates are placed on rotational 
plates this increases oxygen diffusion to the tissue which can be beneficial for tissue viability 146. Davies 
et al assessed a variety of incubation methods for organotypic cultures whilst also assessing the impact 
that transportation and preparation of tissue slices had through the expression of stress proteins 155. 
This study found that the tissue morphology of tissue slices was most similar to that in vivo when they 
were cultured on porous cell culture inserts. In comparison tissue slices cultivated in media alone and 
left to float had condensed apoptotic nuclei and vacuolated structures compared to original tissue 155. 
Oxygen levels were also assessed with cultures exposed to low oxygen levels (<5%) and atmospheric 
oxygen levels (20%). The study determined through immunohistochemical staining that atmospheric 
oxygen levels were important to retain tumour slice viability 155.  Incubation of tissue slices on a 
rotating incubation unit also permitted intermittent immersion of tissue slices in media whilst 
preventing the establishment of an air-filter interface. Hypoxia is a hallmark of most solid tumours 
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with oxygen levels <2% considered to be mild hypoxia and oxygen levels <0.1% considered severe 
hypoxia, whilst tissue normoxia is also much lower than atmospheric levels 156. As tissue slices do not 
have an intact circulation oxygen supply is dependent on gas diffusion through tissue and the 
atmospheric conditions may be sufficient to ensure that deeper layers of the tissue slice have an 
adequate oxygen supply to maintain viability. The effects of tumour transport and cutting were also 
assessed as it was felt that this was likely to induce stress in the tissues, however the results of the 
study found that transportation and cutting did not significantly increase the expression of stress 
biomarkers in tissue slices 155. Tumour slice thickness was also not found to be a major determinant 
of tissue slice viability 155. 
Tissue slices have been used in several studies in the context of precision medicine to assess 
sensitivities to a variety of anti-cancer drugs, although there has been no standardisation in the 
method of cultivation 152-155,157,158. Despite this all studies have confirmed the viability of tissue slices 
in culture and their suitability in the use of anti-cancer treatments with viability in studies ranging 
from 3 – 5 days 152-154,158.  
Given the comprehensive assessment of the tissue slice culture system and the workflow set out be 
Davies et al. we decided to try and recreate this system and potentially optimise this for the evaluation 
of virotherapy. The workflow set out by Davies et al. appeared to be the most completely interrogated 
method of tissue slice preparation for viability. The results from this study and the conditions used 
were also extremely promising in terms of the maintenance of tissue slice architecture and viability. 
This would be an important aspect of our work with the oncolytic vaccinia virus, pro-drug activation 
system and our tissue slice model. 
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4.2 Results 
 
4.2.1 Development of an organotypic tissue culture model in our laboratory 
 
The aim of this section of work was to develop a human tumour slice model in our laboratory and to 
assess the feasibility of developing this model for use in testing novel anti-cancer drugs. As mentioned 
previously tumour slice viability following harvesting, slicing and during incubation would be a key 
aspect of this. 
4.2.2 Tissue slice viability 
 
Tissue slices were prepared from patient tumours at the time of surgical resection as outlined in 
methods, and incubated at 37°C, 5% CO2. Slices were placed in a well plate, floating in culture medium 
on a vibrating plate at <100 rpm. For viability assessment purposes they were then removed from 
culture conditions every 24 hours and fixed in formalin solution. This was done up to 10 days following 
retrieval. After the last tissue slice in the experiment was fixed they were then all processed, paraffin 
embedded and sliced in preparation for IHC staining (see methods). H&E staining, immunostaining as 
well as staining for e-cadherin, collagen IV and Ki67 was performed by the laboratory at the Royal 
Surrey County Hospital, Guildford. Further staining for cleaved caspase 3 and Ki67 was performed in 
the laboratory at the Leggett Building, University of Surrey. 
4.2.3 Preliminary viability results of organotypic cultures 
 
Our initial experiments set out to firstly see if it was possible to develop an organotypic culture system 
in our laboratory and if so what the optimum conditions required so that the organotypic cultures 
would remain viable. The decision to slice the tissue at 300µm intervals was based on existing 
literature regarding the use of organotypic cultures as well as our experience in cutting tumours 155. 
Whilst thinner slices can be produced we found that the cutting of tissue cores at this thickness was 
less consistent. Our choice of media in these experiments was DMEM supplemented with 10% FBS 
and 100 U/mL penicillin and, 100µg/mL streptomycin. We found that this media which was readily 
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available in our laboratory, did not impact adversely on the organotypic cultures, furthermore we saw 
no benefit from using different media which were potentially more costly and also less readily 
available.  
In our initial experiments we assessed the 300µm tumour slices generated by placing them into 
individual wells of a 24-well plate and submerging them in media before being placed in an incubator 
with atmospheric oxygen levels on a shaking plate at <100rpm (Figure 4.1). Staining of the slices with 
Ki67 (cellular marker for proliferation) and cleaved caspase 3 (active version of protein caspase 3, 
which is the converging point of both the extrinsic and intrinsic pathways, and an indicator of 
programmed cell death) to assess for evidence of cell proliferation and apoptosis respectively in these 
culture conditions was also performed.  
 
Figure 4.1 Organotypic cultures obtained during the preliminary experiment set up. Tumour cores taken from freshly 
resected patient specimens were prepared as described in methods before being sliced to 300µm thick tissue cultures. These 
were then placed in 24-well plates and were submerged in media before being placed in an incubator on a rocking plate.  
 
After processing tumour slices using this method it was noted that the architecture of the tissue very 
quickly became distorted compared with controls fixed at timepoint 0 hours. In these slices there was 
histological evidence of vacuolisation and disassociation of the tumour slices when compared to 
control slices and non-sliced tissue fixed in formalin solution at the time of slice preparation (Figure 
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4.2). This finding was also noted by Davies et al when comparing slices left floating in media compared 
to those on filter supports 155. Using this method of culture, the organotypic culture model would not 
have been suitable for the assessment of our oncolytic vaccinia virus and for assessment of the pro-
drug activation system. We therefore adapted our initial method. 
 
Figure 4.2 IHC images of tissue prepared using our initial culture conditions. Organotypic cultures were produced from 
tumour specimens placed in 24-well plate, submerged in media and left on a rocking plate in an incubator for the duration of 
the experiment. Organotypic cultures were fixed at 24-hour intervals. Staining was performed for H&E, Ki67 and cleaved 
caspase 3. Results from our preliminary experiments showed that at 72 hours following incubation there was a marked 
distortion in tissue architecture with loss of cellular content as well as vacuolisation of the tissues which is highlighted in the 
IHC images at 72 hours with black arrows. Images captured at x10 magnification to give an overview of the tissue 
appearances throughout the organotypic cultures. 
 
4.2.4 Adaptation of culture conditions to improve organotypic culture viability 
 
Based on our preliminary findings in viability experiments as well as the results published by Davies et 
al 155 the method of culture was updated so that tissue slices were placed on filter supports and 
incubated on a rotating plate to aid oxygen diffusion to tissue slices. These adaptations were 
recommended in the work published by Davies et al 155. Following these adaptations to our 
organotypic culture methods there appeared to be a reduction in vacuolisation of the tissue slices 
whilst the tissue structure and architecture was maintained and comparable to that seen in the 
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original tissue fixed at the time of tissue preparation (T0 hours) when H&E images were reviewed 
(Figure 4.3). 
 
Figure 4.3 IHC images of prepared organotypic cultures using adjusted culture conditions up to 264 hours. Tissue slices 
were incubated in 6-well plates on filter supports with media added so that the slices were not completely submerged. Within 
the incubator the 6-well plate was placed on a rotating plate to assist with diffusion of oxygen through the tissues. In this 
viability experiment the tissue slices were left for up to 11 days. Organotypic cultures were fixed in formalin at 24-hour 
intervals. The results of H&E staining in this experiment show maintenance of tissue architecture compared with 0-hour 
timepoint. There is also little evidence of any vacuolisation of tissues. These results compare favourably with the results from 
our initial methods shown in Figure 4.2. 
 
As well as performing H&E staining to assess overall architecture and appearance of the tissue slices, 
we also stained the tissue for the immunomarkers cytokeratin 7 (CK7), Cytokeratin 20 (CK20) and 
CDX2. CK7 is a type II keratin of non-keratinizing squamous epithelium specifically expressed in simple 
epithelia lining the cavities of internal organs. Staining is usually negative in colorectal 
adenocarcinoma. CK20 is a major cellular protein found specifically in gastric and intestinal mucosa. 
Staining is usually positive in colorectal adenocarcinoma.  CDX2 is a nuclear homeobox transcription 
factor that is crucial for axial patterning of the GI tract during embryonic development and involved 
in the process of intestinal proliferation, differentiation, adhesion and apoptosis. Staining for CDX2 is 
positive in primary and metastatic colorectal adenocarcinoma. These are the immunomarkers that are 
routinely assessed and stained for by the histopathology services at the Royal Surrey County Hospital 
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when reviewing colorectal tumours. For further detail regarding tissue architecture and viability we 
assessed staining for E-cadherin, a calcium dependent cell-cell adhesion molecule in colorectal 
carcinoma that plays an important role in the maintenance of tissue architecture. We stained for 
collagen IV, of which basement membranes are primarily composed of. Collagen IV provides an 
intermediate adhesion area between parenchymal cells and interstitial matrix and gives detail 
regarding tissue architecture. Finally, we also stained for the proliferation marker Ki67. We were then 
able to compare the staining from our prepared organotypic cultures to the original histopathology 
blocks that were prepared by the histopathology department at the Royal Surrey County Hospital, 
Guildford at the time of surgery. The images were also reviewed by Dr Izar Bagwan, Consultant 
histopathologist at the hospital (Figure 4.4). 
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Figure 4.4 Comparison of organotypic culture architecture compared with histopathology blocks prepared from the 
original tumour specimen. Comparison of IHC staining for H&E to assess overall appearances as well as Ki67 to assess for 
viability through the assessment of cellular proliferation. Staining for E-cadherin and collagen IV performed to further 
interrogate architecture of the tissue. IHC from original tissue blocks found H&E appearances to be consistent with that of 
colorectal liver metastasis. The proliferation index was calculated at 80%. Staining for E-cadherin and collagen IV were both 
positive indicative of preserved basement membrane and therefore architecture within the tissue. In comparison organotypic 
cultures produced as outlined in methods and left in culture conditions for 48 hours also showed H&E appearances consistent 
with the original tissue blocks confirming colorectal liver metastasis. The proliferation index was calculated at 70%, slightly 
less than those of the original tissue at this time point. Staining for E-cadherin and collagen IV were both positive and once 
again indicative or preserved basement membrane and overall tissue architecture. 
 
To assess our methods, we compared staining for these immunomarkers and markers or architecture 
and proliferation in the organotypic cultures prepared in our laboratory with the staining of the 
original tumour specimen (from which our core biopsy was taken, and tissue slices produced). Staining 
for these markers was performed by the histopathology laboratory at the Royal Surrey County 
Hospital, Guildford. The results of the staining confirmed that there was no difference between the 
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original specimen and the organotypic cultures created when assessing these markers. As with the 
original specimen our organotypic cultures stained negatively for CK7 and positively for CK20 an CDX2 
(Figure 4.5). 
 
Figure 4.5 Staining for immunomarkers in prepared organotypic cultures for comparison with original histopathology 
blocks. Organotypic cultures stained negatively for CK7 whilst staining positively for both CK20, and CDX2 which is consistent 
with a diagnosis or colorectal liver metastases. The same staining was also found is the original histopathology blocks 
prepared by the histopathology laboratory at the Royal Surrey County Hospital, Guildford. 
 
The results of the staining for E-cadherin and collagen IV in combination with H&E staining to assess 
for tissue viability found that our adapted culture system resulted in a tissue viability of a maximum 
of 5 days with a minimum viability of 3 days. In all the tumours that were assessed for viability 
purposes we found that the minimum viability of 72 hours was consistent (Table 4.1).  
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Table 4.1 Summary of viability assessment for organotypic cultures prepared from resected tumour specimens in four 
patients 
 Staining 
Patient 
no: 
CK7 CK20 CDX2 Diagnosis 
Proliferation 
index (Ki67) 
Duration of intact 
tissue architecture 
(E-cadehrin and 
collagen IV) 
Overall 
viability 
1 Negative Positive Positive 
Colorectal 
liver 
metastasis 
50% up to 120 
hours, followed by 
a reduction to 5% 
at 144 hours 
Blurring of basement 
membrane at 120 
hours 
120 
hours 
2 Negative Positive Positive 
Colorectal 
liver 
metastasis 
25% at 48 hours 
followed by a 
reduction to 10% 
at 96 hours 
Staining for E-
cadherin lost at 96 
hours 
48-72 
hours 
3 Negative Positive Positive 
Colorectal 
liver 
metastasis 
50% at 72 hours 
with a reduction 
to10% at 144 
hours 
Cells separating from 
basement 
membrane at 72 
hours  
72 hours 
4 Negative Positive Positive 
Colorectal 
liver 
metastasis 
70% up to 120 
hours 
Loss of architecture 
in tissue slice and 
minimal staining for 
E-cadherin at 144 
hours 
120 
hours 
 
The results of our adapted methods showed that we had developed an organotypic culture system 
that was suitable for the assessment of the oncolytic vaccinia virus and for assessment of the pro-drug 
activation model.  
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4.2.5 Treatment of organotypic colorectal liver metastases with Vaccinia Virus 
 
Having established that our methods enabled us to assess organotypic cultures for a minimum of 72 
hours up to 120 hours, we wanted to use this model to assess the effects of oncolytic vaccinia virus 
directly applied to tumour tissue slices. 
4.2.5.1 Evidence of viral presence and effect on tissue slices using immunohistochemical analysis 
 
Tissue slices were prepared as outlined in the methods. In these initial experiments vaccinia virus 
encoding green fluorescent protein was then applied to slices at several concentrations: 104pfu/ml, 
105pfu/ml, 106pfu/ml and 107pfu/ml. The treated tissue slices were left for up to 120 hours (5 days). 
Plaque forming units are a measure of the number of virus particles capable of forming plaques per 
unit volume.  It is a functional measurement rather than a measurement of the absolute quantity of 
particles: viral particles that are defective or which fail to infect their target cell will not produce a 
plaque and thus will not be counted. At 24-hour intervals treated slices and comparative untreated 
controls were fixed in formalin before undergoing processing as outlined in methods. Slices were then 
generated from the paraffin embedded tissue to enable us to perform immunohistochemical analysis. 
H&E staining was performed on these slices to assess for the overall appearance of the tumour tissue 
as well as staining for anti-GFP or anti-vaccinia virus antibody as a marker of viral presence within 
tissue slices. The reason for using two antibodies for viral detection was due to the two forms of 
vaccinia virus that we were using in our experiments. As one expressed GFP we decided to use an 
antibody against this protein, the second form did not have GFP, in its place it expressed the fusion 
suicide gene (FCU1) responsible for the conversion of pro-drug into active 5-fluoruracil. We therefore 
used an anti-vaccinia virus antibody to stain directly against vaccinia virus. Cleaved caspase 3 antibody 
was used to assess for any differences in apoptosis between the treated and untreated tissue slices. 
After confirmation of tumour presence in tissue slices on H&E staining, staining with cleaved caspase 
3 and anti-vaccinia virus antibody, or cleaved caspase 3 and anti-GFP antibody was performed (Figure 
4.6).  
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Results from our experiments showed that the vaccinia virus treated organotypic cultures stained 
positively for anti-GFP antibody or the anti-vaccinia antibody compared with the untreated controls. 
Staining for these two antibodies confirmed viral presence within the treated organotypic cultures. 
There also appeared to be increased staining for cleaved caspase 3 in the treated tissue slices when 
compared to untreated controls. 
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Staining for cleaved caspase 3 is suggestive of apoptosis within the organotypic culture. The increased 
staining in the treated organotypic cultures compared with the untreated controls was suggestive of 
an effect following oncolytic virus application. This was further reinforced in our experiment as there 
appeared to be co-localisation of both anti-vaccinia virus and anti-GFP stains in areas of increased 
cleaved caspase 3 staining. Furthermore, we found that there was an increased expression of cleaved 
caspase 3 with increasing viral concentration suggesting a dose-response relationship. We also treated 
organotypic cultures with heat inactivated virus to further assess that the changes we were seeing in 
treated tissue were a consequence of treatment with oncolytic vaccinia virus. In these treated tissue 
slices there was no positive staining for anti-GFP antibody as compared with the untreated controls 
(figure 4.7).     
 
 
Figure 4.7 Control experiment confirming no effect on tissue slices treated with heat inactivated vaccinia virus at 107 
pfu/ml. Staining for anti-GFP antibody and cleaved caspase 3 similar in untreated slices and those treated with heat 
inactivated virus. Positive controls also shown, positive staining for anti-GFP in tumour slice treated with vaccinia virus 
expressing GFP and tonsil tissue used as a control for cleaved caspase 3 staining. 
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4.2.5.2 Quantification of 3,3′-Diaminobenzidine immunohistochemical staining 
 
We wanted to quantify the staining for cleaved caspase 3 and GFP in the organotypic cultures that 
were treated with increasing pfu/ml of vaccinia virus to get an objective measure of the positivity of 
staining in our slices. Evaluation of immunohistochemical staining was performed using the open 
resource digital image analysis software, ImageJ. The IHC profiler application developed by Varghese 
et al 131 enables automated digital IHC analysis for unbiased, quantitative assessment of antibody 
staining intensity in tissue sections.  To create this programme the authors adopted the spectral 
deconvolution method of DAB/haematoxylin colour spectra by using optimised optical density vectors 
of the colour deconvolution plugin for separation of the DAB colour spectra. The plugin has been 
assessed on thousands of scored DAB stained IHC images. A comparison study between use of the 
plugin and manual analysis resulted in an 88.6% match with a statistical significance of P<0.0001 131. 
After performing this analysis, we found that there was a dose response relationship between pfu/ml 
vaccinia virus and percentage of positive staining for GFP as well as cleaved caspase 3. The percentage 
of positive staining within each slice was variable in all four cases but tended to be maximal at VV 107 
pfu/ml. In three of the four cases there was a significant increase in positive staining for GFP at higher 
concentrations compared with untreated controls. In one case there was a statistically significant 
increase in GFP staining between slices treated at VV107 pfu/ml and those treated at VV104 and VV105 
pfu/ml (figure 4.8). 
When assessing for percentage positive staining for cleaved caspase 3 we saw similar results as to 
those of staining for GFP. In two out of four patients we saw a significant increase in cleaved caspase 
3 positive staining in treated slices compared with untreated controls. In one patient there was a 
statistically significant increase in staining for cleaved caspase 3 at the highest pfu/ml of vaccinia virus 
compared with lower concentrations. 
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The results of this quantification found that staining for cleaved caspase 3 and GFP were similar in all 
four patients. This is a reassuring finding as we would expect that staining for cleaved caspase 3 and 
GFP would correlate. If there was a large disparity between staining, then it would be difficult to 
attribute a relationship between viral infection and effect in tissue as measured by staining of cleaved 
caspase 3. Our results therefore indicate a relationship between viral infection and apoptosis in the 
treated organotypic cultures. 
 
Figure 4.8 Quantification of anti-GFP and cleaved caspase 3 antibody staining using IHC in four patients treated with 
increasing pfu/ml of vaccinia virus expressing GFP compared with untreated controls. Amount of virus used escalated from 
1x104, 1x105, 1x106 and 1x107 pfu/ml. Untreated control used as a comparison to assess the effects of culture conditions on 
the organotypic culture. Treatment was for 5 days after which the slices were fixed in formalin in preparation for IHC analysis. 
These figures show a dose response relationship with an increasing expression of GFP with increasing concentration of virus 
treatment. CC3 – cleaved caspase 3; GFP – green fluorescent protein. Statistical analysis using two-way ANOVA. Statistical 
level of significance: *p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
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4.2.5.3 Evidence of virus presence in organotypic cultures using immunofluorescence   
 
We wanted to further assess for viral presence in our organotypic cultures following the results of 
these initial experiments. As the VACV encoded GFP it was possible to assess for the presence of virus 
using direct immunofluorescence on both the processed paraffin embedded 4µm slices for IHC as well 
as the 300µm slices fixed in formalin before they were processed. 
The 4µm slices were prepared in the same way as those for IHC analysis. These were then de-
paraffinised (as outlined in methods) and then counter-stained with the nuclear stain TOPRO®-3. The 
confocal microscope was used to assess for GFP expression within these treated slices compared with 
untreated controls. 
Using this method, we saw expression of GFP in the cytoplasm of infected cells that were 
counterstained with the TOPRO®-3 nuclear stain. In comparison the untreated controls only stained 
positively for the nuclear stain, there was no GFP expression in these slices. These results confirmed 
viral presence through GFP expression in the treated organotypic cultures (figure 4.9) 
 
Figure 4.9 Confirmation of viral presence through the expression of GFP in treated 4µm tissue slice compared to untreated 
control. Left to right: untreated control tissue stained with nuclear stain TOPRO®-3; tumour slice treated with virus with 
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evidence of expression of GFP in cell cytoplasm with nuclear counterstain confirming viral presence in organotypic cultures 
after treatment with vaccinia virus.  
 
Whilst we saw GFP expression in these fine slices we wanted to assess whether the viral treatment 
was able to penetrate through the organotypic cultures or whether the findings were confined to 
superficial aspects of the organotypic cultures. To do this we decided to perform Z-stack imaging 
through the treated 300µm tissue slices as this would be able to assess the depth of penetrance of 
the oncolytic virus. 
Each tumour core retrieved at the time of surgical resection was prepared as outlined in methods 
before undergoing slicing using a vibratome to 300µm thick slices. Organotypic cultures were treated 
with virus and cultured in the conditions stated in methods. Comparative untreated controls were also 
processed and assessed at the same time. After treatment was completed tissue slices were fixed in 
formalin before being prepared for confocal microscopy as outlined in methods. Using the confocal 
microscope, we were able to perform Z-stack imaging at multiple points through the 300µm slices to 
assess for GFP expression throughout the thickness of the culture. The results from the Z-stack images 
obtained through our tissue slices showed that there was some evidence of penetrance through the 
organotypic cultures with GFP expression seen at 60 - 65µm depth (figure 4.10). 
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Figure 4.10 Original z-stack imaging and volume snapshots of organotypic culture treated with VVGFP 107 pfu/ml. Heat-
map image identifying depth of viral presence through the 300µm tissue slice. Viral presence up to depth of 60 µm. 
 
 
4.2.5.4 Evidence of viral replication in tissue slice model  
 
As well as direct visualisation of virus through GFP expression we wanted to confirm viral replication 
in our model further. To do this we first collected the supernatants of treated tumour slices. These 
were then frozen and sent to Transgene, France where viral titres were calculated. After calculating 
the titres at the end of treatment we compared them to the initial concentration of virus used to treat 
the organotypic cultures initially. This would allow us to assess for any obvious changes, with an 
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increase in viral titre compared with the original viral concentration being indicative of viral replication 
in our organotypic culture system. 
Results from our experiments using three patients with colorectal tumours found an increase in viral 
titres when compared with the original viral concentration applied to slices (Figure 4.11). This was 
assessed from 0 hours and at 24 hour increments thereafter up until 96 hours of treatment. This was 
also within the maximum period of time of 120 hours that the organotypic cultures could be viable for 
using our methods. The results from these investigations showed that there was an increase in viral 
titres in all three treated tumours with all concentrations of virus used. We found that the maximum 
peak in viral titre compared to the initial treatment tended to be at 24 hours in most cases however 
this could also be at 48 or 72 hours before viral titres would start to decline (Figure 4.11). 
These results confirmed that there was evidence of viral replication in organotypic cultures following 
the administration of vaccinia virus. 
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Figure 4.11 Viral titres in supernatants of tissue slices from 3 patients with colorectal liver metastases treated with 
increasing concentrations of virus and assessed at 24-hour intervals up to 96hrs. Increased concentration of virus compared 
with concentration added at 0hrs suggestive of viral replication. Graphs represent data from three independent experimental 
repeats with two samples for each concentration of virus.  
 
Having confirmed the increase in viral replication through the assessment of viral titres in supernatant 
we wanted to assess this visually also. To do this we aimed to assess GFP expression in our organotypic 
cultures at 24-hour intervals up to 5 days which was the maximum period of time that we found that 
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our organotypic cultures could be viable. Organotypic cultures were prepared and treated with virus 
as outlined in methods. In this experiment we used the highest concentration of virus (1x107 pfu/ml) 
expressing GFP to treat our cultures. At 24-hour intervals slices were fixed in formalin before being 
processed in the same ways as previously described for confocal microscopy (see methods). Confocal 
microscopy and z-stack imaging was then performed for each slice to assess for the presence of GFP 
(and therefore virus) in organotypic cultures and also if this expression changed over time. Our time-
course analysis showed that there was an increased expression of GFP throughout the tissue slices up 
to 72 hours before this began to reduce (Figure 4.12). The findings from this experiment corroborated 
our findings from the assessment of viral titres in supernatant as there was evidence of viral replication 
through increased expression of GFP following treatment with oncolytic vaccinia virus. 
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4.2.6 Assessment of FCU1 pro-drug activation in organotypic model 
 
Having established evidence of viral infection in our organotypic cultures using vaccinia virus 
expressing GFP we then wanted to assess the pro-drug activation model of our vaccinia virus 
expressing FCU1. Organotypic cultures were prepared as outlined in methods. They were then treated 
for 48 hours with virus before the addition of 100µM of the pro-drug 5-FC and left for up to 120 hours 
before being fixed in formalin. At the same time 50µL of supernatant was taken after the onset of the 
addition of 5-FC and frozen. These specimens were then sent on ice to Transgene, France where HPLC 
was performed (see methods) to assess the activity of the FCU1 gene in converting 5-FC to 5-FU (figure 
4.13).  
 
 
Figure 4.13 Percentage conversion of 5-FC to 5-FU following its addition to organotypic cultures of colorectal liver 
metastases treated with vaccinia virus expressing the FCU1 fusion suicide gene. % Transformation calculated using HPLC. 
Graphs represent pooled data from three different patients. Pooled data for each time point from two independent samples.  
 
Results from three experiments found variable rates at which 5-FC was converted to 5-FU. In all three 
experiments there was an increase from 72 to 96 hours following the addition of pro-drug to 
organotypic cultures treated with virus expressing FCU1. In two of the three cases was a high 
percentage conversion at 96 hours, this was 48 hours following the addition of 100µM of 5-FC to the 
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organotypic cultures treated with virus. In patient 2 there was a very high conversion of 5-FC to 5-FU 
just 24 hours after the addition of pro-drug. 
The variability in the conversion rates is likely to represent heterogeneity of the tumours of each of 
these patients. The results were encouraging with regards to the pro-drug activation model as there 
was evidence of 5-FU in the supernatant of treated organotypic cultures of all three patients. The high 
percentage of conversion from 5-FC to 5-FU in two of three cases was also promising. 
To further assess the pro-drug activation model, we also assessed treated organotypic cultures 
through immunohistochemical staining with anti-vaccinia virus antibody and anti-cleaved caspase 3 
antibody (Figure 4.14).  
 
 
Figure 4.14 IHC staining for cleaved caspase 3 in organotypic cultures left untreated in media; treated with media and 5-
FC; treated with virus alone and treated with virus and 5-FC. No obvious difference in staining for cleaved caspase 3 in 
organotypic culture treated with media and 5-FC when compared with untreated control. Similar appearance of staining for 
organotypic cultures treated with virus alone or those treated with pro-drug and virus in combination. 
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Results from our IHC staining for cleaved caspase 3 did not show an obvious difference in staining 
between untreated controls and those slices treated with pro-drug and media. These results were 
encouraging and indicate that 5-FC alone does not induce apoptosis in organotypic culture. There 
appeared to be similar staining for cleaved caspase 3 in those organotypic cultures treated with 
vaccinia virus at 107 pfu/ml and those treated with the same concentration of virus and 100µM of 5-
FC. 
As with our previous IHC experiments we used the IHC profiler application for image J to quantify our 
staining. This was performed as described in methods. 
 
 
Figure 4.15 Quantification of anti-VV and cleaved caspase 3 antibody staining in two patients treated with media alone; 
media and pro-drug; virus alone and virus plus pro-drug to assess the pro-drug activation model in organotypic cultures. 
Graphs represent pooled data from two independent experimental repeats. Statistical analysis using two-way ANOVA. 
Statistical level of significance: *p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001. Anti-VV ab – anti vaccinia virus antibody; 
CC3 – cleaved caspase 3 
 
 
Figure 4.15 shows the results of IHC quantification performed to assess the percentage positive 
staining for cleaved caspase 3 and anti-vaccinia virus antibody in organotypic cultures assessing the 
FCU1 pro-drug activation model. As we had found evidence of conversion of 5-FC to 5-FU we wanted 
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to assess if this had any impact on the effects of the vaccinia virus on treating organotypic cultures as 
we had seen in earlier experiments. In these two experiments as with previous experiments the 
percentage of positive staining for virus and cleaved caspase 3 was similar suggestive of a relationship 
between virus presence and cleaved caspase 3 expression. There was no significant difference in 
cleaved caspase 3 expression in organotypic cultures treated with media alone or treated with media 
and 100µM 5-FC. As anticipated there was an increase in staining for cleaved caspase 3 and vaccinia 
virus in cultures treated with virus compare to controls. There was a statistically significant increase 
in cleaved caspase 3 staining in cultures treated with virus or virus and pro-drug when compared to 
controls. In one of the two experiments that was a statistically significant increase in cleaved caspase 
3 staining in organotypic cultures treated with virus and pro-drug compared to virus alone. This result 
was encouraging with regards to the pro-drug activation model but given that it is an isolated result it 
is not possible to conclude a strong difference between treatment with virus alone and virus in 
combination with 5-FC. 
4.2.6.1 Assessment of immunogenicity through HMGB1 expression in tissue slice model 
 
Results from our work with colorectal cancer cell lines suggested that vaccinia virus induced 
predominantly apoptotic cell death, and that this was immunogenic given the increase in various 
markers and determinants for this. Given the upregulation of the marker HMGB1 in all three colorectal 
cell lines, this was felt to be an appropriate marker to assess in the organotypic culture model. HMGB1 
is a DAMP and is released extracellularly in immunogenic cell death. We postulated that if our 
experiments were successful in demonstrating immunogenicity of vaccinia in tissue slices, this would 
be manifest through the extracellular presence of HMGB1 on staining. 
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Figure 4.16 HMGB1 staining in original histopathology blocks in four patients and staining of treated and untreated control 
in prepared organotypic cultures. Evidence of variable HMGB1 expression, with cytoplasmic expression in patients 1 and 2 
whilst staining was nuclear for patients 3 and 4. In untreated organotypic cultures and those treated with vaccinia virus at 
maximum pfu/ml there were no obvious differences in expression with HMGB1 in both being cytoplasmic. 
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Results from our experiments found that whilst we were able to stain for HMGB1 in IHC, the pattern 
of staining did not correspond to whether patients had been treated with vaccinia virus or not. Figure 
4.16 shows the cytoplasmic expression of HMGB1 in both untreated control and at maximal pfu/ml of 
virus. Similarly, its expression in the original patient histopathology blocks was variable with two of 
four patients having cytoplasmic HMGB1 and the others having nuclear HMGB1 expression. 
As there was no clear relationship between HMGB1 and treatment in the organotypic culture model 
we felt that this was not a marker that would help to establish immune mediated cell death in this 
instance.  
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4.3 Discussion 
 
Work in our experiments lead to the successful development of an organotypic culture system in our 
laboratory. Through our own preliminary work and based on the recommended workflow for 
organotypic cultures published by Davies et al 155 we were able to develop an organotypic culture 
system that would enable the interrogation and treatment of tumours from a minimum of 3 days up 
to a maximum 5 days. As per Davies et al155 we found a marked improvement in organotypic culture 
tissue architecture when placing our organotypic cultures on filter supports with tissue morphology 
being most similar to tissue in vivo when incubated on these. The filter supports hold the organotypic 
cultures in place during incubation and this therefore mechanically prevents tissue distortion, as the 
filter support is porous it also allows nutrients from media to bathe the underside of the culture. 
Leaving organotypic cultures to be submerged in media and on a rocking plate led to mechanical 
damage of the organotypic cultures as they washed around unsupported within their wells during 
incubation. This naturally led to the tissue becoming distorted compared with the original and 
manifest in separation of the tissue slices and in severe cases loss of part of the organotypic culture 
or disintegration of the organotypic culture. In our modified version the organotypic cultures were 
placed within wells on filter supports whilst being placed on a rotating plate inside the incubator. This 
enabled nutrients from the prepared media to reach the organotypic cultures as it was continually 
washed over the whole tissue slice repeatedly during rotations, rather than the tissue being 
permanently submerged in media whilst rocking. This improved our incubation methods as it had the 
dual effect of preventing tissue from becoming ‘water-logged’ when constantly submerged in media 
whilst also permitting oxygen to reach the organotypic culture. In the workflow produced by Davies 
et al it was noted that organotypic cultures floating in low oxygen levels led to a significant alteration 
in a number of stress pathways which was accompanied by a loss of tissue integrity. Placing 
organotypic cultures on filter supports in atmospheric oxygen levels ameliorated this. As solid tumours 
are usually hypoxic our atmospheric oxygen conditions produced a hyperoxic environment which 
assisted in the maintenance of the viability of the organotypic cultures 156.  
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As with all in vitro models for cancer research there are limitations with this one also. In order to 
develop a high throughput process there needs to be excellent communication between the team in 
the lab and the surgical team to enable prompt processing of these samples at the time of resection. 
There also needs to be a sufficient availability of patient tumour to enable experiments to be carried 
out. This requires excellent ties with the oncologists and surgeons at the Royal Surrey Hospital, 
Guildford in this instance which we were fortunate to have. Tissue availability is dependent on the 
number of oncological resections being performed as well as the suitability of tumours to be included 
in the study. As well as surgical and institutional factors there are patient or tumour factors that also 
need to be taken into consideration. For instance, certain small tumours cannot be biopsied as there 
is a risk of interfering with the resection margins of clearance and interfering with the 
histopathological processing performed in the pathology department which can have an impact on 
the perceived success of surgery, the need for further treatment and the patients’ prognosis. The 
consistency of tumours is also variable, with larger tumours often possessing necrotic cores that can 
either not be biopsied or that are extremely fragile resulting in the inability of slices to be cut from 
them. In patients undergoing liver resection, many will receive neoadjuvant chemotherapy of variable 
efficacy and this can also unpredictably affect slice viability. Tumour size factors as well as tissue 
composition are often not certain until the time of resection. During these experiments I was present 
at all surgical procedures at the time of tumour resection which enabled me to assess the tumours 
first-hand and assess the suitability for biopsy. This improved over time as my experience working with 
this tissue improved. My presence at these resections also enabled the prompt retrieval of the tissue 
and processing of these tumour cores. Another limitation of the system is the uncertainty of the 
numbers of slices that we would be able to procure from each biopsy taken. This often limited what 
we were able to do experimentally and often would mean that planned experiments would need to 
be adapted in terms of number of duplicates and comparison of differing treatments. Each 
organotypic culture would also be slightly different from the previous one owing to the heterogeneity 
of tumour tissue within each biopsy. Tumour cores that are obtained and sliced at 300µm intervals 
153 
 
will still demonstrate variability from the top of the core to the bottom despite it coming from the 
same area of tumour. Although anticipated, this variability can have an impact when trying to compare 
to treatments, especially if the organotypic culture has varying amounts of cellular and stromal 
material within it. As well as patient or tumour factors, processing factors can also influence the 
culture method. The duration of the process, from being present at the time of surgical resection to 
the production of 300µm slices is extremely time-consuming. It was essential that I would be able to 
process these tumour cores immediately following retrieval to prevent tissue degradation and to 
optimise outcomes. The whole process from theatre to the production of these cultures would often 
take upwards of 3 hours and so it involved a lot of man-hours, often running late into the evening. On 
numerous occasions following the successful processing of organotypic cultures to the point where 
they are ready for histological analysis the results can show that the experiment has been unsuccessful 
in terms of the tissue obtained at the time of biopsy. This can result in the time-consuming process of 
analysis on tissue that ultimately cannot be assessed for these purposes. In total we processed 30 
patient tumours using this method with varying success. We found that of the 30 patient tumours that 
were processed, 21 were of sufficient quality to assess in terms of IHC or immunofluorescence. This 
equals a success rate of 70% for tumour cores that completed processing. When considering the 
number of hours required to process 9 unsuccessful tumour samples it is easy to see how this method 
has not come to be used regularly in the laboratory to assess novel anticancer treatments. The number 
of unsuccessful tumour cores being processed is likely to be higher given that we also assessed further 
tumour cores that were not of sufficient quality to produce 300µm slices. As mentioned earlier, with 
greater experience it was easier to determine whether or not an experiment would be successful in 
terms of the tissue obtained and to decide whether or not to proceed with processing or not. 
Despite these limitations organotypic cultures represent a high content experimental platform for the 
interrogation of tumours in vitro. The organotypic culture model is a powerful technique that is an 
accurate representation of the tumour in vivo including its stroma and heterogeneous 
microenvironment, permitting the interrogation of tumours in the laboratory. We have demonstrated 
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that with close surgical and oncological ties with our local hospital we were able to develop a high 
through-put experimental model for the purposes of our study. 
Satisfied with our culture methods and results from preliminary experiments we wanted to assess of 
it would be possible for us to examine the effects of oncolytic vaccinia virus on organotypic cultures. 
We treated cultures with increasing pfu/ml of virus up to a maximum of 107 pfu/ml in the first instance 
to see if there was any effect of treatment and if there was an effect to see if dose of virus impacted 
on this. We found through IHC staining and immunofluorescence that our organotypic cultures did 
become infected by vaccinia virus during incubation. We found there to be a dose response 
relationship between treatment with virus and expression of GFP and cleaved caspase 3 using IHC 
staining. In order to quantify the staining for cleaved caspase 3 and GFP in the organotypic cultures 
that were treated with increasing pfu/ml of vaccinia virus to get an objective measure of the positivity 
of staining in our slices we used the IHC profiler application developed for imageJ by Varghese et al 
131. These results confirmed the perceived visual dose-response relationship that we had seen in our 
IHC staining. The increase in positivity of staining was statistically increased in 3 of the four patients 
assessed for cleaved caspase 3 staining and GFP at the highest doses of vaccinia virus (106 pfu/ml and 
107 pfu/ml) compared with untreated organotypic cultures or those treated with lower doses of 
vaccinia virus. We also confirmed viral replication and therefore infection using direct visualisation of 
virus through confocal microscopy and through the assessment of viral titres in supernatants. This 
confirming the findings from previous studies of viral replication within 72 hours of infection 101. The 
ability to utilise organotypic cultures to assess treatment this way is further evidence as to the utility 
of the culture method and the additional information that this in vitro method can provide during in 
vitro work with novel oncological therapies.  
Our experiments have highlighted oncolytic vaccinia virus to be an excellent oncolytic virus choice in 
the treatment of colorectal liver metastases. The attenuated vaccinia virus has demonstrated good 
tumour selectivity in our organotypic cultures with no evidence of effects in normal healthy liver in 
155 
 
our experiments. As vaccinia virus has an excellent safety profile in human use as well as its ability to 
evade the host immune response and given the tumour specificity that we have seen it lends itself to 
systemic administration which has been a limitation in the development of oncolytic virotherapy thus 
far 78,101,102. Work using the z-stacking feature of the confocal microscope has also demonstrated that 
vaccinia virus is also able to penetrate our tumour cultures rather than simply having an effect on the 
slice surface alone. Our results found that staining for vaccinia virus extended down to 60µm depth. 
Tumour penetrance is an important consideration in the treatment of solid tumours with oncolytic 
viruses. Barriers that reduce the spread of oncolytic viruses include elevated interstitial pressures, 
dense connective tissue, necrotic tissue, calcification, and reduced vasculature 70. Certain software 
packages available for the confocal microscope enable quantification of staining. We were unable to 
perform this is our laboratory during our experiments as we did not have this software available. 
Quantification of confocal microscopy would have been a useful tool in our experiments and ideally 
would have been performed.  
For many years 5-FU was the principle agent used in the treatment colorectal cancer and is included 
in chemotherapy regimens for the treatment of colorectal liver metastases today. Foloppe et al. first 
used a replication competent Copenhagen strain vaccina virus expressing the transgene FCU1 in the 
pre-clinical setting 130. The study found that the combination of VV-FCU1 and 5-FC resulted in greater 
toxicity to human cancer cell lines compared with virus alone. The same was also found in the 
treatment of nude mice bearing LoVo colorectal tumours subcutaneously that were treated with 
systemic or intratumoral virus administration 130. Our experiments assessed the use of this pro-drug 
activation model in organotypic cultures. Following treatment with virus, frozen supernatants stored 
at 24-hour intervals were sent to Transgene, France. At their laboratory HPLC was performed to assess 
for the conversion of 5-FC into 5-FU. Results from these experiments confirmed a high conversion of 
5-FC to 5-FU suggesting that the pro-drug activation model worked and that it was possible to assess 
this using organotypic cultures. To further assess the effects of the pro-drug activation model we 
assessed the IHC staining for these treated slices and compared them to those treated with virus alone 
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and untreated controls. Both experiments found that there was a significant increase in cleaved 
caspase 3 expression in organotypic cultures treated with VV-FCU1 compared with untreated controls. 
In one of the two experiments, the effect of treatment using the pro-drug activation model was 
significantly greater than treatment with virus alone. Whilst this result is encouraging, it is in isolation 
and further experiments would be required before it would be possible to reach a conclusion as to 
whether this is a better treatment than virus alone. In a study conducted by Heinrich et al they found 
that the same vaccinia virus and pro-drug activation system did not result in a significant additional 
effect on melanoma cells 142. This may be a result of the inhibition of viral replication by 5-FU that has 
been shown with other viruses such as HSV-1 159. 
We had hoped to evaluate the organotypic model for evidence of immunogenicity of treatment with 
oncolytic virus. Given our findings of consistently raised levels of HMGB1 in our tissue culture 
experiments we had hoped that we would be able to stain for this using IHC. Unfortunately, we found 
HMGB1 staining to be an unreliable marker in this model. Staining for this was inconsistent as 
demonstrated in Figure 4.14. Original tissue blocks for different patients stained differently for 
HMGB1 with regards to staining being nuclear or extracellular. This appeared to be variable in all four 
patients rather than us seeing it predominantly being stained for in the nuclei. This made the 
assessment of ICD in our organotypic cultures treated with vaccinia virus difficult. Of the prepared 
organotypic cultures that were treated we found no obvious effect of treatment with oncolytic 
vaccinia virus. Staining was extracellular in both the untreated and maximally treated slices. This 
finding could indicate that in making the organotypic cultures we alter the expression of HMGB1. 
Another important consideration is that as cancers evolve they are detected by the host immune 
system thus triggering anti-tumour responses. Immune damage of cancers is a natural occurrence 
which can affect ICD assessment as this natural response to tumour will increase markers of ICD within 
the tumour tissue, and we may not see a difference in this following virotherapy compared topre-
treatment. Other markers of ICD can be stained for in IHC including calreticulin and CD8 and these 
could also be used to assess for ICD in the organotypic culture model 160.  
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4.4 Conclusion 
 
We have developed a high-throughput, high content organotypic model in our laboratory with which 
to assess patient tumours. In optimal culture conditions these organotypic cultures are viable for a 
minimum of 72 hours and a maximum of 120 hours which enables the assessment of oncological 
treatments such as oncolytic viruses, as we have done. Oncolytic vaccinia virus was able to replicate 
in and exert anti-tumour effects in this model as evidenced by direct immunofluorescence, 
assessment of viral titres in supernatants and through IHC staining. The effect on organotypic cultures 
of virus alone was similar to that of virus expressing FCU1 and the addition of pro-drug although one 
experiment did demonstrate a significant increase in expression of cleaved caspase 3 in the virus and 
pro-drug model compared with virus alone. Having demonstrated in a tissue culture model that cell 
death following treatment with vaccinia was immunogenic we were unsuccessful in our attempts to 
assess this using staining for HMGB1 in IHC. Further work is required to assess this in an organotypic 
culture model. 
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Chapter 5 - Treatment of organotypic cultures derived from 
colorectal liver metastases with oncolytic vaccinia virus and exposure 
to cavitational ultrasound and sulphur hexafluoride microbubbles 
 
 
5.1 Introduction 
 
Oncolytic virotherapy is a powerful emerging tool in the treatment of cancer. Clinical trials have 
confirmed the therapeutic effects of oncolytic virotherapy in the treatment of multiple solid tumours 
66,122,161. A limitation of this novel treatment is the restricted ability of oncolytic viruses to reach and 
to penetrate target tumours following intravenous administration. This hurdle has limited their clinical 
utility with many oncolytic virotherapies reliant on intratumoral administration. Whilst this approach 
provides a localised anti-tumour effect and has the ability to stimulate the generation of systemic anti-
tumour immunity it does not utilise the unique ability of viruses to infect and destroy metastatic 
tumour deposits. This route of administration can also pose a problem in certain patients such as those 
with colorectal liver metastases in whom some tumours may not be amenable to intratumoral 
injection. This can be due to their anatomical location within the liver as well as their proximity to 
major vessels in the abdominal cavity such as the vena cava. 
Oncolytic viruses are unique as a cancer therapeutic in their ability to replicate and self-amplify within 
the target tumour bed and subsequently spread within and between tumours. For localised tumours 
intratumoral administration of virus is easily implemented. For patients with metastatic disease such 
as those with colorectal liver metastases, intravenous administration of oncolytic virus is seen as the 
preferred method of administration as it provides access to all vascularised tumour sites within the 
body 162. The goal of systemic therapy is to exceed the viremic threshold above which the virus infect 
a critical number of tumour sites and replicate with a resultant destruction of tumour deposits 163. 
Current research in oncolytic virus delivery has focused on limiting sequestration of virus in the liver 
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and spleen, evading viral neutralisation in patient serum, targeting viruses to vascular endothelia cells 
lining tumour bloods vessels and selectively enhancing their permeability 163. 
 
5.2 Strategies to improve intravenous delivery of oncolytic virus therapy 
 
5.2.1 Limiting viral sequestration in the liver and spleen 
 
Intravenous viruses are rapidly cleared from the circulation following sequestration by the 
mononuclear phagocytic system of the spleen and liver. Prior to clearance viruses are opsonised with 
antibodies, complement, coagulation factors and other proteins that result in their recognition by the 
macrophages of the spleen and the Kuppfer cells of the liver 163. Their recognition results in 
phagocytosis and clearance from the circulation 164. 
Strategies used to overcome sequestration have included chemical modification of viral coats by 
conjugation of biocompatible polymers such as polyethylene glycol (PEG). The result of polymer 
coating in clinical practice has been shown to increase the circulating half-life of treatments 165,166. The 
result of polymer coating can be a reduction in viral infectivity, however this can be restored by re-
engineering receptor binding ligands onto the surface of shielded particles 167. A different approach to 
limit the sequestration of viruses readily bound by IgM and complement proteins is to decrease the 
amount of these factors in patient serum by pre-treatment agents such as cyclophosphamide 168. This 
has been shown to facilitate the initial infection of tumours by oncolytic viruses 168. 
Tao et al confirmed that it is possible for the mononuclear phagocytic system to become saturated, 
leading to increased circulating volumes of virus 169. Sequestration of the mononuclear phagocytic 
system can be achieved by pre-conditioning to saturate scavenger receptors or by poisoning the 
endothelial cells 163. Saturation of scavenger receptors has been demonstrated in mouse studies in 
which pre-dosing with polyinosinic acid which binds to scavenger receptors on endothelial cells and 
macrophages in the liver and spleen reduced sequestration of treatment with oncolytic adenovirus 
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170. Depletion of Kupffer cells of the liver and splenic macrophages has been achieved in mouse models 
by treatment with clodronate-loaded liposomes. This technique has been combined with oncolytic 
virotherapy to improve treatment of oncolytic adenoviral treatment 171. Other methods of 
sequestration include pre-treatment with gadolinium chloride, gamma globulins or pre-dosing with 
high doses of viral particles prior to administering a second dose after a 4 hour period 172-174. 
5.2.2 Evasion of viral neutralisation by serum factors 
 
Attempts have been made to overcome factors in serum such as neutralising antibodies, complement 
or scavenging by Kuppfer cells by hiding onvolytic viruses inside carrier cells 163. In pre-clinical models 
techniques such as infusing ex vivo infected cell lines or using normal primary cells such as dendritic 
and T-cells that can home to tumour beds 175,176. Other cell types used to carry oncolytic viruses to 
tumours include mesenchymal stem cells 177. These cells preferentially engraft in solid tumours and 
have been shown to deliver virus in the presence of neutralising antibodies 178,179. 
5.2.3 Increasing the permeability of tumour blood vessels 
 
The presence of fenestrae and intracellular gaps between the tumour endothelial cells far larger than 
those of normal blood vessels causing the tumour vasculature to be more susceptible to the passage 
of macromolecules, viruses and nanoparticles 180-182. Poor lymphatic drainage and the increased 
interstitial pressure arising from the presence of dense stromal tissue impedes virus extravasation and 
diffusion 163. To overcome this issue the increased vascular permeability of tumours can be increased 
by the administration of factors such as interleukin-2 and tumour necrosis factor alpha prior to 
treatment with the desired anti-cancer agent 163. Another method of reducing the interstitial pressure 
within tumours and thereby overcoming the reduced extravasation in tumours is through treatment 
with chemotherapeutic agents 181. The tumour vascular permeability is maintained following 
chemotherapy 181. Another agent that has been shown to increase the vascular permeability of tumour 
blood vessels and improve oncolytic virotherapy is an inhibitor vascular endothelial growth factor 
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(VEGF). In a mouse model, the administration of VEGF inhibitors along with oncolytic virus treatment 
resulted in an improved oncolytic virus infection 183.  
 
5.3 Systemic administration of vaccinia virus 
 
Vaccinia virus has biological characteristics that make it particularly encouraging for use an oncolytic 
agent. These characteristics include its stability intravenously and its ability to reach target tumours 
in the blood, its rapid spread within tumour tissues, the ability for the virus to be engineered to encode 
large transgenes as well as its safe historical use in humans as a vaccine against smallpox 78. Moreover 
genetically modified vaccinia virus is able to selectively target tumour cells whilst sparing non-
malignant cells, thereby reducing damage to healthy tissues 81. As well as its selective targeting of 
tumour cells its safety is further enhanced due to its site of replication in the cytoplasm of cells, which 
prevents the integration of viral DNA into host chromosomes and the passage of viral progeny into 
daughter cells 184.    
The infectious forms of vaccinia virus include the intracellular mature virion, the intracellular 
enveloped virion, the cell associated enveloped virion and the extracellular enveloped virion. Of these 
the most commonly produced during assembly are the intracellular mature virion and the extracellular 
enveloped virion, with assembly taking place in viral factories within the cytoplasm 81. 
The intracellular mature virion is the simplest form of vaccinia virus, and consists of a single 
phospholipid bilayer 184. Sometimes this will change into an extracellular enveloped virion. This occurs 
as a result of intracellular mature virions exiting the cytoplasm via microtubules and undergoing extra 
modifications including the assembly of an additional membrane that is formed by viral transport 
through endosomal or trans-golgi cisternae 103,184. The extracellular enveloped virion is able to spread 
more rapidly from cells compared with the intracellular mature virion due to its early release from 
cells following replication 185. The extracellular enveloped virions also have fewer viral antigens 
exposed on their outer surface as well as incorporating host cell proteins which enable it to go 
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undetected by the hosts immune system and limits viral destruction in circulation prior to arrival at 
the target tumour site 104.  
5.3.1 Evasion of the immune response by Vaccinia Virus 
 
Vaccinia virus also has several other countermeasures that enable them to replicate despite the innate 
immune response of the host. The host complement system is a an important host defence that 
destroys virus or virus infected cells and promotes phagocytosis of virions that have been opsonised 
by antibody via recognition of the Fc region bound to immunoglobulin 186. To counteract the 
complement system vaccinia virus expresses an abundant protein called vaccinia virus complement 
protein (VCP) 186. This protein is secreted from infected cells and binds to the complement components 
C3b and C4b, working as a co-factor with factor I in promoting cleavage of these two components and 
subsequently inhibiting activation of the complement cascade 187. It has also been found on the 
surface of infected cells as well as extracellular enveloped virions helping to defend these infectious 
virions against the complement system to 186. A second protein, B5 is a type 1 integral membrane 
protein that is found on the outer membrane of extracellular enveloped virions 188. Rather than 
protecting against complement this protein is required for the formation of extracellular enveloped 
virions and promotes dissemination of virus 188. Another defence against the host complement system 
is the acquisition of host protein CD55 in the extracellular enveloped virion envelope 189. This protein 
helps the extracellular enveloped virion to evade destruction by the complement system and is 
implicated in the greater resistance of these particles compared to intracellular mature vaccinia 
virions, which are extremely sensitive to the complement system 186. 
Interferons (IFN) are another part of the host-immune response against viral infection. These are 
grouped into three classes: Type 1 interferons include IFN-α and IFN-β, and these exert their effects 
via the ubiquitously expressed type I IFN receptor 186. Type II IFN is secreted by activated immune cells 
such as natural killer cells and T-cells and activates macrophages and promotes cell mediated adaptive 
immune response 186. Type III IFN are also secreted following viral infection however these have a 
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more limited distribution within tissues. Each of these three interferons have a role in the host defence 
against vaccinia infection 186.  
Interferon response is initiated after sensing viral associated pathogen-associated molecular patterns 
(PAMPs) through host pattern recognition receptors (PRRs) 186. Vaccinia viruses inhibit the host 
interferon response at multiple levels. The virus restricts PAMP production or minimises PAMP 
recognition by expressing proteins that block the pattern recognition receptor induced signalling 
pathway that activates transcription factors that lead to interferon induction, and by inhibiting host 
protein synthesis 186. Vaccinia virus also secrete proteins from the infected cell that capture interferons 
in solution or on the cell surface, preventing interferon from reaching receptors 186. They also block 
signal transduction of interferons by binding to their receptors 186. Finally they produce additional 
proteins within the infected cells that inhibit the action of interferon induced anti-viral proteins 186. 
Tumour necrosis factor, interleukin-1 (IL-1) and IL-18 are pro-inflammatory cytokines that amplify the 
innate immune response to virus infection and influence the subsequent adaptive immune response. 
The cytokine tumour necrosis factor also has direct antiviral activity inducing apoptosis of infected 
cells 186.  
Similar to the inhibition of interferons, vaccinia virus has developed strategies to block these cytokines 
at various levels. This includes the inhibition of proteolytic maturation of cytokines, the expression of 
soluble decoy receptors and inhibiting cytokine induced signal transduction.  
Against IL-1 vaccinia virus acts by inhibiting the production of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), which is required for the transcription and synthesis of pro-IL-
1β (an inactive intracellular form of IL-1) 186. A second signal that is required to activate caspase-1, 
which cleaves pro-IL-1β into active IL-1β, is provided by the activation of large protein complexes 
containing pattern recognition receptors called inflammasomes 190. Vaccinia virus has developed 
mechanisms to inhibit this process. Firstly, it expresses the F1 protein that is able to bind directly to 
the nucleotide-binding domain, leucine-rich repeat and pyrin domain containing protein 1 (NLRP1) 
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inflammasome and reduce the amount of active caspase-1 and IL-1β secretion 190. Certain strains of 
vaccinia virus also have a functional B13R gene that produce the protein B13 that binds caspase-1 and 
inhibits pro-IL-1β cleavage within infected cells, though this is not present in the Copenhagen strain 
of the virus 186. Secondly it combats the production of IL-1β from uninfected cells by expressing soluble 
IL-1R that is released from infected cells, capturing IL-1β in solution. It also expresses the protein B15 
that that is similar to the extracellular ligand binding domain of cellular IL-1R, therefore binding to IL-
1β with high affinity and preventing it from binding to its natural receptor 191. 
IL-18 is another pro-inflammatory cytokine. Similarly, with IL-1β it is synthesised from as an inactive 
precursor that requires cleavage by caspase-1. IL-18 helps clearance of infected cells by inducing IFN-
γ synthesis and activating the natural killer and CD8+ T cells 186.  Vaccinia virus has been shown to 
inhibit IL-18 through the production of the B13 protein that inhibits caspase-1, the secretion of a 
soluble IL-18 binding protein (C12) that prevents IL-18 reaching its receptor on cells and diminishes 
the production of IFN-γ and therefore diminishes NK cell and CD8+ T cell responses 186. 
TNF-α and -β are pro-inflammatory cytokines that can induce cell death. TNF-α is thought to be 
produced predominantly from macrophages and activated T-cells. Its activity is attributed to the 
promotion of an anti-viral state in neighbouring, uninfected cells, selective cytolysis of infected cells 
as well as apoptosis and the recruitment of lymphocytes to sites of infection 192. Vaccinia virus acts to 
secrete proteins that mimic TNF receptors (vTNFRs) and prevent cellular binding as well as proteins 
that interfere with cellular signalling 186. TNF is also a target gene of NF-κB and therefore intracellular 
inhibitors of this also affect the production of TNF 186. 
Chemokines are small chemoattractant cytokines that act to recruit leukocytes to sites of infection ad 
inflammation 186. They are produced in response to infection and inflammation and bind to 
glycosaminoglycans on the surface of adjacent endothelial cell walls, establishing a concentration 
gradient. In the circulation, leukocytes express chemokine receptors on their surface and bind to 
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chemokines via their receptor-binding site. Chemokine production from the first infected cells by virus 
is important in the induction of the host immune response 186.    
Vaccinia virus inhibits the production or function of chemokines in several ways. Following infection, 
engagement of pattern recognition receptors leads to interferon related factor 3 (IRF3) and NF-κB 
activation and the transcription of chemokine genes driven by these transcription factors 186. Varying 
strains of vaccinia virus such as Western Reserve, Wyeth and the Lister strain of the virus express 
immunomodulatory proteins that block intracellular signalling leading to chemokine production 193,194. 
Vaccinia virus also expresses chemokine-binding proteins such as vaccinia virus CC chemokine 
inhibitor (vCCI), which binds to CC chemokines and is secreted from infected cells early during 
infection and is able to prevent the binding of chemokines to their target receptors 186. Another 
protein A41, like vCCI, is also secreted from cells early during infection, binding with chemokines with 
a lower affinity than vCCI with the resultant effect of preventing the establishment of the chemokine 
concentration gradient on endothelial cell walls which reduces the release of chemokines at sites of 
infection 186. 
To prevent the initiation of the caspase cascade and the onset of apoptotic cell death vaccinia virus 
directly subverts the intrinsic pathway of the caspase-cascade by expressing F1 and N1 proteins 186. F1 
protein adopts a Bcl-2-like (anti-apoptotic protein Bcl-2) fold and binds the apoptotic effector protein 
Bak at the mitochondrion preventing apoptosis 186. The F1 protein also binds to NLRP-1 which is an 
upstream activator of caspase-1 and reduces the inflammatory response 190. The N1 protein also has 
a Bcl-2-like fold and has a groove in its surface enabling it to bind with the pro-apoptotic Bcl2 proteins 
Bid and Bad and therefore inhibiting apoptosis 186.  
As well as these anti-apoptotic, Bcl-2-like proteins some strains of vaccinia virus also express the 
proteins B13 and viral Golgi anti-apoptotic protein (vGAAP). The B13 protein has been shown to inhibit 
the activity of capsase-1 as well as the extrinsic pathway of apoptosis triggered by TNF-α or Fas ligand 
195. The vGAAP protein is similar to the human version of the protein. These proteins are part of the 
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transmembrane Bax inhibitor-containing motif (TMBIM) family, including anti-apoptotic and calcium-
modulating proteins like Bax inhibitor I 186. They act by modulating intracellular calcium stores 196.  
These proteins can protect cells from apoptosis via both the intrinsic and extrinsic pathways. These 
proteins however are less commonly expressed by various strains of vaccinia virus than the proteins 
F1 and N1 186. 
Natural killer cells are specialised cells that act against virus-infected and tumour cells. These granular 
lymphocytes are highly cytolytic and are a host first-line defence against viral infection prior to the 
development of specific antibody against the virus and a cytotoxic T lymphocyte response 186. Despite 
being a first-line defence, natural killer cells still require activation prior to action. This is mediated by 
several cytokines (IFN-α and -β, as well as IL-12 and -18) but is mainly regulated by several activating 
and inhibitory receptors that integrate signals that are received from the surface of target cells 186,197. 
Vaccinia virus is able to modulate natural killer cell activation through the effects that it exerts on 
cytokines and interferons as highlighted earlier 186. Several receptors are involved in the activation of 
natural killer cells including the natural cytotoxicity receptors including NKp30 197. The vaccinia virus 
protein A56 (haemagglutinin), which is a known virulence factor of the virus, has been identified as a 
novel viral ligand for the natural killer cell activating receptors. The A56 protein, present on the surface 
of infected cells has been shown to block the activation of natural killer cells through the NKp30 
receptor. This interaction between A56 and the NKp30 receptor has been found to lead to a decrease 
in the lysis of infected cells by natural killer cells when present on the surface of vaccinia virus infected 
cells 198. The A56 protein of vaccinia virus is the only known modulator of natural killer cell activity 198. 
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5.4 Challenges faced in the systemic administration of oncolytic virus to treat solid 
tumours 
 
5.4.1 Tumour vasculature 
 
The broad ability of vaccinia virus to evade the host immune response, enabling infection and viral 
replication highlight its potential as a candidate for intravenous oncolytic therapy. Solid tumours such 
as colorectal liver metastases pose a treatment difficulty for anti-cancer treatments. This is because 
of several factors that result in a non-uniform distribution of treatment as well as insufficient levels of 
treatment reaching the tumour 199. These occur due to abnormalities in the tumour architecture and 
vasculature which lead to deficiencies in vascular and interstitial transport of these agents to tumours 
199.  
In comparison with healthy tissue, tumour vasculature is leaky with endothelial cells containing large 
gaps between endothelial cells. The vasculature is also distributed in a chaotic fashion with varying 
vessel length and diameter. These vessels can also be tortuous and saccular as well as having 
haphazard interconnections, all of which render the tumour vasculature functionally abnormal 199. The 
proliferation of tumour cells can also exert extra-luminal pressure on these vessels with a resultant 
impairment in tumour blood flow 199. As the tumour vasculature is leaky and there is a lack of 
functional lymphatic drainage of the tumour there is a resultant increase in the interstitial pressure of 
the tumour compared to normal tissues. There is also a reduction in the plasma to interstitial gradient 
of oncotic pressure. Both the increased interstitial pressure and the reduction in the plasma to 
interstitial gradient of oncotic pressure contribute to the sub-optimal delivery of anti-cancer agents 
to solid tumours 199.    
Another factor that results in insufficient delivery of anti-cancer therapy to tumours is the increased 
distance between tumour cells and their blood vessels. High rates of tumour proliferation can also 
result in tumour cells forcing vessels apart, this can result in tumour being more than 100µm from 
their surrounding vasculature which can already be haphazard as described earlier 199. This can also 
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result in the tumour becoming hypoxic – limiting the efficacy of radiotherapy treatment, as well as the 
lowering of tumour pH through the accumulation of metabolic products such as lactic acid which can 
affect the cellular uptake of some anti-cancer drugs 199. 
5.4.2 Tumour extracellular matrix 
 
The extracelluar matrix can also prove to be a barrier in the successful delivery of anti-cancer 
treatment to solid tumours. The extracellular matrix consists of proteoglygans, collagens and other 
additional molecules produced and assembled by stromal and tumour cells 199. Higher collagen 
content in the extracellular matrix has been shown to reduce the diffusion of large macromolecules 
such as viruses through the tumour, thus limiting their ability to reach tumour cells 199. It can also 
physically obstruct the delivery of virus if the virus particles are larger than the gaps between these 
fibres in the extracellular matrix 199. Treatment with collagenase has been shown to increase 
interstitial transport of oncolytic viruses through the extracellular matrix 200. Collagen can also bind 
and stabilise glycosaminoglycans and hyaluronic acid which can result in increased interstitial pressure 
and reduce interstitial transport 201.  
The tumour microenvironment is a significant obstacle when aiming to achieve uniform and sufficient 
delivery of anti-cancer therapy to solid tumours. Once overcome this could substantially improve the 
treatment of these types of tumour. Several strategies have been developed in an attempt to 
overcome this issue. These include co-injection of anti-cancer treatment with collagenase as well as 
the use of external sources of energy in combination with specific carriers that respond to the external 
energy source for targeted treatment release amongst others 199. One such technique that has been 
developed to help achieve this is ultrasound. Ultrasound can be used in several ways to help overcome 
the problems posed in the treatment of solid tumours by the extracellular matrix. 
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5.5 Therapeutic Ultrasound  
 
Ultrasound has been traditionally used in healthcare for diagnostic purposes as an imaging modality. 
Ultrasound is usually produced from a piezoceramic crystal in short pulses. Diagnostic ultrasound is 
usually characterised by the center frequency of these pulses (between 2-12 MHz) which is usually a 
frequency related to the thickness of the crystal 202. Increasing the pressure amplitude, the frequency 
or the propagation length can distort the waveform and can result in tissue heating as well as 
enhancing non-thermal mechanisms 202. A decrease in the frequency increases the chance of 
cavitation and gas body activation. Power increase or increase in intensity tends to increase the 
likelihood and the size of all the bio-effect mechanisms of ultrasound 202. 
5.5.1 Ultrasound induced heating 
 
This is the result of the absorption of ultrasound energy in tissue. In comparison with diagnostic 
ultrasound, temperature elevations and the potential for bio-effects are kept relatively low by 
carefully described indications for use, applying the ALARA (as low as reasonably achievable) principle, 
limiting temporal average intensities and short exposure durations 202. In its use in therapy, ultrasonic 
heating utilises longer duration of heating with unfocused ultrasound beams or utilise higher intensity 
focused ultrasound compared to diagnostic ultrasound 202. Unfocused heating using ultrasound can 
be used in physical therapy to promote healing in highly absorbing tissues such as bones and tendons. 
Alternatively, focused beams can concentrate heat in tissue and this results in tissue coagulation of 
the purposes of tissue ablation. The result of ultrasound heating can vary from mild heating to 
coagulative necrosis to tissue vaporisation depending on temperature gradients 202.  
5.5.2 Cavitation and gas body activation 
 
Ultrasonic cavitation and gas body activation are similar mechanisms that rely on the rarefractional 
pressure amplitude of ultrasound waves. The transmission of ultrasound into tissues can exert 
rarefractional pressure amplitudes of several megaPascals. High rarefractional pressure can result in 
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cavitation activity in tissue when suitable cavitation nuclei are present, or directly induce pulsation of 
pre-existing gas bodies in tissues such as lungs and intestines, or with contract agents. Both cavitation 
and gas body activation primarily cause local tissue injury including cell death and haemorrhage of 
blood vessels 202. 
5.5.3 Cavitation Nuclei 
 
Gas bubbles with a stabilising shell are used in ultrasound imaging and have been used in pre-clinical 
studies of enhanced drug delivery. The shell of the microbubble can be coupled to therapeutics such 
as liposomes or can even be coated with drug. The gas core can also be utilised to transport oxygen 
or other useful cargo 203. Ultrasound wave reflections from tissue increase in proportion to variations 
in density and compressibility of the medium and gas bubbles that are highly compressible produce 
strong ultrasound echoes. In response to ultrasound waves these bubbles expand and contract. When 
they are exposed to a frequency that is near to the resonance frequency of the bubble they can expand 
in size. As they subsequently collapse the microbubble wall can reach hundreds of meters per second 
203. The collapse of microbubbles can also lead to the formation of small jets that can impact nearby 
cell membranes with a resultant increase in transport of materials to the cell 203. In addition to the 
formation of jets additional mechanisms in microbubble-enhanced delivery include radiation forces 
and microstreaming of fluid. Radiation forces occur where micro-bubbles are displaced following 
exposure to ultrasound in the direction that the waves are displacing these. Local motion of fluid 
surrounding the oscillating bubble is known as microstreaming and has been shown to increase the 
uptake of therapies at a cellular level 203.  
5.5.4 Thermal ultrasound applications 
 
It is important that there is tight control of gene therapy. The aim of strategies trying to control gene 
therapy is to improve targeting and efficiency of gene delivery. Methods have been developed to 
control temporal transgene expression using gene promoters that that respond to external chemical 
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factors such as small molecules or antibiotics 199. Systemic administration of agents such as these 
however result in delivery of transgene to non-target tissues.   
Heat shock protein transcription is initiated in tissues, within moments of exposure to temperature 
elevations higher than those required for maximum growth. This has been identified as a selective 
way of regulating gene transcription in tissues. Heat shock protein 70 (HSP70) is one such protein and 
has been identified as having the best overall response as well as being the first of the heat shock 
proteins to be repressed in the absence of a stimulus 199. 
High intensity frequency ultrasound (HIFU) is able to generate increases in temperatures within tissues 
and subsequently turn on genes through HSP70 promoters. HIFU can be guided with imaging 
modalities such as magnetic resonance imaging (MRI), thus enabling accurate placement of the 
ultrasound beam and tight control of gene expression within target tissues 199. 
The use of heat sensitive liposomes to encapsulate drugs is a method of improving drug delivery to 
solid tumours. Enhancement of drug accumulation in tumour can be achieved by incorporating 
polyethylene glycol (PEG) into the membrane. This results in a prolonged clearance time due to the 
protective effects of the PEG barrier against interactions with plasma proteins and the 
reticuloendothelial system 199. Liposomes can be designed to undergo change when heated and result 
in release of drug into tissues. By combining these liposomes with the heat induced by ultrasound 
waves there is a resultant improvement in delivery of drug to target tissues 199.  
HIFU can also be used to cause thermal ablation of tissues. Pre-clinical studies have highlighted the 
potential of combining HIFU with chemotherapy for the treatment of cancers 199. It is believed that 
the combined treatment of tumours with chemotherapeutic agents and HIFU either sensitises the 
tissues to the usually sub-lethal effects of HIFU, or that the HIFU exposure increases the uptake of 
chemotherapeutic agents to these tissues 199.  
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5.5.5 Non-thermal ultrasound applications 
 
Acoustic cavitation is defined as the growth, oscillation, and collapse of small stabilised gas bubbles 
under the pressure field of an ultrasound wave in a fluid medium 199. Two types of cavitation exist, 
these are called inertial and stable cavitation. Stable cavitation occurs where a gas bubbles oscillates 
around its equilibrium radius over several acoustic cycles. Inertial cavitation refers to bubbles growing 
several times their initial radius before collapsing under the inertia of the media that they are in 199. 
Factors affecting acoustic cavitation include the number of gas bubbles available, also termed 
cavitation nuclei. There is an increase in cavitation with increasing numbers of gas bubbles. These are 
scarce in human tissues. Other factors include the availability of physical space for bubbles to form 
and grow, and it can be difficult for cavitation to be induced inside intact cells and in the extra-cellular 
matrix 199.  
In open medium, following the collapse of cavitating bubbles, it has been noted that there are large 
increases in temperature locally and that these changes lead to the formation of hydroxyl molecules 
from dissociated water molecules. This can result in DNA damage, inactivation of proteins and 
enzymes and lipid peroxidation as a result of free radical formation 199.  More pronounced effects of 
inertial cavitation occur within an area enclosed by a rigid boundary. As a result of being enclosed 
within an area there will be constraints in fluid flow. There is a resultant asymmetrical collapse of the 
bubble and the far side impacts and penetrates the bubble surface close to the boundary creating a 
jet. These have been shown to cause cracks in tissue surfaces, leaving them damaged 199. 
Acoustic cavitation has been used as a therapeutic tool to disrupt the blood-brain barrier. Whilst 
continuous HIFU has been utilised to cause targeted ablation of plaques in the basal ganglia of patients 
with Parkinsons disease it can also be used in a pulsed manner. This subsequently lowers the rate of 
energy deposition within tissues and is not destructive. When this is utilised in a pulsed manner it 
leads to the reversible disruption of the blood-brain barrier. This is thought to occur due to the 
mechanical stress induced by the stably oscillating bubbles causing mechanical stress in adjacent 
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blood vessel walls without causing damage to brain tissue 199. Disruption at the blood brain barrier 
allows the extravasation of therapeutic agents. This has been utilised with some anti-cancer 
treatments that are usually unable to cross the blood brain barrier in the attempt to treat brain 
malignancies 199. 
Inertial cavitation occurs where an ultrasound frequency causes the violent collapse of bubbles. This 
can be used to improve the permeability of individual cells and increase delivery of drugs and genes 
at a cellular level. This process is known as sonoporation and results following the creation of pores in 
cellular membranes by ultrasound waves. Sonoporation is a reversible process and as opposed to 
other mechanisms that attempt to improve gene delivery it is non-invasive and has the ability to be 
used in all tissues 199. 
5.5.6 Use of ultrasound with oncolytic virotherapy 
 
Cavitational ultrasound has been predominantly used on drug or gene therapy agents that do not have 
the capacity to replicate. It is potentially a strategy that could improve systemic oncolytic virotherapy. 
Oncolytic viruses are tumour selective, able to self-amplify and express therapeutic proteins from 
within solid tumours. The use of these anti-cancer agents is likely to continue to develop over the 
forthcoming years as clinical testing ensues in combination with conventional anti-cancer therapies as 
well as immuno-oncological approaches. Combining these two technologies could result in enhanced 
systemic delivery of oncolytic virus and more successful therapeutic outcomes in patients with solid 
tumours. In combination with systemic oncolytic adenovirus treatment, cavitational ultrasound and 
sulphur hexafluoride microbubbles were found to significantly increase tumour transgene expression 
without causing tissue damage in a mouse model 204. As well as sulphur hexafluoride microbubbles, 
inertial polymeric nano-cups have also been assessed as the nuclei to establish inertial cavitation 
following focused ultrasound exposure in tumours of mice treated with systemic oncolytic virus 205.  
Bazan-Peregrino et al described the use of cavitational ultrasound to enhance treatment of tumours 
with oncolytic adenovirus 204. In this study an adenovirus expressing luciferase or green fluorescent 
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protein was used in the treatment of breast cancer in a murine model. Tumours were treated with 
intravenous or intratumoral adenovirus with sulphur hexafluoride microbubbles. In tumours that were 
treated intratumorally, these were sonicated using cavitational ultrasound for 20 seconds 2 minutes 
post injection. Fluoresence was measured 24 hours following treatment. Mice treated intravenously 
were pre-treated 24 hours prior to injection with clodronate liposomes. Adenovirus was injected at 
the start and 120 seconds later whilst exposure to cavitational ultrasound went on for 240 seconds 
from the initial administration of virus. The study saw an overall enhanced delivery of adenovirus to 
tumours exposed to sulphur hexafluoride microbubbles and ultrasound at the same time. There was 
no tissue damage seen following the addition of ultrasound and microbubbles with adenovirus 
through optimisation of these parameters. The study found that stable cavitation did not increase the 
effects of oncolytic adenovirus in tumour however inertial cavitation did result in an increased 
luciferase expression in tumours in vivo. This was variable from mouse to mouse and is due to tumour 
heterogeneity. The maximum increase in expression was up to 50-fold. The study concluded that 
oncolytic adenovirus delivery was enhanced with the addition of cavitational ultrasound and that this 
improved intratumoral spread of virus and increase its bioavailability 204. 
Carlisle et al also assessed cavitational ultrasound and microbubbles with oncolytic adenovirus but 
also assessed ‘stealthing’ of oncolytic adenovirus using polymers that degraded upon exposure to the 
tumour milieau 206. A murine breast cancer model was again used. Mice were pre-treated with 
clodronate liposomes 24 hours to IV administration of virus. Virus was injected intravenously at 0 and 
240 seconds with sulphur hexafluoride microbubbles whilst being exposed to cavitational ultrasound. 
The study found that stealthing of the oncolytic adenovirus reduced its clearance by complement. The 
low tumour pH resulted in uncoating of virus. There was an increased half-life of adenovirus that was 
coated compared with uncoated adenovirus. The study saw a two-fold increase in virus in tumour 
tissue following exposure to cavitational ultrasound and sulphur hexafluoride microbubbles. After 72 
hours a 30-fold increase in virus expression was seen in tumours compared to unstealthed controls. 
Overall Carlisle et al concluded that stealthing oncolytic adenovirus in combination with ultrasound 
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and microbubbles led to a longer circulating time of virus as well as a greater reduction in tumour 
growth 206. 
Myers et al assessed the use of specialised polymeric nanocups that were more efficient in instigating 
acoustic cavitation in tumours than the sulphur hexafluoride microbubbles 205. This study utilised 
oncolytic vaccinia virus in conjunction with cavitational ultrasound and polymeric nanocups in the 
treatment of liver tumours. The same cavitational ultrasound parameters and set up were used as in 
the Bazan-Peregrino and Carlilse studies 204,206. Virus was administered intravenously and cavitational 
ultrasound exposure lasted for up to 10 minutes with exposure at different points on the tumour. This 
study found that there was an increased expression of luciferase in tumours treated with virus and 
polymeric cups compared with microbubbles or virus treatment alone. It also saw a 10,000-fold 
increase in viral gene expression in tumours treated with ultrasound, nanocups and vaccinia virus 
compared with those that were treated with ultrasound, microbubbles and vaccinia virus after 5-days 
205.  
Based on these studies we felt that the organotypic culture model would be an effective way to assess 
the effect that cavitational ultrasound and microbubbles had on colorectal liver metastases that were 
treated with oncolytic vaccinia virus.  
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5.6 Aims 
 
In this chapter we hoped to evaluate the use of cavitational ultrasound and sulphur hexafluoride 
microbubbles with vaccinia virus in our established organotypic model. We had previously established 
that oncolytic vaccinia virus infects and replicates in these organotypic cultures as well as exerting its 
anti-cancer effects through the increased expression of cleaved caspase 3 in treated slices when 
compared to untreated controls on immunohistochemical staining as reported in chapter 4. The aims 
of the chapter were to: 
1. Assess viral infection through immunofluorescence in organotypic cultures treated in 
combination with virus, sulphur hexafluoride microbubbles and cavitational ultrasound 
compared with controls. 
2. Assess the effects of cavitational ultrasound and sulphur hexafluoride microbubbles on 
organotypic cultures through the expression of cleaved caspase 3 
3. Assess the effect of virus on organotypic cultures through immunohistochemical staining for 
cleaved caspase 3 in organotypic cultures treated in combination with virus, sulphur 
hexafluoride microbubbles and cavitational ultrasound compared with controls. 
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5.7 Results 
 
5.7.1 Assessment of the combination of oncolytic vaccinia virus with ultrasound and sulphur 
hexafluoride microbubbles in the treatment of organotypic cultures derived from colorectal 
liver metastases 
 
As described in methods organotypic cultures were prepared and placed in culture conditions. To 
assess the effects of combination treatment organotypic cultures were placed inside a Millipore® 
Millicell® cell culture insert within a tissue culture plate. The specified treatment was then added 
within the cell culture insert containing the tissue slice and sealed with the sonolid. The apparatus was 
then placed within the system for acoustic transfection (SAT) chamber and exposed to the cavitational 
ultrasound frequency. Ultrasonic exposures were carried out using the System for Acoustic 
Transfection (SAT) chamber. This system was based on prior design by Carugo et al 132 but modified to 
allow a decrease in the exposure area for the prepared tumour slices. We were able to utilise an 
existing system that was brought to our laboratory allowing us to utilise this technology in conjuction 
with oncolytic virotherapy. 
In this first experiment using combination therapy the concentration of virus that was used was 107 
pfu/ml. This was the highest concentration of virus that had been used in previous experiments with 
organotypic cultures. Using 107 pfu/ml vaccinia virus to treat organotypic cultures we had previously 
demonstrated viral presence in tissues through the expression of green fluorescent protein compared 
to untreated controls. It was not possible to quantify the amount of positive staining using this method 
due to the software available with the software available. It was therefore necessary to determine 
differences in staining subjectively.    
179 
 
 
 
 
 
 
 
 
 
Figure 5.1 Confocal microscope image of organotypic cultures from the same patient treated with vaccinia virus expressing 
green fluoresecent protein compared with untreated control. Evidence of expression of green fluorescent protein in tissue 
slice treated with vaccinia virus compared to untreated control. Images taken at x40 magnification. Liver sections were 
prepared from human tissue obtained at the time of surgical resection. Organotypic cultures created from 8mm punch 
biopsies were left untreated or treated with vaccinia virus expressing green fluorescent protein at a concentration of 1x107 
pfu/ml in culture for 72 hours. Cultures were fixed in formalin at 72 hours. Fixed tissue was then counterstained with nuclear 
stain TOPRO®-3 and left for 30 minutes before being mounted on a slide with a coverslip. Images were obtained by confocal 
microscopy. Blue staining corresponds to TOPRO®-3. 
 
 
In this initial experiment, we assessed the following treatments: 
1. Untreated control 
2. Exposure to cavitational ultrasound and sulphur hexafluoride microbubbles without virus 
3. Exposure to cavitational ultrasound without microbubbles and virus 
4. Exposure to vaccinia virus alone 
5. Exposure to vaccinia virus, cavitational ultrasound and sulphur hexafluoride microbubbles 
 
Control VV10
7  
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These variations in the treatment of organotypic cultures were performed to ensure that both 
exposure to cavitational ultrasound alone and exposure to cavitational ultrasound and microbubbles 
did not exert any effects on the tissue slices by themselves. To assess the effects of these exposures 
on the organotypic cultures z-stack imaging was performed as outlined in methods to assess for the 
presence of green fluorescent protein as an indication of viral presence as well as 
immunohistochemical staining to assess for expression of the apoptotic marker cleaved caspase 3 as 
an indication of apoptotic cell death. 
Using the confocal microscope to create z-stack images through the 300µm thick organotypic cultures 
we compared the untreated control with virus treatment alone and virus treatment plus cavitational 
ultrasound and the sulphur hexafluoride microbubbles. On z-stack images there was evidence of 
expression of green fluorescent protein in both organotypic cultures treated either with vaccinia virus 
alone or with vaccinia virus in combination with cavitational ultrasound and sulphur hexafluoride 
microbubbles when compared with untreated controls (Figure 5.2). There was no obvious difference 
in the amount of green fluorescent protein expressed with vaccinia virus treatment alone or in 
combination therapy in this instance. 
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Immunohistochemical staining was performed to assess for cleaved caspase 3, a marker of apoptotic 
cell death as described in materials and methods. After staining was performed images were taken 
using the Zeiss Primo Star microscope at x40 magnification at three random areas throughout each 
stained organotypic culture. Review of these images indicated an increased expression of the 
apoptotic marker, cleaved caspase 3 in the slices treated with vaccinia virus alone and vaccinia virus 
plus cavitational ultrasound and sulphur hexafluoride microbubbles, compared to the control (Figure 
5.3). 
 
 
 
 
 
 
 
Control VV10
7
 VV107 + US + microbubbles 
Figure 5.2 Z-stack imaging demonstrating green fluorescent protein expression in organotypic cultures treated with vaccinia 
virus and vaccinia virus plus ultrasound and sulphur hexafluoride microbubbles compared with untreated control.  Images 
taken at x20 magnification. Liver sections were prepared from human tissue obtained at the time of surgical resection. 
Organotypic cultures created from 8mm punch biopsies were left untreated or treated with vaccinia virus expressing green 
fluorescent protein at a concentration of 1x107 pfu/ml in culture for 72 hours. Cultures were fixed in formalin at 72 hours. Fixed 
tissue was then counterstained with nuclear stain TOPRO®-3 and left for 30 minutes before being mounted on a slide with a 
coverslip. Images were obtained by confocal microscopy. Blue staining corresponds to TOPRO®-3. 
182 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
To quantify immunohistochemical staining the digital IHC profiler application for ImageJ was utilised  
 
as outlined in methods. This software assessed positivity of diaminobenzide (DAB) substrate staining 
in treated organotypic cultures. The average score was taken from three separate images taken at x40 
magnification from each slice, giving an overall impression of the staining throughout each slice.  
In untreated controls, organotypic cultures treated with media and ultrasound, and organotypic 
cultures treated with media, ultrasound and sulphur hexafluoride microbubbles the percentage 
Control 
 
Media and US and microbubbles Media and US 
VV10
7
 VV10
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and US and microbubbles 
Figure 5.3 Immunohistochemical staining for cleave caspase 3 in organotypic cultures from the same patient either 
untreated or treated with cavitational ultrasound alone, cavitational ultrasound and sulphur hexafluoride microbubbles, 
vaccinia virus alone or vaccinia virus plus cavitational ultrasound and sulphur hexafluoride microbubbles. Images were 
taken at x40 magnification. These are representative images taken for each treatment. Liver sections were prepared from 
human tissue obtained at the time of surgical resection and following a specific period of time fixed in formalin and then 
paraffin embedded. Slides were then prepared using 4µm slices before undergoing immunohistochemical staining for cleaved 
caspase 3. Staining was performed using diaminobenzide substrate (brown) for peroxidase. These images demonstrate an 
increased staining for cleaved caspase 3 in tissue slices that had either been treated with vaccinia virus alone or as well as 
ultrasound and microbubbles. Combination treatment with virus, cavitational ultrasound and microbubbles appeared to show 
the most staining for cleaved caspase 3 indicating increased apoptosis in these treated tumour slices. 
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positive staining for cleaved caspase 3 was 2.83%, 5.43% and 3% respectively. In the organotypic 
cultures treated with vaccinia virus at 107 PfU/ml the percentage positive staining was 13.73%. The 
highest percentage of positive staining for cleaved caspase 3 was seen in the organotypic cultures that 
were treated with a combination of vaccinia virus at 107 PfU/ml, cavitational ultrasound and sulphur 
hexafluoride microbubbles. In these cultures, the average percentage staining was 25.67% (Figure 
5.4); this represents a near 2-fold increase compared to treatment with vaccinia virus alone. There 
was no significant difference between the cleaved caspase 3 staining between all three controls 
(untreated; media and ultrasound; media, ultrasound and sulphur hexafluoride microbubbles) 
suggesting that none of these exerted any apoptotic effects on the organotypic cultures. There was a 
statistically significant difference in cleaved caspase 3 staining between untreated controls and 
vaccinia virus alone (p=0.0199) as well as cultures treated with ultrasound and microbubbles 
compared to virus alone (p=0.0220). Combination therapy with vaccinia virus, ultrasound and 
microbubbles showed a statistically significant increase in positive staining for cleaved caspase 3 
compared to all other treatments (Figure 41) (vs untreated control (p=<0.0001); vs media and 
ultrasound (p=0.0002); vs vaccinia virus at 107 pfu/ml (p=0.0107)). Combination treatment showed a 
significant increase in cleaved caspase 3 staining indicative of an increased effect of this treatment 
through apoptosis in these treated tumour slices compared with other treatments. 
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5.7.2 Treatment of organotypic cultures with vaccinia virus in combination with cavitational 
ultrasound and sulphur hexafluoride microbubbles at a lower concentration of virus 
 
The combination of cavitational ultrasound and sulphur hexafluoride microbubbles has previously 
been shown to cause a fifty-fold increase in tumour transgene expression in combination with 
oncolytic adenovirus 204. Following on from our successful initial experiments with combination 
therapy, we went on to assess whether it was possible to use a lower concentrations of vaccinia virus 
to achieve evidence of infection of organotypic cultures derived from colorectal liver metastases. 
In preliminary experiments, we found that organotypic cultures showed evidence of infection by 
vaccinia virus through the expression of green fluorescent protein on confocal microscopy and z-stack 
imaging as well as through staining for the apoptotic marker, cleaved caspase 3 during 
immunohistochemical analysis. 
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Figure 5.4 Percentage positive staining of cleaved caspase 3 comparing combination treatment with other controls. There 
was a statistically significant increase in positive staining for cleaved caspase 3 in slices treated with combination of vaccinia 
virus and cavitational ultrasound and sulphur hexafluoride microbubbles compared to all other treatments and controls. 
Treatment with vaccinia virus alone showed a statistically significant increase in staining for cleaved caspase 3 compared 
with untreated controls and slices exposed to cavitational ultrasound and sulphur hexafluoride microbubbles. Quantification 
of positive staining undertaken using IHC profiler application software for ImageJ. Statistical analysis using two-way ANOVA. 
Statistical level of significance: *p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
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From a translational medicine viewpoint, the ability to utilise a lower concentration of virus is 
desirable as it reduces the risk of the side effects associated with the systemic administration of 
oncolytic virotherapy. In previous clinical trials that have utilised the systemic administration of 
oncolytic vaccinia virus to treat cancer, doses as high as 3x107 PfU/kg have been utilised 122. Whilst 
oncolytic vaccinia virus is a fairly well tolerated oncolytic virotherapy, all patients will experience 
episodes of pyrexia or chills that last less than 24 hours following intravenous administration, 
moreover they commonly experience transient episodes of hypotension often requiring pre-hydration 
or intravenous fluid administered post-infusion. The majority of side effects experienced are grade 1 
(mild) or 2 (moderate) as per the MedDRA grading system. There have not been any severe (grade 3), 
life threatening (grade 4) or deaths (grade 5) related to the systemic administration of oncolytic 
vaccinia virus 122. The ability to use a lower concentration of virus whilst maintaining clinical efficacy 
is an ideal situation.  
In earlier experiments, we had found that there was a dose-response relationship in the treatment of 
organotypic cultures derived from colorectal liver metastases by vaccinia virus. Immunohistochemical 
staining for cleaved caspase 3 and for viral presence showed improved results of treatment with the 
highest concentration of virus (1x107 pfu/ml) compared to lower concentrations (1x104, 1x105 and 
1x106 pfu/ml) as detailed in results chapter 1. 
The highest concentration of vaccinia virus was utilised in the first experiments performed in the 
assessment of combination therapy. As described earlier there was evidence of infection of these 
tissues with vaccinia virus through the expression of green fluorescent protein on confocal microscopy 
and there was an increased expression of cleaved caspase 3 in slices treated with combination therapy 
compared with untreated controls and virus alone. The purpose of the next experiment was to assess 
the following, lower concentrations of virus: 1x105 pfu/ml and 1x106 pfu/ml as these had 
demonstrated evidence of infection in treated organotypic cultures in previous experiments (see 
results chapter 1). The experiment was carried out in the same way that the first experiment was 
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performed (see methods). Results were assessed through the expression of green fluorescent protein 
on confocal microscopy and z-stack imaging (Figure 5.5). Results of treatment with vaccinia virus at 
1x106 pfu/ml has not been shown. 
In this experiment, we saw that there was evidence of expression of green fluorescent protein 
suggestive of vaccinia virus presence in tissue slices following treatment with vaccinia virus at 1x105 
pfu/ml after 72 hours when compared to untreated controls. In combination with cavitational 
ultrasound and sulphur hexafluoride microbubbles there was a subjective increase in the expression 
of green fluorescent protein compared to virus treatment alone (Figure 5.5). As per the initial 
experiment, this was suggestive of an improved effect of virus when used in combination compared 
to its use alone. Due to limitations in the number of tissue slices that were obtained from this patient 
tumour, it was not possible to further validate the findings on confocal microscopy with 
immunohistochemical staining as was performed in our initial experiment.  
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Figure 5.5 Z-stack imaging demonstrating green fluorescent protein expression in organotypic cultures treated with vaccinia virus and 
vaccinia virus plus ultrasound and sulphur hexafluoride microbubbles compared with untreated control. Images taken at x20 
magnification. Liver sections were prepared from human tissue obtained at the time of surgical resection. Organotypic cultures created 
from 8mm punch biopsies were left untreated or treated with vaccinia virus expressing green fluorescent protein at a concentration of 
1x105 pfu/ml in culture for 72 hours. Cultures were fixed in formalin at 72 hours. Fixed tissue was then counterstained with nuclear stain 
TOPRO®-3 and left for 30 minutes before being mounted on a slide with a coverslip. Images were obtained by confocal microscopy. Blue 
staining corresponds to TOPRO®-3. 
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As there was evidence of viral presence in organotypic cultures at this lower concentration of virus, it 
was decided that further experiments would be carried out at this concentration of virus. As 
mentioned previously, the ability to use a lower concentration of virus whilst maintaining efficacy is 
desirable in the treatment of cancer in order to reduce side effects of treatment.  
Analysis of the remaining experiments would take place with combined analysis of both confocal 
microscope z-stacked images as well as through the quantification of DAB staining in 
immunohistochemistry. 
5.7.3 Evaluation of the treatment of colorectal liver metastases with vaccinia virus at 1x105 
pfu/ml, cavitational ultrasound and sulphur hexafluoride microbubbles 
 
Three subsequent experiments were performed in order to validate our findings of an improved 
treatment effect following combination therapy with vaccinia virus treatment compared with virus 
alone. Organotypic cultures were procured from punch biopsies obtained at the time of resection of 
colorectal liver metastases as described in methods. These were then exposed to treatments as 
previously described before being returned to media and left in culture conditions for 24 hours. These 
were then fixed in formalin before undergoing subsequent analysis through either confocal 
microscopy or through immunohistochemical staining. 
Two of the three patient tumours treated showed evidence of successful infection by oncolytic 
vaccinia virus through the expression of green fluorescent protein following virus application to tissue 
slices (Figure 5.6). In one patient, there was no convincing evidence of viral infection on confocal 
microscopy (Figure 5.7). 
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To further evaluate these treated organotypic cultures immunohistochemical analysis was performed 
and quantification of DAB staining undertaken using the IHC profiler application for ImageJ software 
as described in methods. 
To ensure that there was evidence of tumour tissue within the punch biopsy H&E staining was 
performed. In preliminary experiments performed with organotypic cultures we had confirmed 
through immunostaining for CK7, CK20 and CDX2 (panel of markers used to confirm liver metastases 
originate from the gastrointestinal tract) that tissue taken at the time of resection of pathological 
specimens was a colorectal liver metastasis. Results were also corroborated through the official 
histological reports for the resected specimens. 
 
VV 1x10
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pfu/ml +US + microbubbles  
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Figure 5.7 Z-stack images from confocal microscopy with no evidence of viral infection following combination treatment 
with vaccinia virus at 1x105 pfu/ml plus cavitational ultrasound and microbubbles. Images from viral treatment alone and 
untreated controls are not shown. Images taken at x20 magnification. Liver sections were prepared from human tissue 
obtained at the time of surgical resection. Organotypic cultures created from 8mm punch biopsies were left untreated or 
treated with vaccinia virus expressing green fluorescent protein at a concentration of 1x105 pfu/ml and then left in culture 
conditions for 72 hours. Cultures were fixed in formalin at 72 hours. Fixed tissue was then counterstained with nuclear stain 
TOPRO®-3 and left for 30 minutes before being mounted on a slide with a coverslip. Images were obtained by confocal 
microscopy. Blue staining corresponds to TOPRO®-3. 
 
190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
n
tr
o
l 
M
ed
ia
 +
 U
S 
+ 
m
ic
ro
b
u
b
b
le
s 
V
V
 1
x1
0
5  
p
fu
/m
l 
V
V
 1
x1
0
5  
p
fu
/m
l +
 U
S 
+ 
m
ic
ro
b
u
b
b
le
s 
C
o
n
tr
o
l 
M
ed
ia
 +
 U
S 
+ 
m
ic
ro
b
u
b
b
le
s 
V
V
 1
x1
0
5  
p
fu
/m
l 
V
V
 1
x1
0
5  
p
fu
/m
l +
 U
S 
+ 
m
ic
ro
b
u
b
b
le
s 
Cleaved caspase 3 (x40 magnification) H&E (x20 magnification) 
Fi
g
u
re
 5
.8
 I
H
C
 i
m
a
g
es
 o
f 
o
rg
a
n
o
ty
p
ic
 c
u
lt
u
re
s 
d
er
iv
ed
 f
ro
m
 c
o
lo
re
ct
a
l 
liv
er
 m
et
a
st
a
si
s 
in
 o
n
e 
p
a
ti
en
t 
fo
llo
w
in
g
 i
m
m
u
n
o
h
is
to
ch
em
ic
a
l 
st
a
in
in
g
 f
o
r 
b
o
th
 H
&
E 
a
n
d
 c
le
a
ve
d
 
ca
sp
a
se
 3
 f
o
r 
u
n
tr
ea
te
d
 c
o
n
tr
o
l;
 c
a
vi
ta
ti
o
n
a
l u
lt
ra
so
u
n
d
 a
n
d
 m
ic
ro
b
u
b
b
le
s 
a
lo
n
e;
 v
a
cc
in
ia
 v
ir
u
s 
a
lo
n
e 
a
n
d
 v
a
cc
in
ia
 v
ir
u
s 
in
 c
o
m
b
in
a
ti
o
n
 w
it
h
 u
lt
ra
so
u
n
d
 a
n
d
 m
ic
ro
b
u
b
b
le
s.
 
H
&
E 
im
a
g
es
 t
a
ke
n
 a
t 
x2
0
 m
a
g
n
if
ic
a
ti
o
n
 g
iv
in
g
 a
n
 o
ve
rv
ie
w
 o
f 
th
e 
ti
ss
u
e 
sl
ic
e 
a
n
d
 e
vi
d
en
ce
 o
f 
tu
m
o
u
r 
m
a
te
ri
a
l. 
C
le
a
ve
d
 c
a
sp
a
se
 3
 s
ta
in
ed
 im
a
g
es
 t
a
ke
n
 a
t 
x4
0
 m
a
g
n
if
ic
a
ti
o
n
. E
a
ch
 
im
a
g
e 
re
p
re
se
n
ts
 o
n
e 
o
f 
th
re
e 
fi
el
d
s 
o
f 
vi
ew
 u
se
d
 t
o
 q
u
a
n
ti
fy
 t
h
e 
p
o
si
ti
vi
ty
 o
f 
D
A
B
 s
ta
in
in
g
. 
H
&
E 
st
a
in
ed
 im
a
g
es
 s
h
o
w
 c
el
lu
la
r 
co
n
te
n
t 
w
it
h
in
 e
a
ch
 s
lic
e 
a
n
d
 e
vi
d
en
ce
 o
f 
tu
m
o
u
r 
p
re
se
n
ce
. C
le
a
ve
d
 c
a
sp
a
se
 3
 s
ta
in
in
g
 a
p
p
ea
rs
 t
o
 b
e 
g
re
a
te
st
 in
 s
lic
e 
tr
ea
te
d
 w
it
h
 v
ir
u
s 
in
 c
o
m
b
in
a
ti
o
n
 c
o
m
p
a
re
d
 t
o
 o
th
er
 t
re
a
tm
en
ts
 (
se
e 
Fi
g
u
re
 9
 f
o
r 
q
u
a
n
ti
fi
ca
ti
o
n
 o
f 
st
a
in
in
g
) 
  
191 
 
 
While H&E staining was being performed, staining for cleaved caspase 3 was undertaken. Cleaved 
caspase 3 is a marker of apoptotic cell death. We compared the staining of cleaved caspase 3 in 
untreated controls; cultures treated with media, ultrasound and microbubbles; and vaccinia virus 
alone, with combination treatment. This would enable us to make an assessment of virus activity 
through staining for apoptosis. Figure 5.8 gives a representative example of the images acquired at 
the time of analysis. Images for H&E staining were taken at x20 magnification to give an overall 
perspective of the tissue slices created. Images were taken at x40 magnification for cleaved caspase 3 
staining for a more detailed assessment of staining. To ensure that the staining calculated for each 
slice was representative of staining within the whole slice rather than the area at which the x40 
magnification image was taken the process was repeated at random 3 times within each culture. 
Positive staining was then quantified using the IHC profiler application for image J and an average 
score was then taken for each slice (Figure 5.9).  
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Figure 5.9 Percentage positive staining for cleaved caspase 3 in a colorectal liver metastasis comparing no treatment, 
cavitational ultrasound and microbubbles; virus alone or virus in combination with ultrasound and microbubbles. There was a 
statistically significant increase in positive staining for cleaved caspase 3 in slices treated with combination of vaccinia virus and 
cavitational ultrasound and sulphur hexafluoride microbubbles compared to all other treatments and controls. Treatment with 
vaccinia virus alone showed a statistically significant increase in staining for cleaved caspase 3 compared with untreated controls 
and slices exposed to cavitational ultrasound and sulphur hexafluoride microbubbles. Quantification of positive staining 
undertaken using IHC profiler application software for ImageJ. Statistical analysis using two-way ANOVA. Statistical level of 
significance: *p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
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Analysis of DAB stained tissue slices for cleaved caspase 3 (figure 5.9) showed similar positive staining 
in the control groups (untreated and exposure to ultrasound and microbubbles alone) of 4.1% and 
5.67% indicating that there was no increased apoptotic activity with exposure to cavitational 
ultrasound and sulphur hexafluoride microbubbles compared to tissue slices left untreated in culture 
conditions. There was an increase in positive staining for cleaved caspase 3 in organotypic cultures 
that had been treated with vaccinia virus alone with a score of 10.1%. This was a statistically significant 
increase in staining compared to both control groups (untreated vs VV 1x105 pful/ml (p=0.03) and 
media, ultrasound and microbubbles vs VV 1x105 pfu/ml (p=0.03)). Positive staining for cleaved 
caspase 3 was highest in the organotypic cultures treated in combination with vaccinia virus, 
ultrasound and microbubbles with a score of 18.2%. This showed that staining for cleaved caspase 3 
in these organotypic cultures was higher than controls (combination vs untreated (p=0.0002); 
combination vs media, ultrasound and microbubbles (p=0.0002)) and compared with treatment of 
slices with virus alone was also statistically significant (p=0.009). These results would suggest an 
increased effect of virus in combination with cavitational ultrasound and sulphur hexafluoride 
microbubbles compared to treatment with vaccinia virus alone.  
In a second patient, similar results were seen. Analysis of DAB staining for cleaved caspase 3 (figure 
5.10) showed similar positive staining in both the untreated control slice (2.03%) and those treated 
with cavitational ultrasound and sulphur hexafluoride microbubbles (2.70%). There was a slight 
increase in positive staining for cleaved caspase 3 with virus treatment alone (3.93%), however 
treatment of virus in combination with ultrasound and microbubbles showed the highest staining for 
cleaved caspase 3 (13.47%). In this patient, there was no statistical difference in cleaved caspase 3 
positive staining between the control groups and virus treatment alone. In this repeat experiment 
combination treatment with vaccinia virus, cavitational ultrasound and sulphur hexafluoride 
microbubbles was found to cause a statistically significant increase in cleaved caspase 3 staining 
compared to other treatments (combination vs control (p=<0.0001); combination vs media, 
ultrasound and microbubbles (p=0.0002); combination vs virus alone (p=0.0002)). 
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In a subsequent experiment assessing the same treatments there was no evident infection of the 
tissue slice by oncolytic vaccinia virus in combination with ultrasound and microbubbles and by itself 
(Figure 5.7). Due to the workflow and the time taken to evaluate treated organotypic cultures using 
immunohistochemistry slices were often first assessed by confocal microscopy and z-stack imaging 
prior to immunohistochemical analysis due to the speed at which slices could be processed in this 
way. Review of H&E stained images of tumour from the patient in whom the treatment was 
unsuccessful, control tissue showed that this was a mucinous cystic tumour (Figure 5.11). Within each 
slice there was very little in the way of cellular material. There were also large gaps between cells 
which would have limited vaccinia virus spread given that it spreads from cell to cell. It was felt that 
this histological appearance was likely to account for results seen in this instance. 
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Figure 5.10 Percentage positive staining for cleaved caspase 3 in another patient with colorectal liver metastasis, comparing 
no treatment; cavitational ultrasound and microbubbles; virus alone or virus in combination with ultrasound and 
microbubbles. There was a statistically significant increase in positive staining for cleaved caspase 3 in slices treated with 
combination of vaccinia virus and cavitational ultrasound and sulphur hexafluoride microbubbles compared to all other 
treatments and controls. There was no significant increase in staining for cleaved caspase 3 inslices treated with vaccinia virus 
alone compared with untreated controls and slices exposed to cavitational ultrasound and sulphur hexafluoride microbubbles. 
Quantification of positive staining undertaken using IHC profiler application software for ImageJ. Statistical analysis using two-
way ANOVA. Statistical level of significance: *p<0.05; **p<0.01; ***p<0.001 and ****p<0.0001 
 
  
194 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Comparison of immunohistochemical staining for H&E in organotypic cultures from two patients that 
underwent combination treatment of vaccinia virus with cavitational ultrasound and sulphur hexafluoride microbubbles. 
Images were taken at x20 magnification. Image a) shows the histological appearance of the organotypic culture with large 
areas of mucin (demonstrated by the arrow) within the tumour. There is also scanty cellular material and no glandular 
architecture that is typically seen in colorectal liver metastases. Image b) shows the typical architecture of an organotypic 
culture derived from a colorectal liver metastasis with maintenance of the glandular architecture that is typically seen and a 
marked increase in cellular material in comparison with image a). Liver sections were prepared from human tissue obtained 
at the time of surgical resection and following a specific period of time fixed in formalin and then paraffin embedded. Slides 
were then prepared using 4µm slices before undergoing immunohistochemical staining for H&E. Staining was performed 
using DAB substrate (brown) for peroxidase.  
 
a b 
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5.8 Discussion 
 
The aims of this chapter were to assess the use of cavitational ultrasound and sulphur hexafluoride 
microbubbles with virus in the treatment of colorectal liver metastases and to see if this improved 
infection of organotypic cultures. Having previously demonstrated that vaccinia virus successfully 
infected organotypic cultures in earlier experiments, we wanted to assess if there was any 
improvement in viral infection of cultures treated in this way. This could potentially represent a means 
of improving the effects of systemically administered vaccinia virus, which has so far been limited in 
current literature. Infection of tissue slices was assessed through the expression of green fluorescent 
protein in treated slices using confocal microscopy as well as through the assessment of apoptotic 
activity within treated tissue slices using immunohistochemical analysis. We also wanted to confirm 
that any effects observed within treated tissues, were not a consequence of exposure to ultrasound 
frequencies and the sulphur hexafluoride microbubbles alone. 
There has so far been limited success following the intravenous administration of virus in trials despite 
it being generally well tolerated. This is reflected in the fact that the only oncolytic virotherapy 
currently approved for use by the U.S Food and Drug Administration is talimogene leherparepvec (T-
VEC), a second-generation oncolytic herpes simplex virus. This has been approved for use in the 
treatment of advanced melanoma and is administered intra-tumorally 67. Whilst intra-tumoral 
administration of virus maximises initial delivery into the tumour, there is a reduction in hydraulic 
conductivity within the tumour due to high interstitial hydrostatic pressure as well as the high levels 
of extracellular matrix 207. Oncolytic virus particles can be lost quickly from the tumour due to 
circulatory clearance or through leakage along the tract of injection 207. If the success of the viral 
treatment is dose related, then this reduction in viral particles would suggest that intra-tumoral 
delivery of oncolytic viruotherapy is an inefficient method of treatment 207. As some cancers are not 
amenable to intra-tumoral injection this method also limits the tumours that can be treated. It is 
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therefore desirable to administer this tumour-targeted treatment systemically to broaden the use of 
oncolytic virotherapy.  
A study by Bazan-Peregrino et al. found that the combination of an oncolytic adenovirus in 
combination with cavitational ultrasound and sulphur hexafluoride microbubbles caused a 50-fold 
increase in tumour transgene expression in the treatment of breast cancer in a mouse model 204. This 
was assessed through the expression of luciferase using an in vivo imaging system to measure 
fluorescence in a flank mouse model 204. The sulphur hexafluoride microbubbles act as cavitation 
nuclei when exposed to certain ultrasound frequencies and these cause shockwaves and 
microstreaming within tissues with a resultant propulsion of oncolytic virus throughout the tumour 
205.  
Myers et al. combined oncolytic vaccinia virus with cavitational ultrasound and a different form of 
cavitation nuclei (polymeric cups) in a mouse flank model of colon carcinoma and hepatocellular 
carcinoma. In this study, the oncolytic virus used also expressed the luciferase transgene and so this 
expression was measured using an in vivo imaging system to assess fluorescence. This study found 
that there was a significant increase in viral transgene expression in tumours following exposure to 
virus, ultrasound and polymeric cups 205.  
Both of these studies have demonstrated a statistically improved infection of tumour tissue using an 
in vivo model with different oncolytic virotherapies. This data is promising with regards to the 
optimisation of systemically administered oncolytic virotherapy. Given the success of this method in 
mouse models, it seemed appropriate to assess the effects of our oncolytic vaccinia virus in the 
organotypic cultures derived from human tumours. Being derived from human tumours, organotypic 
cultures are a more representative model with which to assess both oncolytic virotherapy as well as 
combining this treatment with cavitational ultrasound and sulphur hexafluoride microbubbles. 
Tumours derived from immortalised cell lines are subject to the genetic changes that take place in 
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these immortalised cell lines in culture over time making them less representative of patient tumours 
and often over-emphasising the effects of anti-cancer treatments 147. 
Given that organotypic cultures are only 300µm thick and that the cavitational ultrasound and sulphur 
hexafluoride microbubbles had not been used in combination with tissue slices before it was not 
certain that the tissue may have become damaged by these treatments rather than the organotypic 
culture. Previous papers have proposed that damage to tissues can occur following exposure of 
microbubbles to cavitational ultrasound and so it was necessary to ensure that any effects observed 
in the tissue slice model was not a result of this 208,209. During the experiment, we utilised ultrasound 
frequencies that had previously been shown not to cause tissue damage 132. To demonstrate this in 
our experiments we compared the effects or organotypic cultures exposed to ultrasound frequency 
and sulphur hexafluoride microbubbles with those treated with virus as well as ultrasound and 
microbubbles. The effects were assessed through immunohistochemical staining for cleaved caspase 
3, a marker of apoptotic cell death. Staining was quantified using the IHC profiler software available 
for Image J 131. We found that positive staining for cleaved caspase 3 was low in our experiments with 
positive staining less than 5% for both the organotypic cultures left untreated in culture conditions as 
well as those exposed to cavitational ultrasound and microbubbles. There was no statistical difference 
between the staining in these control groups. These findings confirmed that there was no effect on 
tissue seen following exposure to cavitational ultrasound and microbubbles. Furthermore, we saw a 
statistically significant increase in staining for cleaved caspase 3 in tissue slices when treated with 
oncolytic vaccinia virus as well as being exposed to cavitational ultrasound. This result suggests an 
improvement in tumour treatment with this method and further supports the use of combination 
therapy to improve the effects of oncolytic virotherapy in patients with colorectal liver metastases. 
 In one of the experiments performed there was no evidence of successful infection with oncolytic 
vaccinia virus. The morphology of the tissue was assessed through H&E staining and found that the 
histological appearance of the tumour was that of a colorectal liver metastasis, however this was 
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found to be a mucinous tumour with scanty cellular material when compared with the tissue obtained 
from previous positive experiments as highlighted in Figure 5.11. As vaccinia virus spreads from cell 
to cell 188, the lack of cellular material and large quantities of mucin may have dampened any potential 
treatment effect. This result highlights the importance of tumour morphology in treatment of tumours 
with oncolytic virotherapy. This variable morphology seen between the same types of tumour indicate 
that this treatment, as with all anti-cancer therapies is not a panacea and that there will always be 
variability from patient to patient. The effects in clinical practice will be variable with inter-patient 
tumour variation likely affecting virus spread. The result also highlights the limitations of animal 
models which are derived from immortalised cell lines that are more homogeneous. Results in these 
models can be far more consistent in pre-clinical trials before seeing a potential reduction in efficacy 
when it comes to clinical application in clinical trials.  
In the successful experiments performed treatment with vaccinia virus alone was seen to have a 
greater effect through the expression of cleaved caspase 3 than untreated controls, whilst treatment 
with vaccinia virus and exposure to cavitational ultrasound and sulphur hexafluoride microbubbles 
resulted in a statistically significant improvement in treatment effect compared to treatment with 
virus alone. Previous studies assessing the combination of oncolytic virotherapy with ultrasound and 
various cavitation nuclei have shown an increased infection of up to one thousand-fold 204-206. We did 
not see an improvement as extensive as this with our results showing a two-fold increase in infection 
with virus plus exposure to ultrasound and microbubbles compared with virus treatment alone. This 
may be due to the lower concentration of virus used in our experiments compared to these other 
studies (vaccinia virus concentration 1x105 pfu/ml in our experiments) as well as the brief period that 
the organotypic cultures were exposed to the virus for (20 seconds). 
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5.9 Conclusion 
 
Overall, we found that the combined treatment of colorectal liver metastases with vaccinia virus and 
exposure to cavitational ultrasound and sulphur hexafluoride microbubbles improved the anti-cancer 
effects of this oncolytic virus. Combining this treatment with oncolytic virotherapy is a promising 
technique to improve the effect of the systemic administration of oncolytic vaccinia virus. The results 
from these preliminary experiments are small in number and so further repeat experiments would 
help to validate the initial findings of these experiments and support the use of this technique in the 
clinical setting. This is a promising finding for patients with colorectal liver metastases that are not 
amenable to surgical resection of their disease. These patients could have intravenous virotherapy 
administered with focused cavitational ultrasound over specific tumour sites, thereby promoting viral 
penetrance into tumour following systemic administration and potentially enhancing replication. 
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Chapter 6 
 
 
 
General Discussion 
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Chapter 6 – General discussion 
 
6.1 Oncolytic vaccinia virus in the treatment of colorectal cancer 
 
Colorectal cancer is the fourth most common cancer in the developed world with approximately 50% 
of patients going on to develop metastatic disease 9. Only 20% of patients with colorectal liver 
metastases have disease that is initially considered to be surgically resectable 12. Although progress 
has been made in the development of effective agents in the treatment of metastatic colorectal 
cancer, survival remains stubbornly low. Patients not eligible to have surgical treatment will have a 
median survival of between 16- 24 months 15. Given that surgical resection gives the greatest 
possibility of cure, the need for the development of further agents remains. 
Oncolytic viruses are an attractive new treatment option in patients with metastatic colorectal cancer. 
It has long been recognised that viruses have the ability to kill cancer cells and recent clinical trials 
have shown evidence of therapeutic benefit in patients with multiple tumour types 65-67. The 
mechanism by which anti-tumour activity is mediated by oncolytic viruses is not completely 
understood. Two distinct mechanisms are thought to contribute to this; these are, selective replication 
within and lysis of tumour cells in situ and activation of systemic anti-tumour immunity 68. Vaccinia 
virus is a promising oncolytic virotherapy as it has a broad tumour tropism and is stable in the 
bloodstream enabling treatment of distant metastases. It also spreads rapidly within tumours, whilst 
having a large transgene-encoding capacity 78,101. Vaccinia virus also has an established safety profile 
in humans given its use in the smallpox vaccination process 102. The vaccinia virus JX-594, which has 
the immunomodulatory gene encoding for granulocyte monocyte colony-stimulating factor (GM-CSF) 
and β-galactosidase is the best studied vaccinia virus in cancer treatment and has been shown to be 
effective in the treatment of patients with colorectal liver metastases in phase I clinical trials 66.  
In our experiments we found oncolytic vaccinia virus to be an effective treatment in colorectal cancer 
using both tissue culture and our developed organotypic culture system. There was a reduction in the 
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viability of three colorectal cancer cell lines with low MOIs of 0.001 and 0.01 respectively. This finding 
is encouraging as one of the limitations of oncolytic virotherapy is patient toxicity. To be able to treat 
patients with a low pfu of virus would potentially limit the side effects of any treatment. The 
mechanisms by which oncolytic vaccinia virus induces tumour cell death are poorly understood and 
several modes of cell death have been implicated to varying degrees. These include apoptosis, 
necrosis, necroptosis and autophagy 133. Vaccinia virus strain also is a factor in the type of cancer cell 
death that occurs 133. We have evaluated cell death pathways following infection of colorectal cancer 
cell lines with oncolytic vaccinia virus. The results of our experiments have provided evidence to 
suggest that cell death in colorectal cancer cell lines treated with oncolytic vaccinia virus was 
predominantly apoptotic. The same mode of cell death has also been reported in the treatment of 
melanoma cells with this virus 142. The type of cell death induced is important with regards to 
immunogenicity of the virus and the influence that it has on the tumour microenvironment. 
Our oncolytic vaccinia virus induced parts of immunogenic cell death in all three colorectal cancer cell 
lines. Different parts of immunogenic cell death were induced in each cell line. In the HCT116 cell line 
there were increases in calreticulin and HMGB1 expression; there was an increase in FAS and HMGB1 
in the SW620 cell line and there was an increase in CD80 and HMGB1 expression in the HT29 cell line. 
These increases were statistically significant. Increased expression of HMGB1 has also been seen in 
other studies using vaccinia virus 210,211. Two types of immunogenic cell death induction exist, of which 
oncolytic viruses appear to be type II inducers 142. In our colorectal cancer model vaccinia virus was 
not able to induce a full picture of immunogenic cell death. Interrogation of the organotypic culture 
system was unsuccessful for in the assessment for HMGB1. Further work is required in this system to 
assess these organotypic cultures for evidence of immunogenic cell death. Following oncolytic cell 
death tumour cells release viral PAMPs as well as danger associated molecular patterns (DAMPs) 
including heat shock proteins (HSPs), high mobility group box 1 proteins (HMGB1), calreticulin, 
adenosine triphosphate (ATP), and uric acid. They also release cytokines that promote the maturation 
of antigen presenting cells such as dendritic cells. These cytokines include type 1 interferons, tumour 
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necrosis factor-α (TNF- α), interferon gamma (IFN-γ) and interleaukin-12 (IL-12) 68. These then activate 
CD4+ and CD8+ T cell responses 68. Other DAMPs, cytokines in supernatant or activated CD4+ and CD8+ 
T cells may be other targets to assess for ICD in organotypic cultures treated with this vaccinia virus. 
 
6.2 Assessment of the pro-drug activation system with the fusion suicide gene (FCU1) 
 
Most cancer therapies rely on the use of multiple agents in conjunction with one another. Similarly, it 
has been demonstrated that there is a superior effect when oncolytic virotherapy is used in 
combination with traditional therapies 212. An example of this includes the treatment of patients with 
advanced hepatocellular carcinoma. JX-594 oncolytic vaccinia virus was combined with Sorafenib, 
which is a small-molecule molecule multikinase inhibitor with antiproliferative and antiangiogenic 
effects. The combination of these two agents was found to induce tumour necrosis in patients and 
limit disease progression, whilst use of the virus alone did not achieve such results 120.  
For many years 5-FU has been the principle active agent to treat colorectal cancer and is still included 
in chemotherapy regimens such as FOLFOX and FOLFIRI for the treatment of colorectal liver 
metastases. One such way of incorporating this treatment with oncolytic virotherapy is through the 
use of pro-drug activation model which converts 5-FC to toxic 5-FU through the viral expression of the 
fusion suicide gene (FCU1). Vaccinia virus encoding the fusion suicide gene is a promising candidate in 
the use of patients with colorectal cancer and liver metastases. The ability of the virus to convert non-
toxic fluorocytosine into its active metabolite 5-fluorouracil lends itself to the treatment of these 
cancers as this is one of the predominant chemotherapy agents used in the treatment of patients with 
colorectal cancer that has metastasised to the liver. This has been demonstrated in pre-clinical work 
in cell lines as well as in murine models  130,142. We have assessed the use of this vaccinia virus in our 
experiments, firstly in tissue culture and found that oncolytic vaccinia virus has a potent effect on the 
killing of the colorectal cancer cell lines HCT116, HT29 and SW620, with only low MOIs of 0.001 and 
0.01 required to reduce cell proliferation by 50%. In our hands we were unable to show success of 
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pro-drug activation and an improved anti-cancer efficacy compared with virus treatment alone in 
tissue culture experiments. This is in contrast to the results published by Foloppe et al that saw a 
greater reduction of cell viability in colorectal cancer cells (WiDr, LoVo and A549) treated with virus 
and pro-drug compared with virus alone 130. The same study also found in a murine orthoptic mouse 
model for liver metastases that there was a greater reduction in tumour burden following the systemic 
administration of virus and oral administration of 5-FC compared to virus alone. Heinrich et al used 
the same virus and pro-drug activation model in melanoma cell lines 142. Whilst this study did find a 
reduction in cell viability in cells treated with virus and 5-FC compared to those treated with virus 
alone it was not a significant amount 142. Studies have shown that in the presence of chemotherapeutic 
agents such as 5-FU the replication of oncolytic viruses can be inhibited and this may be a limitation 
of the pro-drug activation model used with oncolytic virotherapy 159. In Herpes simplex virus this issue 
has been overcome through the use of a mutant HSV-1 missing one copy of its ICP0, ICP4, and ICP34.5 
gene which resulted in enhanced viral replication 212. Despite our unsuccessful results in tissue culture 
we did demonstrate an effect of virus and pro-drug in the treatment of organotypic cultures when 
compared with treatment with virus alone. This was a solitary result in which we saw a significant 
increase in the expression of cleaved caspase 3 in the organotypic culture compared with virus 
treatment alone in one of two cases that were assessed. In combination with other published results 
from different groups using the pro-drug activation model with vaccinia virus the inconclusive results 
from this study does not advocate the use of this model in the treatment of colorectal liver metastases 
in combination with oncolytic virotherapy.  
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6.3 The organotypic culture model 
 
Given the limitations of existing 2D and 3D models in vitro we wanted to develop and assess the 
feasibility of using an organotypic culture model for the treatment of oncolytic vaccinia virus. 
Following the workflow set out by Davies et al we achieved this 155. Following the recommendations 
set out, as well as our experience in creating these organotypic cultures we were able to refine our 
methods and produce a workflow for this technique. One of the key issues in this particular culture 
system is the viability of the organotypic cultures once created. This factor was critical in our work as 
we hoped to assess the effect of treatment with oncolytic vaccinia virus as well as a pro-drug activation 
model. Given that treatment of slices would have required some time to enable virus to infect tissue 
and replicate a short viability of less than 48 hours would have been unsuitable for assessment. Our 
initial work assessing the organotypic culture viability found that these were viable for a minimum of 
72 hours in our hands and a maximum period of 120 hours (5 days). These results are in keeping with 
other groups’ work using differing methods of creating organotypic cultures as well as different tissues 
152-154,158.  
In actuality the use of these slices was an excellent modality for the assessment of our vaccinia virus 
as we were able to visualise infection and spread of virus through tissue using confocal microscopy 
whilst being able to assess for this and quantify viral presence and effect using IHC and staining for 
anti-vaccinia virus, anti-GFP and cleaved caspase 3 antibody. Furthermore, the excellent results that 
we saw were encouraging given the fact that these slices had been created from actual patient tumour 
without any manipulation. For this reason, organotypic cultures represent a complete 3D 
representation of the actual tumour microenvironment in vitro. These slices capture the architecture, 
heterogeneity and native cellular elements of the tumour of interest rather than surrounding tumour 
with artificial matrices. 
Whilst organotypic cultures are not a panacea for the assessment of tumours ex-vivo and novel 
oncological therapies they do represent an adjunct that can aid in the assessment of these. That said, 
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the model does have its limitations, as with other systems. Critical to the process is the availability of 
patient tissue, as well as the successful processing of the tumour tissue which we found to be variable. 
We were fortunate to have excellent ties with our local hepatobiliary surgical department which 
enabled regular access to this. Further limitations included the heterogeneity of tumours in terms of 
size and cellular content as well as the expense of this system and the time involved from the start of 
processing to the end of assessment which often took several weeks once IHC staining and confocal 
microscopy had been completed.  
Despite the limitations of this method, organotypic cultures represent a high content experimental 
platform for the interrogation of tumours in vitro. The organotypic culture model is a powerful 
technique that is an accurate representation of the tumour in vivo including its stroma and 
heterogeneous microenvironment, permitting the interrogation of tumours in the laboratory. 
 
6.4 Use of cavitational ultrasound to improve the effects of oncolytic vaccinia virus 
 
Oncolytic virotherapy is a powerful emerging tool in the treatment of cancer. Clinical trials have 
confirmed the therapeutic effects of oncolytic virotherapy in the treatment of multiple solid tumours 
66,122,161. A limitation of this novel treatment is the restricted ability of oncolytic viruses to reach and 
to penetrate target tumours following intravenous administration. This hurdle has limited their clinical 
utility with many oncolytic virotherapies reliant on intratumoral administration. Whilst this approach 
provides a localised anti-tumour effect and has the ability to stimulate the generation of systemic anti-
tumour immunity it does not utilise the unique ability of viruses to infect and destroy metastatic 
tumour deposits. 
For patients with metastatic disease such as those with colorectal liver metastases, intravenous 
administration of oncolytic virus is seen as the preferred method of administration as it provides 
access to all vascularised tumour sites within the body 162. Current research in oncolytic virus delivery 
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has focused on limiting sequestration of virus in the liver and spleen, evading viral neutralisation in 
patient serum, targeting viruses to vascular endothelia cells lining tumour bloods vessels and 
selectively enhancing their permeability 163. 
Vaccinia virus has biological characteristics that make it particularly encouraging for use an oncolytic 
agent. These characteristics include its stability intravenously and its ability to reach target tumours 
in the blood, its rapid spread within tumour tissues, the ability for the virus to be engineered to encode 
large transgenes as well as its safe historical use in humans as a vaccine against smallpox 78. Moreover 
genetically modified vaccinia virus is able to selectively target tumour cells whilst sparing non-
malignant cells, thereby reducing damage to healthy tissues 81. As well as its selective targeting of 
tumour cells its safety is further enhanced due to its site of replication in the cytoplasm of cells, which 
prevents the integration of viral DNA into host chromosomes and the passage of viral progeny into 
daughter cells 184.  Cavitational ultrasound has been predominantly used on drug or gene therapy 
agents that do not have the capacity to replicate. It is potentially a strategy that could improve 
systemic oncolytic virotherapy. In combination with systemic oncolytic adenovirus treatment, 
cavitational ultrasound and sulphur hexafluoride microbubbles were found to significantly increase 
tumour transgene expression without causing tissue damage in a mouse model 204. 
Our results showed that in combination with cavitational ultrasound and sulphur hexafluoride 
microbubbles there was the highest percentage of positive staining for cleaved caspase 3 in IHC 
compared with virus at 107 PfU/ml alone. In these cultures, the percentage staining was 25.67% which 
represented a near 2-fold increase compared to treatment with vaccinia virus alone. Combination with 
vaccinia virus, ultrasound and microbubbles showed a statistically significant increase in positive 
staining for cleaved caspase 3 compared to all other treatments in our experiments. The combination 
of cavitational ultrasound and sulphur hexafluoride microbubbles also enabled us to use a lower 
concentration of vaccinia virus whilst having similar efficacy on the organotypic cultures as vaccinia 
virus at the highest concentration of virus. Once again combination treatment with virus resulted in 
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improved results compared with virus alone. These results echo the findings from previous published 
experiments, albeit to a lesser extent 204,205. This may be a reflection of the heterogeneity of tumour 
tissue or of the brief period of time that organotypic cultures were exposed to virus for and the lower 
concentrations of virus that we used in our experiments. 
Overall, we have found the combination of oncolytic vaccinia virus with cavitational ultrasound to be 
a promising treatment modality. Further repeat experiments are required to confirm this association 
as our experiments are small in number and so further repeat experiments would help to validate our 
findings. We also did not assess the pro-drug activation model using this system and further 
experiments would be required to investigate this.  
 
6.5 Future work 
 
In this thesis we set out to establish an organotypic culture model in our laboratory and work to date 
has gone some way to achieving this. To further establish the model further work should involve 
increasing our experience with colorectal liver metastases, creating more tissue slices and establishing 
a standardised protocol that enables us to evaluate organotypic cultures with different viruses as well 
as in different solid tumours. It is important to note that a change in tissue and tumour site would also 
warrant full optimisation as we have done in the case of colorectal liver metastases. 
Vaccinia virus was assessed for immunogenic cell death and was found to induce this partly in our 
work with colorectal cancer cell lines. Despite this we were unable to evaluate this in our organotypic 
culture model. Further work assessing ICD in the organotypic culture model could be performed by 
staining for different markers in IHC such as calreticulin, another option would be to assess for 
cytokines in the supernatants of treated slices compared with controls to assess for any difference 
following virotherapy. Another option could be to assess immunogenicity with differing 
209 
 
concentrations of virus, it may be that a lower dose could produce a better response in the organotypic 
culture model. 
Our work combining oncolytic virotherapy using cavitational ultrasound and sulphur hexafluoride 
microbubbles has been promising in the optimisation of oncolytic virotherapy in solid tumours. The 
next step would be to assess this in vivo using a murine subcutaneous flank model. Oncolytic virus 
could be administered locally and systemically with or without the combination of cavitational 
ultrasound and microbubbles and the responses could be assessed. This could also be undertaken in 
a murine liver metastasis model too.  
Finally, newer technologies are in development to optimise the effects of cavitational ultrasound. One 
such technique is to use polymeric nanocups rather than simple sulphur hexafluoride microbubbles 
to further enhance this effect. These provide the nuclei for instigation of sustained cavitational events 
within tumours as they have a longer half-life than microbubbles. In early studies this technology has 
been shown to increase virus activity in solid tumour up to 10,000-fold which is stark in comparison 
to the two-fold increase that we have seen 205.  
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